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A B S T R A C T
Background
Schizophrenia is a mental illness causing disordered beliefs, ideas and sensations. Many people with schizophrenia smoke cannabis, and
it is unclear why a large proportion do so and if the effects are harmful or beneficial. It is also unclear what the best method is to allow
people with schizophrenia to alter their cannabis intake.
Objectives
To assess the effects of specific psychological treatments for cannabis reduction in people with schizophrenia.
To assess the effects of antipsychotics for cannabis reduction in people with schizophrenia.
To assess the effects of cannabinoids (cannabis related chemical compounds derived from cannabis or manufactured) for symptom
reduction in people with schizophrenia.
Search methods
We searched the Cochrane Schizophrenia Group Trials Register, 12 August 2013, which is based on regular searches of BIOSIS,
CINAHL, EMBASE, MEDLINE, PUBMED and PsycINFO.
We searched all references of articles selected for inclusion for further relevant trials. We contacted the first author of included studies
for unpublished trials or data.
Selection criteria
We included all randomised controlled trials involving cannabinoids and schizophrenia/schizophrenia-like illnesses, which assessed:
1) treatments to reduce cannabis use in people with schizophrenia;
2) the effects of cannabinoids on people with schizophrenia.
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Data collection and analysis
We independently inspected citations, selected papers and then re-inspected the studies if there were discrepancies, and extracted data.
For dichotomous data we calculated risk ratios (RR) and for continuous data, we calculated mean differences (MD), both with 95%
confidence intervals (CI) on an intention-to-treat basis, based on a fixed-effect model. We excluded data if loss to follow-up was greater
than 50%. We assessed risk of bias for included studies and used GRADE to rate the quality of the evidence.
Main results
We identified eight randomised trials, involving 530 participants, which met our selection criteria.
For the cannabis reduction studies no one treatment showed superiority for reduction in cannabis use. Overall, data were poorly
reported for many outcomes of interest. Our main outcomes of interest were medium-term data for cannabis use, global state, mental
state, global functioning, adverse events, leaving the study early and satisfaction with treatment.
1. Reduction in cannabis use: adjunct psychological therapies (specifically about cannabis and psychosis) versus treatment as
usual
Results from one small study showed people receiving adjunct psychological therapies specifically about cannabis and psychosis were no
more likely to reduce their intake than those receiving treatment as usual (n = 54, 1 RCT, MD -0.10, 95% CI -2.44 to 2.24, moderate
quality evidence). Results for other main outcomes at medium term were also equivocal. No difference in mental state measured on the
PANSS positive were observed between groups (n = 62, 1 RCT, MD -0.30 95% CI -2.55 to 1.95, moderate quality evidence). Nor for
the outcome of general functioning measured using the World Health Organization Quality of Life BREF (n = 49, 1 RCT, MD 0.90
95% CI -1.15 to 2.95, moderate quality evidence). No data were reported for the other main outcomes of interest
2. Reduction in cannabis use: adjunct psychological therapy (specifically about cannabis and psychosis) versus adjunct non-
specific psychoeducation
One study compared specific psychological therapy aimed at cannabis reduction with general psychological therapy. At three-month
follow-up, the use of cannabis in the previous four weeks was similar between treatment groups (n = 47, 1 RCT, RR 1.04 95% CI
0.62 to 1.74, moderate quality evidence). Again, at a medium-term follow-up, the average mental state scores from the Brief Pscychiatric
Rating Scale-Expanded were similar between groups (n = 47, 1 RCT, MD 3.60 95% CI - 5.61 to 12.81, moderate quality evidence).
No data were reported for the other main outcomes of interest: global state, general functioning, adverse events, leaving the study early
and satisfaction with treatment.
3. Reduction in cannabis use: antipsychotic versus antipsychotic
In a small trial comparing effectiveness of olanzapine versus risperidone for cannabis reduction, there was no difference between groups
at medium-term follow-up (n = 16, 1 RCT, RR 1.80 95% CI 0.52 to 6.22, moderate quality evidence). The number of participants
leaving the study early at medium term was also similar (n = 28, 1 RCT, RR 0.50 95% CI 0.19 to 1.29, moderate quality evidence).
Mental state data were reported, however they were reported within the short term and no difference was observed. No data were
reported for global state, general functioning, and satisfaction with treatment.
With regards to adverse effects data, no study reportedmedium-termdata. Short-termdata were presented but overall, no real differences
between treatment groups were observed for adverse effects.
4. Cannabinoid as treatment: cannabidiol versus amisulpride
Again, no data were reported for any of the main outcomes of interest at medium term. There were short-term data reported for mental
state using the BPRS and PANSS, no overall differences in mental state were observed between treatment groups.
Authors’ conclusions
Results are limited and inconclusive due to the small number and size of randomised controlled trials available and quality of data
reporting within these trials. More research is needed to a) explore the effects of adjunct psychological therapy that is specifically
about cannabis and psychosis as currently there is no evidence for any novel intervention being better than standard treatment,for
those that use cannabis and have schizophrenia b) decide the most effective drug treatment in treating those that use cannabis and
have schizophrenia, and c) assess the effectiveness of cannabidiol in treating schizophrenia. Currently evidence is insufficient to show
cannabidiol has an antipsychotic effect.
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P L A I N L A N G U A G E S U M M A R Y
Cannabis for schizophrenia
Many people with the serious mental illness schizophrenia smoke cannabis but it is not known why people do so or the effects of
smoking cannabis. It is unclear what the best methods are that help people to reduce or stop smoking cannabis. Cannabis is the most
consumed illicit drug in the world - amounting to 120 to 224 million users. Cannabis, which is usually smoked or eaten, gives a feeling
of well-being, but in high doses it may also cause mental illness or psychosis. Clinical evidence suggests people who have schizophrenia
have a worse overall outcome from using cannabis, however, there are some people with schizophrenia who claim that using cannabis
helps their symptoms and reduces the side effects of antipsychotic medication. This review aims to look at the effects of cannabis, both
its use and withdrawal, in people who have schizophrenia. A search for trials was conducted in 2013, eight randomised trials, involving
530 participants were included. Five trials investigated the effects of using a specific psychotherapy aimed at reducing cannabis intake,
two investigated the effects of antipsychotic medication for cannabis reduction and one investigated the use of cannbidiol (a compound
found in cannabis) as a treatment for the symptoms of schizophrenia.
The results of the review are limited as trial sizes were small and data were poorly reported.
Overall, there is currently no evidence for any intervention, whether it is psychological therapy ormedication, being better than standard
treatment or each other in reducing or stopping the use of cannabis. More research is needed to explore the benefits of medication or
psychological therapy for those with schizophrenia who use cannabis. It is unclear if cannabidiol has an antipsychotic effect.
Ben Gray, Service User Expert, Rethink Mental Illness.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
REDUCTION IN CANNABIS USE: TREATM ENT AS USUAL AND PSYCHOLOGICAL THERAPY compared with TREATM ENT AS USUAL
Patient or population: pat ients with SCHIZOPHRENIA AND CANNABIS USE
Settings: Inpat ient, outpat ient
Intervention: TREATMENT AS USUAL AND PSYCHOLOGICAL THERAPY
Comparison: TREATMENT AS USUAL
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of Participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
TREATM ENT AS
USUAL
CANNABIS WITH-
DRAWL: TREATM ENT
AS USUAL AND PSY-
CHOLOGICAL THER-
APY
Behaviour: Cannabis
use: 1. frequency of
use (group-based ther-
apy) (high = bad) -
medium term
Cannabis use. Scale
f rom: 0 to 17.
Follow-up: 1 year
The mean behaviour:
cannabis use: 1. f re-
quency of use (group-
based therapy) (high =
bad) - medium term in
the control groups was
0 points
The mean behaviour:
cannabis use: 1. f re-
quency of use (group-
based therapy) (high =
bad) - medium term in
the intervent ion groups
was
0.1 lower
(2.44 lower to 2.24
higher)
54
(1 study)
⊕⊕⊕©
moderate1
M ental state 4 PANSS
score Positive symp-
toms - medium term
PANSS Scale f rom: 7 to
49.
Follow-up: 12 months
The mean mental state
4 PANSS score posit ive
symptoms - medium
term in the control
groups was
- 0.8 points
The mean mental state
4 PANSS score posit ive
symptoms - medium
term in the intervent ion
groups was
0.3 lower
(2.55 lower to 1.95
62
(1 study)
⊕⊕⊕©
moderate1
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higher)
Global state: relapse -
medium term - not re-
ported
See comment See comment Not est imable - See comment
General Functioning 1:
Subjective quality of
life (WHO QOL, BREF) -
medium term
WHO QOL quest ion-
naire. Scale f rom: 0 to
20.
Follow-up: 1 years
The mean general func-
t ioning 1: subject ive
quality of lif e (WHO
QOL, BREF) - medium
term in the control
groups was
- 0.7 points
The mean general func-
t ioning 1: subject ive
quality of lif e (WHO
QOL, BREF) - medium
term in the intervent ion
groups was
0.9 higher
(1.15 lower to 2.95
higher)
49
(1 study)
⊕⊕⊕©
moderate1
Adverse effects: no
clinically important ad-
verse effects - medium
term - not measured
See comment See comment Not est imable - See comment
Leaving the study early
- medium term - not re-
ported
See comment See comment Not est imable - See comment
Satisfaction with treat-
ment - medium term -
not measured
See comment See comment Not est imable - See comment
* The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% conf idence interval) is
based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95% CI).
CI: Conf idence interval;
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our conf idence in the est imate of ef fect.
M oderate quality: Further research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: Further research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: We are very uncertain about the est imate.5
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1 Imprecision: rated ’serious’ - only one study included with few part icipants, few events and wide conf idence intervals.
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B A C K G R O U N D
Description of the condition
Schizophrenia is a complex mental condition that affects approxi-
mately 1% of the population at some stage in their life (Kolliakou
2011). It is characterised by three symptom categories: positive
symptoms, including delusions, thought and speech disorders, and
hallucinations that range from visual to gustatory; negative symp-
toms, such as blunted affect, avolition, anhedonia and asociality;
and cognitive dysfunction related to executive function, attention
and working memory (Tanda 1997; Lynskey 2002). Schizophre-
nia is a condition that can be severely disabling, producing mul-
tiple effects which impact on sufferers, their relatives, and ln the
broader social context. Schizophrenia is associated with low rates
of employment, low levels of activity, a low prevalence of intimate
relationships, and a quality of life that links with anxiety, depres-
sion and substance abuse (Miles 2001). The dramatic impact of
schizophrenia as an affective disorder is represented in the mor-
tality rates of sufferers, which are significantly higher than in the
wider population, and which highlight the fact that suicide is the
largest single cause of this excess mortality (Henquet 2008).
Description of the intervention
Cannabis (Cannabis sativa and Cannabis indica) is a plant that
grows wild throughout the world (Figure 1). It has been used to
make rope and material, and has been used as a psychoactive drug
for at least 2700 years (Russo 2008). When used as a recreational
drug it is normally either as a compressed resin or made from
the flowering tops and leaves, which is then either smoked or in-
gested. There are around 60 chemical compounds within the plant
which have been described as “cannabinoids”; these are cannabis-
related compounds either derived from the cannabis plant or
synthetically manufactured. Of these, the major active cannabi-
noid is the psychoactive constituent delta-9-tetrahydrocannabi-
nol (THC). THC produces a euphoric high, feeling of relaxation,
and intensification of sensation, but it can cause some short-lived
schizophrenic symptoms in some healthy people (D’Souza 2009).
Figure 1. Cannabis sativa
Cannabis is at present the most consumed illicit drug in the world
- the prevalence of which in 2010 was 2.6% to 5.0%, amount-
ing to 120 to 224 million users. It is produced and consumed
in every country in the world, and in amounts which far exceed
other illicit drugs.Within developed countries the amount of con-
sumption is broadly stable, although in many developing coun-
tries it is increasing (UNODOC). The proportion of people with
schizophrenia who use cannabis varies, yet surveys commonly find
prevalence rates to be about 40% (Table 1), much higher than the
general population. Cannabis is used to reduce distressing psy-
chotic symptoms as a form of self-medication (Dixon 1990), or
to reduce the unpleasant adverse effects caused by antipsychotic
drug treatment. It has also been proposed that the negative symp-
toms of schizophrenia (affective flattening, poor volition, poverty
of thought, social withdrawal) may be improved by the use of
cannabis (D’Souza 2005). This theory may be corroborated by
recent literature that suggests therapy with cannabidiol can lead to
significant clinical improvement in psychotic symptoms (Casadio
2011).
How the intervention might work
There is some research evidence supporting the theory that reduc-
ing the intake of cannabis can help prevent and improve the symp-
toms of schizophrenia. The use of cannabis has been associated
with an increased risk of developing psychosis and also exacerbat-
ing the symptoms of schizophrenia. Although there has been sug-
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gestions that the increased risk of developing schizophrenia could
be due to confounders such as other drug use, urbanicity or social
class; or be due to reverse causality, whereby people who are at
risk of developing schizophrenia, start taking cannabis in order
to diminish their prodromal symptoms; however, even when tak-
ing these factors into account, cannabis has been associated with
an increased risk of developing schizophrenia (Matheson 2011).
Multiple meta-analyses have demonstrated an increased risk due
to cannabis. An increase in psychosis has been significantly asso-
ciated with cannabis use in several meta-analyses with odds ratios
of 1.41 and 2.93 reported.This effect also appeared to be dose-de-
pendent and more acute with use at an early age (Henquet 2005,
Semple 2005, Moore 2007, D’Souza 2009).
Conversly, some research suggest cannabinoids in small doses
can have a beneficial effect on the symptoms of schizophrenia.
Cannabinoids (Figure 2) exert their effect through cannabinoid
receptors, CB1 and CB2. CB1 receptors are distributed within the
central nervous system (brain and spine) and in various periph-
eral organs and tissues. The location of CB receptors may explain
the effects of cannabis use on learning, memory, emotion, moti-
vation and motor (control of muscle) ability (Freund 2003). Nor-
mally, these receptors are activated by endogenous cannabinoids -
these are chemicals with a similar structure to cannabinoids found
within cannabis but which are made by the body. The major effect
of these endogenous cannabinoids is control of neurotransmitter
release such as GABA (gamma-aminobutyric acid) and glutamate
within the brain.
Figure 2. delta-9-tetrahydrocannabinol (THC)
Why it is important to do this review
Substance misuse has been reported to be the most prevalent co-
morbid condition associated with schizophrenia (Regier 1990)
and cannabis is the most frequently used substance (Sinclair 2008,
Kavanagh 2004, Hall 1999, Farrell 1998). The reported rates of
cannabis abuse among people with schizophrenia vary widely both
within and between different countries, but are consistently higher
than in other people with mental illnesses or in the general popu-
lation (Smith 1994).
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The association between schizophrenia and cannabinoids has been
well documented; as a result this review aims to look at methods
that assist patients in altering their consumption of cannabis, and
if consumption of cannabinoids affects the symptoms of a person
with schizophrenia.
O B J E C T I V E S
To assess the effects of specific psychological treatments for
cannabis reduction in people with schizophrenia.
To assess the effects of antipsychotics for cannabis reduction in
people with schizophrenia.
To assess the effects of cannabinoids for symptom reduction in
people with schizophrenia.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We included randomised controlled trials. If a trial had been de-
scribed as ’double-blind’, but it was only implied that the study
was randomised, we would have included these trials in a sensitiv-
ity analysis. If there was no substantive difference within primary
outcomes (see Types of outcome measures) when these ’implied
randomisation’ studies were added, then we would have included
these in the final analysis. If there was a substantive difference, we
would only use clearly randomised trials and would have described
the results of the sensitivity analysis in the text.We excluded quasi-
randomised studies, such as those allocating by using alternate
days of the week.
Types of participants
We included people with schizophrenia and other types of
schizophrenia-like psychosis (e.g. schizophreniform and schizoaf-
fective disorders), irrespective of the diagnostic criteria used. There
is no clear evidence that the schizophrenia-like psychoses are
caused by fundamentally different disease processes or require dif-
ferent treatment approaches (Carpenter 1994). The interventions,
which included cannabis reduction specific psychological treat-
ment and antipsychotic versus placebo or antipsychotic, included
only people with schizophrenia and who used cannabis.
Types of interventions
1. Cannabis reduction: specific psychological treatment (any
dose and pattern of administration) versus:
1.1 treatment as usual
1.2 non cannabis specific psychological treatment
2. Cannabis reduction: any (atypical/typical) antipsychotic
(any dose and pattern of administration) versus:
2.1. placebo
2.2. any (atypical/typical) antipsychotics
3. Cannabinoids as treatment: (any dose and pattern of
administration) versus:
3.1 placebo
3.2 any (atypical/typical) antipsychotics
Types of outcome measures
We grouped outcomes into the short term (up to 12 weeks),
medium term (13 to 26 weeks), and long term (more than 26
weeks).
Primary outcomes
1. Behaviour - Cannabis use
2. Mental state - No clinically important change in general
mental state (medium term)
3. Global state - Relapse (medium term)
Secondary outcomes
1. Mental state
1.1 No clinically important change in general mental state (short
and long term)
1.2 Not any change in general mental state
1.3 Average endpoint general mental state score
1.4 Average change in general mental state scores
1.5 No clinically important change in specific symptoms (positive
symptoms, negative symptoms, depression, mania)
1.6 Not any change in specific symptoms
1.7 Average endpoint specific symptom score
1.8 Average change in specific symptom scores
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2. Global state
2.1 Relapse (short and long term)
2.2 Time to relapse
2.3 No clinically important change in global state
2.4 Not any change in global state
2.5 Average endpoint global state score
2.6 Average change in global state scores
3. Behaviour
3.1 No clinically important change in general behaviour (short
and long term)
3.2 Not any change in general behaviour
3.3 Average endpoint general behaviour score
3.4 Average change in general behaviour scores
3.5No clinically important change in specific aspects of behaviour
3.6 Not any change in specific aspects of behaviour
3.7 Average endpoint specific aspects of behaviour
3.8 Average change in specific aspects of behaviour
4 General functioning
4.1 No clinically important change in general functioning
4.2 Not any change in general functioning
4.3 Average endpoint general functioning score
4.4 Average change in general functioning scores
4.5 No clinically important change in specific aspects of function-
ing, such as social or life skills
4.6Not any change in specific aspects of functioning, such as social
or life skills
4.7 Average endpoint specific aspects of functioning, such as social
or life skills
4.8 Average change in specific aspects of functioning, such as social
or life skills
5. Adverse effects
5.1 Death (suicide, natural causes, resulting from adverse effects)
5.2 Clinically important general adverse effects
5.3 Any general adverse effects
5.4 Average endpoint general adverse effect score
5.5 Average change in general adverse effect scores
5.6 No clinically important change in specific adverse effects
5.7 Not any change in specific adverse effects
5.8 Average endpoint specific adverse effects
5.9 Average change in specific adverse effects
6. Leaving the study early
6.1 For specific reasons
6.2 For general reasons
7. Engagement with services
7.1 No clinically important engagement
7.2 Not any engagement
7.3 Average endpoint engagement score
7.4 Average change in engagement scores
8. Satisfaction with treatment
8.1 Recipient of care not satisfied with treatment
8.2 Recipient of care average satisfaction score
8.3 Recipient of care average change in satisfaction scores
8.4 Carer not satisfied with treatment
8.5 Carer average satisfaction score
8.6 Carer average change in satisfaction scores
9. Quality of life
9.1 No clinically important change in quality of life
9.2 Not any change in quality of life
9.3 Average endpoint quality of life score
9.4 Average change in quality of life scores
9.5 No clinically important change in specific aspects of quality
of life
9.6 Not any change in specific aspects of quality of life
9.7 Average endpoint specific aspects of quality of life
9.8 Average change in specific aspects of quality of life
10. Economic outcomes
10.1 Direct costs
10.2 Indirect costs
11. ’Summary of findings’ table
Weused theGRADEapproach to interpret findings (Schunemann
2008) and used the GRADEPRO profiler to import data from
Review Manager (RevMan) to create ’Summary of findings’ ta-
bles. These tables provide outcome-specific information concern-
ing the overall quality of evidence from each included study in the
comparison, the magnitude of effect of the interventions exam-
ined, and the sum of available data on all outcomes we rated as
important to patient-care and decision making. We selected the
following main outcomes for inclusion in the ’Summary of find-
ings’ table.
1. Behaviour - cannabis use (medium term).
2. Mental state - no clinically important change in general mental
state (medium term).
3. Global state - relapse (medium term).
4. General functioning - no clinically important change in general
functioning (medium term).
5. Adverse effects - no clinically important adverse effects were
observed (medium term).
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6. Leaving the study early - there were not excessive attrition rates
(medium term).
7. Satisfaction with treatment - participants were broadly satisfied
with treatment (medium term).
Search methods for identification of studies
Electronic searches
1. Electronic searching
We searched the Cochrane Schizophrenia Group register (25
July, 2013) with the phrase:((*Marijuana* or *Marihuana* or
*Cannabi* or *Hashish* or *Skunk* or *Hemp* or *Ganja* or
*Bhang* or *Sinsemilla*):TI or (*Marijuana* or *Marihuana* or
*Cannabi* or *Hashish* or *Skunk* or *Hemp* or *Ganja* or
*Bhang* or *Sinsemilla*):AB) in Appendix 1.
This register is compiled by systematic searches ofmajor databases,
handsearches and conference proceedings (see Group Module).
Searching other resources
1. Reference lists
We searched all references of articles selected for inclusion for
further relevant trials.
2. Personal contact
If necessary we contacted the first author of each included study
for information regarding unpublished trials or data.
Data collection and analysis
Methods used in data collection and analysis for this update (2013
search) are below; for previous methods please see Appendix 3.
Selection of studies
Review authorsMr B.CMcloughlin (BM) andMr J Pushpa-Rajah
(JP) inspected citations from the new electronic search and iden-
tified relevant abstracts. BM and JP also inspected full articles of
the abstracts meeting the inclusion criteria. Co-author Dr Donna
Gillies (DG) carried out the reliability checks on 20% of citations
from the new electronic search.
Data extraction and management
1. Extraction
Review authors BC and JP extracted data from included studies. If
we found data presented only in graphs and figures, we extracted
this datawhenever possible but only used these data if both authors
independently had obtained the same result. If further information
was necessary, we contacted authors of studies in order to obtain
missing data or for clarification. If studies weremulti-centre, where
possible, we extracted data relevant to each component centre
separately. Co-author DG carried out reliability checks on 20%
of the data.
2. Management
2.1 Forms
We extracted data onto standard, simple forms.
2.2 Scale-derived data
We included continuous data from rating scales only if:
a. the psychometric properties of the measuring instrument have
been described in a peer-reviewed journal (Marshall 2000); and
b. the measuring instrument has not been written or modified by
one of the trialists for that particular trial.
Ideally, the measuring instrument should either be i. a self-report
or ii. completed by an independent rater or relative (not the ther-
apist). We realise that this is not often reported clearly; we have
noted whether or not this is the case in Description of studies and
in the ’Risk of bias’ tables.
2.3 Endpoint versus change data
There are advantages of both endpoint and change data. Change
data can remove a component of between-person variability from
the analysis. On the other hand, calculation of change needs two
assessments (baseline and endpoint), which can be difficult in
unstable and difficult tomeasure conditions such as schizophrenia.
We decided primarily to use endpoint data, and only use change
data if the former were not available. We combined endpoint and
change data in the analysis as we used mean differences (MD)
rather than standardised mean differences throughout (Higgins
2011, Chapter 9.4.5.2).
2.4 Skewed data
Continuous data on clinical and social outcomes are often not
normally distributed. To avoid the pitfall of applying paramet-
ric tests to non-parametric data, we aimed to apply the follow-
ing standards to all data before inclusion: a) standard deviations
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(SFs) and means are reported in the paper or obtainable from the
authors; b) when a scale starts from the finite number zero, the
SD, when multiplied by two, is less than the mean (as otherwise
the mean is unlikely to be an appropriate measure of the centre
of the distribution (Altman 1996)); c) if a scale started from a
positive value (such as the Positive and Negative Syndrome Scale
(PANSS, Kay 1986), which can have values from 30 to 210), we
modified the calculation described above to take the scale starting
point into account. In these cases skew is present if 2 SD > (S-S
min), where S is the mean score and S min is the minimum score.
Endpoint scores on scales often have a finite start and end point
and these rules can be applied. We entered skewed endpoint data
from studies of fewer than 200 participants as other data within
the data and analyses section rather than into statistical analysis.
Skewed data pose less of a problem when looking at mean if the
sample size is large; we would have entered skewed endpoint data
from studies with over 200 participants into statistical analyses.
When continuous data are presented on a scale that includes a
possibility of negative values (such as change data), it is difficult
to tell whether data are skewed or not, we entered skewed change
data into statistical analyses.
2.5 Common measure
To facilitate comparison between trials, we intended to convert
variables that can be reported in different metrics, such as days in
hospital (mean days per year, per week or permonth) to a common
metric (e.g. mean days per month).
2.6 Conversion of continuous to binary
Where possible, we made efforts to convert outcome measures
to dichotomous data. This can be done by identifying cut-off
points on rating scales and dividing participants accordingly into
’clinically improved’ or ’not clinically improved’. It is generally
assumed that if there is a 50% reduction in a scale-derived score
such as the Brief Psychiatric Rating Scale (BPRS, Overall 1988)
or the PANSS (Kay 1986) this could be considered as a clinically
significant response (Leucht 2005; Leucht 2005a). If data based
on these thresholds were not available, we used the primary cut-
off presented by the original authors.
2.7 Direction of graphs
Where possible, we entered data in such a way that the area to the
left of the line of no effect indicated a favourable outcome for the
relevant intervention in each case. Where keeping to this made it
impossible to avoid outcome titles with clumsy double-negatives
(e.g. ’Not improved’) we reported data where the left of the line
indicates an unfavourable outcome. This was noted in the relevant
graphs.
Assessment of risk of bias in included studies
Review authors, BM and JP worked independently by using cri-
teria described in the Cochrane Handbook for Systematic Reviews of
Interventions (Higgins 2011) to assess trial quality. This new set
of criteria is based on evidence of associations between overesti-
mate of effect and high risk of bias due to sequence generation,
allocation concealment, blinding, incomplete outcome data and
selective reporting.
Where inadequate details of randomisation and other characteris-
tics of trials were provided, we contacted authors of the studies in
order to obtain additional information. We noted any response in
Characteristics of included studies.
We have noted the level of risk of bias in both the text of the review
and in the ’Summary of findings’ tables.
Measures of treatment effect
1. Binary data
For binary outcomes, we calculated a standard estimation of the
risk ratio (RR) and its 95% confidence interval (CI). It has been
shown that RR is more intuitive (Boissel 1999) than odds ratios
and that odds ratios tend to be interpreted as RR by clinicians
(Deeks 2000). If heterogeneity had been identified (Assessment
of heterogeneity), we would have used a random-effects model.
For statistically significant results, we used ’Summary of findings’
tables to calculate the number needed to treat/harm for an addi-
tional beneficial/harmful outcome statistic and its 95% CI.
2. Continuous data
For continuous outcomes, we estimated mean difference (MD)
between groups. We prefer not to calculate effect size measures
(standardised mean difference (SMD)). However, if scales of very
considerable similarity had been used, we would have presumed
there was a small difference in measurement, and calculated effect
size and transformed the effect back to the units of one or more
of the specific instruments.
Unit of analysis issues
1. Cluster trials
Studies increasingly employ ’cluster randomisation’ (such as ran-
domisation by clinician or practice), but analysis and pooling of
clustered data pose problems. Authors often fail to account for in-
tra-class correlation in clustered studies, leading to a ’unit of analy-
sis’ error (Divine 1992), whereby P values are spuriously low, con-
fidence intervals unduly narrow and statistical significance overes-
timated. This causes type I errors (Bland 1997; Gulliford 1999).
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If we had included any cluster trials, and found cases where clus-
tering was not accounted for in primary studies, we would have
presented data in a table, with an (*) symbol to indicate the pres-
ence of a probable unit of analysis error. In subsequent versions of
this review, if any cluster trials are identified, we will seek to con-
tact first authors of such studies to obtain intra-class correlation
coefficients (ICCs) for their clustered data and to adjust for this
by using accepted methods (Gulliford 1999).
Had clustering been incorporated into the analysis of primary
studies, wewould have presented these data as if from a non-cluster
randomised study, with adjustment for the clustering effect.
We have sought statistical advice and have been advised that the
binary data as presented in a report should be divided by a ’design
effect’. This is calculated by using themean number of participants
per cluster (m) and the ICC [Design effect = 1 + (m1) * ICC]
(Donner 2002). Again, if we had found any cluster trials, or if
subsequent versions of this review should identify such trials, when
the ICC is not reported it will be assumed to be 0.1 (Ukoumunne
1999).
2. Cross-over trials
A major concern of cross-over trials is the carry-over effect. It oc-
curs if an effect (e.g. pharmacological, physiological or psycho-
logical) of the treatment in the first phase is carried over to the
second phase. As a consequence, on entry to the second phase
the participants can differ systematically from their initial state,
despite a wash-out phase. For the same reason cross-over trials are
not appropriate if the condition of interest is unstable (Elbourne
2002). As both effects are very likely in severe mental illness, we
planned to use only the data of the first phase of cross-over studies.
However, although one study would have required this method,
we were unable to obtain the requisite data, and so none of the
studies included in the final review required this.
3. Studies with multiple treatment groups
Had a study involvedmore than two treatment arms, if relevant, we
planned to present the additional treatment arms in comparisons.
If data were binary, we would simply have added these and com-
bined them within the two-by-two table. If data were continuous,
we would have combined data following the formula in section
7.7.3.8 (Combining groups) of the Handbook (Higgins 2011). If
the additional treatment arms were not relevant, we would not
have reproduced these data. However, none of the studies included
in the final review required this.
Dealing with missing data
1. Overall loss of credibility
At some degree of loss of follow-up, data must lose credibility (Xia
2009). We chose that, for any particular outcome, should more
than 50% of data be unaccounted for, we would not reproduce
these data or use themwithin analyses. If, however,more than 50%
of those in one arm of a study were lost, but the total loss was less
than 50%, we would address this within the ’Summary of findings’
tables by down-rating quality. Finally, we also downgraded quality
within the ’Summary of findings’ tables where loss was 25% to
50% in total.
2. Binary
In the case where attrition for a binary outcome is between 0%
and 50% and where these data were not clearly described, we
presented such data on a ’once-randomised-always-analyse’ basis
(an intention-to-treat analysis). Those leaving the study early were
all assumed to have the same rates of negative outcome as those
who completed. We undertook a sensitivity analysis to test how
prone the primary outcomes were to change when data only from
people who complete the study to that point were compared to
the intention-to-treat analysis using the above assumptions.
3. Continuous
3.1 Attrition
In the case where attrition for a continuous outcome was between
0% and 50%, and data only from people who complete the study
to that point were reported, we used these data.
3.2 Standard deviations
If standard deviations (SDs) were not reported, we first tried to
obtain the missing values from the authors. If not available, where
there are missing measures of variance for continuous data, but
an exact standard error (SE) and confidence intervals available for
group means, and either ’P’ value or ’t’ value available for differ-
ences in mean, we can calculate them according to the rules de-
scribed in the Cochrane Handbook for Systemic reviews of Interven-
tions (Higgins 2011): When only the SE is reported, SDs are cal-
culated by the formula SD = SE * square root (n). Chapters 7.7.3
and 16.1.3 of the Cochrane Handbook for Systemic reviews of Inter-
ventions (Higgins 2011) present detailed formulae for estimating
SDs from P values, t or F values, confidence intervals, ranges or
other statistics. If these formulae do not apply, we can calculate the
SDs according to a validated imputation method which is based
on the SDs of the other included studies (Furukawa 2006). Al-
though some of these imputation strategies can introduce error,
the alternative would be to exclude a given study’s outcome and
thus to lose information. We nevertheless examined the validity of
the imputations in a sensitivity analysis excluding imputed values.
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3.3 Last observation carried forward
We anticipated that in some studies the method of last observa-
tion carried forward (LOCF) would have been employed within
the study report. As with all methods of imputation to deal with
missing data, LOCF introduces uncertainty about the reliability of
the results (Leucht 2007). Therefore, where LOCF data had been
used in the trial, if less than 50% of the data have been assumed,
we presented and used these data and indicated that they are the
product of LOCF assumptions.
Assessment of heterogeneity
1. Clinical heterogeneity
We considered all included studies initially, without seeing com-
parison data, to judge clinical heterogeneity. We simply inspected
all studies for clearly outlying people or situations which we had
not predicted would arise. When such situations or participant
groups arose, we fully discussed these.
2. Methodological heterogeneity
We considered all included studies initially, without seeing com-
parison data, to judge methodological heterogeneity. We simply
inspected all studies for clearly outlyingmethodswhichwe had not
predicted would arise. When such methodological outliers arose,
we fully discussed these.
3. Statistical heterogeneity
3.1 Visual inspection
We visually inspected graphs to investigate the possibility of sta-
tistical heterogeneity.
3.2 Employing the I2 statistic
We investigated heterogeneity between studies by considering the
I2 method alongside the Chi2 P value. The I2 provides an estimate
of the percentage of inconsistency thought to be due to chance
(Higgins 2003). The importance of the observed value of I2 de-
pends on i. magnitude and direction of effects and ii. strength
of evidence for heterogeneity (e.g. P value from Chi2 test, or a
confidence interval for I2). An I2 estimate greater than or equal to
around 50% accompanied by a statistically significant Chi2 statis-
tic was interpreted as evidence of substantial levels of heterogene-
ity (Higgins 2011). When substantial levels of heterogeneity were
found in the primary outcome, we explored reasons for hetero-
geneity (Subgroup analysis and investigation of heterogeneity).
Assessment of reporting biases
Reporting biases arise when the dissemination of research findings
is influenced by the nature and direction of results (Egger 1997).
These are described in Section10of theHandbook (Higgins 2011).
We are aware that funnel plots may be useful in investigating
reporting biases but are of limited power to detect small-study
effects. However, as funnel plots were only planned for analyses
of 10 or more studies, there were not enough studies which could
be synthesised for a funnel plot to be done
Data synthesis
We understand that there is no closed argument for preference for
use of fixed-effect or random-effects models. The random-effects
method incorporates an assumption that the different studies are
estimating different, yet related, intervention effects. This often
seems to be true to us and the random-effects model takes into
account differences between studies even if there is no statistically
significant heterogeneity. There is, however, a disadvantage to the
random-effects model: it puts added weight onto small studies,
which often are the most biased ones. Depending on the direction
of effect, these studies can either inflate or deflate the effect size.
We chose the fixed-effect model for all analyses. The reader is,
however, able to choose to inspect the data using the random-
effects model.
Subgroup analysis and investigation of heterogeneity
1. Subgroup analyses
1.1 Clinical state, stage or problem
We proposed to undertake this review and provide an overview
of the effects of the interventions for people with schizophrenia
in general. In addition, however, we tried to report data on sub-
groups of people in the same clinical state, stage and with similar
problems. However as there were not enough data to produce any
comparisons, it was impossible/unnecessary to subgroup.
2. Investigation of heterogeneity
If inconsistency was high, we have reported this. First, we inves-
tigated whether data had been entered correctly. Second, if data
were correct, we visually inspected the graph and successively re-
moved outlying studies to see if homogeneity was restored. For this
review we decided that should this occur with data contributing
to the summary finding of no more than around 10% of the total
weighting, we would present data. If not, then we would not pool
data but would discuss these issues. We know of no supporting
research for this 10% cut-off, but we use prediction intervals as an
14Cannabis and schizophrenia (Review)
Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
alternative to this unsatisfactory state. Should unanticipated clin-
ical or methodological heterogeneity be obvious, we will simply
state hypotheses regarding this observation for future reviews or
versions of this review. However none of the studies included in
the final review required this.
Sensitivity analysis
We would have applied the following sensitivity analyses to only
primary outcomes of this review if required, however none of the
studies finally included did require this.
1. Implication of randomisation
We aimed to include trials in a sensitivity analysis if they were de-
scribed in some way so as to imply randomisation. For the primary
outcomes wewould have included these studies and if therewas no
substantive difference when the implied randomised studies were
added to those with better description of randomisation, then we
would have entered all data from these studies. However none of
the studies included in the final review required this.
2. Assumptions for lost binary data
Where assumptions had to be made regarding people lost to fol-
low-up and missing SD data (see Dealing with missing data),
we planned to compare the findings on primary outcomes when
we used our assumption compared with complete data only. We
planned to undertake a sensitivity analysis to test how prone re-
sults were to change when ’completer’ data only were compared to
the imputed data using the above assumption. If there was a sub-
stantial difference, we would have reported results and discussed
them but continued to employ our assumption.However none of
the studies included in the final review required this.
3. Risk of bias
We planned to analyse the effects of excluding trials that were
judged to be at high risk of bias across one or more of the domains
of randomisation (implied as randomised with no further details
available): allocation concealment, blinding and outcome report-
ing for the meta-analysis of the primary outcome. If the exclusion
of trials at high risk of bias did not substantially alter the direction
of effect or the precision of the effect estimates, then we would
have included data from these trials in the analysis. However none
of the studies included in the final review required this.
4. Imputed values
We also planned to undertake a sensitivity analysis to assess the
effects of including data from trials where we used imputed values
for ICC in calculating the design effect in cluster randomised trials.
If we noted substantial differences in the direction or precision of
effect estimates in any of the sensitivity analyses listed above, we
would not have pooled the data from the excluded trials with the
other trials contributing to the outcome, but would have presented
them separately. However none of the studies included in the final
review required this.
5. Fixed-effect and random-effects
We synthesised data using a fixed-effect model.
R E S U L T S
Description of studies
Results of the search
Our search identified a total of 250 references, with three more
found through other sources; 226 studies were identified for initial
screening once duplicates had been removed. Fifty studies were
then screened via the abstract, resulting in 15 studies retrieved in
full text that were assessed for eligibility, finally eight studies were
considered acceptable for inclusion in the quantitative analysis
(Figure 3). All eight were published in English.
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Figure 3. Study flow diagram: 2013 search.
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Included studies
We were able to include eight studies involving 530 participants
(please see Characteristics of included studies). Seven compared
the effects of therapies on reducing cannabis use (of those, six
used psychological therapies and one used drug therapy) and one
compared the effects of cannabinoids on symptoms.
4.1 Length of trials
The length varied from 28 days (Leweke 2012) to 12 months
(Madigan 2012 and Bonsack 2011). The mean length was 28
weeks and four days.
Duration (weeks) Number of studies Studies
1-6 2 Leweke 2012, van Nimwegen 2008
6-36 2 Brunette 2011, Akerele 2007
36-52 2 Edwards 2006, Hjorthoj 2013
52 2 Madigan 2012, Bonsack 2011
4.2 Participants
Participants included in the studies were all diagnosed with
schizophrenia/schizoaffective disorder plus current co-morbid
substance use problems and were diagnosed using the DSM-IV
(Diagnostic and Statistical Manual ofMental Disorders) schedule.
One study used the ICD-10 (International Classification of Dis-
eases) criteria (Hjorthoj 2013); all others used DSM-IV. Edwards
2006 specifically used first episode psychosis criteria; Leweke 2012
used “acutely exacerbated schizophrenia”. All other studies used
a broad criteria for inclusion: any DSM IV diagnosis of psy-
chotic disorder i.e. schizophrenia, schizophreniform, schizoaffec-
tive, delusional disorder, bipolar disorder, major depressive disor-
der with psychotic features, psychosis not otherwise stated, and
brief reactive psychosis.
4.3 Setting
The studies varied in geographical location, however all took place
within more economically developed countries. Five studies took
place in Europe (Switzerland, Denmark, Germany, Ireland); two
took place in USA and one took place in Australia.
4.4 Study size
The number of participants ranged from 28 (Akerele 2007) to 129
participants (van Nimwegen 2008), the mean size of study was
66.25; the total number of participants was 530.
4.5 Interventions
Seven studies compared treatments in reducing cannabis use. One
compared two different psychological treatments (Edwards 2006),
and three compared psychological treatments versus treatment as
usual (Madigan 2012, Hjorthoj 2013, Bonsack 2011). Two trials
compared the effects of using different antipsychotics on cannabis
use (Akerele 2007, van Nimwegen 2008), and one compared the
effects of clozapine versus continuing with previous antipsychotic
(Brunette 2011).
One trial (Leweke 2012), investigated cannabis as a treatment
using drug intervention: amisulpride versus cannabidiol.
4.5.1 Psychoeducation versus psychological treatment (cannabis and
psychosis therapy)
Edwards 2006 compared cannabis and psychosis therapy - an in-
dividually delivered cognitive behaviour therapy involving ide-
ally 10 (mean = 7.6) weekly 20- to-60 minute sessions over three
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months designed to influence behaviour change. Delivered over
three months, it involves education about cannabis and psychosis,
motivational interviewing, goal setting, and relapse prevention.
Participants receive a booster session three months after the end
of treatment.
The active control was psychoeducation; this involved ideally 10
(mean = 8.4) individual sessions guided by presentation slides
and covering the nature of psychosis, treatment and relapse, but
avoided discussing cannabis.
The treatments were given by four clinical psychologists trained
in cognitive behaviour therapy and first episode psychosis.
In addition to the above interventions, participants also received
standard care, which included regular psychiatric review and med-
ication. access to mobile assessment and treatment, family and
group work and a recovery clinic
4.5.2 Treatment as usual versus psychological treatment
Three studies compared psychological treatment versus treatment
as usual. In two of those studies (Hjorthoj 2013 and Bonsack
2011), patients in the treatment as usual arm still received some
psychological input that they would have received if they were not
within the trial but in standard care.
Each study tested a different specific psychological intervention
that had been developed within the centre. Broadly, these included
motivational interviewing, cognitive behavioural therapy and psy-
choeducation.
The intervention in Madigan 2012 was Group Psychological In-
tervention (plus treatment as usual) once a week for 12 weeks
plus one booster session six weeks afterwards, provided by a clini-
cal psychologist. The intervention included anxiety management,
motivational interviewing and cognitive behavioural therapy. The
techniques used were based on Edwards 2006.
Treatment as usual in Madigan 2012 involved care from a multi-
disciplinary team including medication and regular review.
In Hjorthoj 2013 the intervention was CapOpus. It lasted six
months and consisted of ideally two sessions a week for the first
month and one weekly session for the remaining five months.
The intervention started with motivational interviewing and then
moved between cognitive behavioural therapy and repeat motiva-
tional interviewing depending on individual need, there was also
development of personalised strategies.
The control was treatment as usual, which was provided by staff
not involved by CapOpus. The treatment involved anti psychotic
medication and cognitive behavioural therapy but not specifically
targeted at cannabis use. Treatment as usual continued after the
six months.
In Bonsack 2011, the intervention was motivational Intervention
+ treatment as usual. Themain aim ofmotivational intervention is
reduction of cannabis use. The sessions were on an individual basis
and consisted of four to six motivational Intervention sessions; the
first session consisted of 60minutes, followed by a feedback session
of 45 to 60 minutes within the next week. Two to four booster
sessions of 30 to 45 minutes took place during the first six months;
these sessions explored the connection between cannabis use and
psychosis, and would discuss the advantages and disadvantages of
cannabis use. In addition, participants were offered three optional
group motivational sessions.
Treatment as usual consisted of psychiatric management by a clin-
ical team consisting of a psychiatrist and a nurse/clinical psychol-
ogist, with access to community or inpatient treatment. Treat-
ment included medication, regular visits within the community
or clinic, rehabilitation, and standard psychoeducation and coun-
selling on substance abuse. Participants were not exposed to any
specific motivational intervention, and no attempt was made to
standardise treatment, as this was based on the participants needs.
4.5.3 Clozapine versus any antipsychotic; olanzapine versus
risperidone
Three studies looked at differing antipsychotic medication inter-
ventions and their effect on cannabis usage. Two studies looked at
olanzapine versus risperidone, the other study looked at clozapine
versus the participant’s current antipsychotic medication.
In Akerele 2007 participants received either olanzapine (dose 5
to 20 mg/day or risperidone: dose 3 to 9 mg/day). The trial was
divided into three phases; during the first two weeks participants
were kept on their current medication; during the second phase
participants were tapered off their current medication on to either
olanzapine or risperidone. The final phase lasted 10 weeks during
which the participants weremaintained on the intervention, either
risperidone or olanzapine.
Doses were increased in a steps; in the risperidone group, partic-
ipants received 3 mg/day for three days, then 6 mg/day for four
days, then 9 mg until the end of the study.
In the olanzapine group, participants received 5 mg/day for three
days, then 10 mg/day for the next four days, then 15 mg/day for
the next five days, then 20 mg/day until the end of the study.
Doses were adjusted if a participant’s symptoms worsened. Partic-
ipants met the research team three times per week for the entire
14 weeks of the study for monitoring of symptoms.
vanNimwegen 2008 also compared olanzapine versus risperidone.
In the first week, participants received flexible dosing of olanza-
pine (dose: 5, 10, 15, or 20 mg/day); or risperidone (dose: 1.25,
2.5, 3.75, or 5 mg/day), which was then given as a fixed dose for
the following five weeks. All participants also received psychoedu-
cation about psychosis, substance abuse and social skills training.
In Brunette 2011, if the participant was randomised to clozapine,
their dose of clozapine was increased over four weeks to reach an
ideal daily dose of 400 mg; during this period the participant’s
currentmedicationwas gradually reduced and then stoppedwithin
four weeks. The dose was adjusted according to response and side
effects, so if required the maximum daily dose of clozapine could
be increased to 550 mg per day subsequently.
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Those randomised to stay on their currentmedicationwere kept on
a steady dose if possible, but if symptoms or side effects increased
the dose was adjusted accordingly.
Participants attended weekly visits over 12 weeks and were assessed
at each visit.
4.5.4 Amisulpride versus cannabidiol
Only one study Leweke 2012, compared amisulpride versus
cannabidiol (a non-psychotropic component of cannabis). Partic-
ipants had no medication at all for the first three days, then re-
ceived either amisulpride or cannabidiol, both starting with 200
mg per day and then increasing stepwise to 200 mg four times a
day (total daily dose was 800 mg) within the first week; this dose
then continued for a further three weeks. If there were increased
side effects, the total daily dose could be reduced to 600 mg per
day. In addition, up to 7.5 mg per day of lorazepam was allowed
during the study if necessary.
4.6 Outcomes
4.6.1 Rating scales
4.6.1.1 Mental state
4.6.1.1.1 Brief Psychiatric Rating Scale-E (BPRS) (Overall 1988)
The BPRS is an 18-item scale measuring positive symptoms, gen-
eral psychopathology and affective symptoms. The original scale
has 16 items, but a revised 18-item scale is commonly used. Scores
can range from zero to 126. Each item is rated on a seven-point
scale varying from ’not present’ to ’extremely severe’, with high
scores indicating more severe symptoms. The BPRS-E is an ex-
panded positive symptom subscale formed by summing concep-
tual disorganisation, hallucinations, unusual thought content and
suspiciousness items. Higher scores indicate a worse outcome.
4.6.1.1.2 Beck Depression Inventory (BDI SF) (Beck 1972)
This is a 13-item self-rating scale for depression. Each item com-
prises four statements (rated zero to four) describing increasing
severity of the abnormality concerned. The person completing the
scale is required to read each group of statements and identify the
one that best describes the way they have felt over the preceding
week. A total of 12/13 is an indicative score for presence of signif-
icant depression.
4.6.1.1.3 Scale for the Assessment of Negative Symptoms (SANS)
(Andreasen 1983)
This scale allows a global rating of the following negative symp-
toms of schizophrenia: alogia (impoverished thinking), affective
blunting, avolition-apathy, anhedonia-asociality and attention im-
pairment. Assessments are made on a six-point scale (0 = not at all
to 5 = severe). Higher scores indicate more symptoms.
4.6.1.1.3 Scale for the Assessment of Positive Symptoms (SAPS)
(Andreasen 1984)
This scale allows a global rating of the following positive symp-
toms of schizophrenia: hallucinations, delusions, formal thought
disorder and bizarre behaviour. Assessments are made on a six-
point scale (0 = not at all to 5 = severe). Higher scores indicate
more symptoms.
4.6.1.1.4 Positive and Negative Syndrome Scale for Schizophrenia
(PANSS) (Kay 1987)
The 30-item PANSS is an operationalised, drug-sensitive instru-
ment that provides balanced representation of positive and nega-
tive symptoms and gauges their relationship to one another and to
global psychopathology. It thus constitutes four scales measuring
positive and negative syndromes, their differential, and general
severity of illness
4.6.1.1.5 Calgary Depression Scale for Schizophrenia (CDSS) (
Addington 1993)
This is a nine-item scale, scored on a four-point basis, where the
higher the score, the more severe the depressive symptoms.
4.6.1.1.6 Birchwood Insight Scale (Birchwood 1993)
Thismeasures three areas of insight: awareness of illness, symptoms
and the need for treatment, scored on a 13-point basis. Higher
scores indicate better insight.
4.6.1.1.7 Obsessive Compulsive Drug use Scale (OCDUS) (
Franken 2002)
This scale has 12 items each with five points, measuring drug
craving in the past week. Higher scores equal higher craving for
cannabis
4.6.1.2 Global state
4.6.2.2.1 Knowledge About Psychosis Questionnaire (KAPQ) (
Birchwood 1992)
This questionnaire tests people’s understanding of psychosis and
treatments.
4.6.1.3 Behaviour
4.6.1.3.1 Cannabis and Substance Use Assessment Schedule (CA-
SUAS) (Wing 1990)
This scale measures the percentage of days using cannabis in the
past four weeks and includes an index of severity of cannabis use.
The scale is modified from the Schedule for Clinical Assessment
on Neuropsychiatry and includes similar information to the Ad-
diction Severity Index.
4.6.1.3.2. Marijuana Craving Questionaire (MCQ) (Heishman
2006)
The MCQ consists of four constructs or factors that characterise
cannabis craving: compulsivity, emotionality, expectancy, and pur-
posefulness. A separate score is calculated for each factor. The
MCQ can be used to measure cue-elicited craving in a research
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setting or natural craving in cannabis-dependent individuals pre-
senting for treatment.
4.6.1.3.3 Addiction Severity Index (ASI) (McLellan 1980)
The ASI is a structured clinical interview that evaluates six areas
within addiction, each area is scaled on a 10-point rating.
4.6.1.3.4 Cannabis use 2 - Percentage days used cannabis in last
four weeks
This outcome measured percentage of days in the past four weeks
that cannabis had been used. It was used in Edwards 2006.
4.6.1.3.5 Cannabis use 3 - Number of joints of cannabis in pre-
ceding month
This was a self-reported outcome with recall helped with the use
of Timeline Follow-Back (Sobell 1992). Joint sizes were defined as
having 0.5 g of cannabis resin, this number was multiplied if more
potent cannabis was used, This outcome was used in Hjorthoj
2013.
4.6.1.3.6 Cannabis use 4 - Number of days abstinent
This outcome was measured using the Cannabis and Substance
Use assessment scale, although the data are not based on the scale
but on the actual raw data; the scale is used to structure the inter-
view. It was used in Bonsack 2011.
4.6.1.3.7 Cannabis use 5 - Number of days of binge use
This outcome was measured using the Cannabis and Substance
Use assessment scale (Wing 1990), although the data are not based
on the scale but on the actual raw data, the scale is used to structure
the interview. It was used in Bonsack 2011.
4.6.1.3.8 Cannabis use 6 - Joints per week
This outcome was self-reported by participants, number of joints
smokedperweek. Itwas used in van Nimwegen 2008 andBrunette
2011.
4.6.1.4. General Functioning
4.6.1.4.1 Social and Occupational Functioning Assessment Scale
(SOFAS) (Goldman 1992)
The SOFAS focuses on the individual’s level of social and occu-
pational functioning while excluding severity of symptoms. It is a
100-point scale, with higher scores indicating better functioning.
4.6.1.4.2 Global Assessment of Functioning (GAF) (Bodlund
1994)
The GAF is a 100-point scoring system (higher scores equal better
functioning) measuring social, occupational, and psychological
functioning.
4.6.1.4.3 The The World Health Organization Quality of Life
(WHOQOL) (WHOQOL)
This instrument comprises 26 items, which measure the following
broad domains: physical health, psychological health, social rela-
tionships, and environment. The WHOQOL is a shorter version
of the original instrument that may be more convenient for use in
large research studies or clinical trials.
4.6.1.4.4 Drug Attitude Inventory (DAI-30) (Hogan 1983)
This scale determines the participants attitude to the medication
and their experience of using it. It is a 30-item scale; each item is
a true or false option.
4.6.1.5.Adverse Effects
4.6.1.5.1 The Simpson Angus Scale (SAS) (Simpson 1970)
The scale is composed of 10 items and used to assess pseudoparkin-
sonism. Grade of severity of each item is rated using a five-point
scale. SAS scores can range from zero to 40. Signs assessed include
gait, arm-dropping, shoulder shaking, elbow rigidity, wrist rigid-
ity, leg pendulousness, head dropping, glabella tap, tremor, and
salivation.
4.6.2 Dichotomous data
4.6.2.1 Cannabis use - used cannabis in last four weeks
This outcomemeasuredwhether the participant hadused cannabis
in the past four weeks, either yes or no. The outcome was then
scored as a percentage of participants who had used cannabis in
the past four weeks. It was used in Edwards 2006.
4.6.2.2 Cannabis use 7 - traces of cannabis breakdown products
in urine
Urine was screened three times a week for cannabis, and either
classed as positive or negative, the cut-off point for positive was
100 nanograms/mL. If any of the three screens in a week were
positive, that week was classed as positive. This was used in Akerele
2007.
4.6.2.3 Adverse effects - Measured adverse events
Participants reporting any adverse events were noted, the number
of participants and type of adverse event was recorded. This was
used in Brunette 2011.
4.6.2.4 Adverse effects 2 - weight gain (kg)
Body weight (kg) was measured to quantify side effects of medi-
cation. This was used in Leweke 2012.
4.6.2.5 Adverse effects 3 - prolactin (nanograms/L)
Serum prolactin (nanograms/L) was measured to quantify side
effects of medication. This was used in Leweke 2012.
4.6.2.6 Leaving the study early - reasons
Reasons for leaving were grouped into not interested, intolerable
adverse effects, needing hospital admission. This outcome was
used by Akerele 2007.
4.6.2.7 Leaving the study early - time in treatment (weeks)
To quantify study retention, time to dropout was measured in-
cluding those that completed the entire trial. This was used by
Akerele 2007.
4.7 Contact of Authors
We contacted the lead authors of all included and excluded studies,
and requested complete data if possible. Only the authors of
Bonsack 2011 replied with complete data, and clarification on
queries. This is noted in the Characteristics of included studies
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Excluded studies
We excluded six studies all on the basis of no usable data, because
the necessary data were not provided by the authors (please see
Characteristics of excluded studies).
Awaiting assessment
One study is awaiting assessment. D’Souza 2005 is a randomised,
double blind trial comparing placebo with 2.5 mg and 5 mg of
delta-9-tetrahydrocannabinol in people with schizophrenia. It was
a cross-over study and we are awaiting first phase data from the
authors, as our protocol details that only data from the first phase of
a cross-over study may be included.(See Characteristics of studies
awaiting classification)
Ongoing studies
We are not aware of any ongoing trials.
Risk of bias in included studies
We assessed the risk of bias in our eight included studies.Generally
the risk of bias was considered low across the eight studies. For
a graphical overview of the risk of bias see Figure 4 and Figure
5. Details about the studies can be found in Characteristics of
included studies.
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Figure 5.
Allocation
We determined that the risk of allocation (selection) bias in five
of our eight included studies was low. Methods of randomisation
among these studies ranged from computer-generated randomi-
sation to drawing lots from a bowl. In the two studies where the
level of bias was unclear (Akerele 2007; Brunette 2011) it was not
fully apparent how randomisation had been carried out.
Blinding
Of our included studies, five displayed a low risk of bias. These
studies utilised single rater blinding or double blinding, and in
most cases those using a single blind method employed indepen-
dent parties to run the blinding. One of our included studies
(Akerele 2007) displayed an unclear risk of bias due to blinding
not being tested. Two of our included studies displayed a high risk
of bias: Brunette 2011 because clinicians and participants were
not blinded; and Hjorthoj 2013 because 14 patients or managers
accidentally broke the blind.
Incomplete outcome data
In this category, five out of our eight included studies displayed an
unclear risk of bias. In four cases the risk of bias was not specified,
whilst in Akerele 2007 there was no indication within the report
how losses to follow-up were managed. The risk was found to be
low in Bonsack 2011, Edwards 2006 and Leweke 2012, where
missing data were handled using last observation carried forward
(LOCF). The LOCF method involves imputing missing values
based on existing data.
Selective reporting
The reporting bias of Akerele 2007was high risk, as some outcomes
were reported by the groups, whereas others were not. In all of
our other included studies it was unclear what the level of risk of
reporting bias.
Other potential sources of bias
The key area of concern with regards to other potential sources of
bias in the studies we included was the source of funding. Akerele
2007 was funded by a company with pecuniary interest in the
results (Eli Lilly - producers of olanzapine), thus the risk of bias
was found to be high. It is however unclear to what extent this may
have influenced the trial. In contrast, although van Nimwegen
2008 was also funded by Eli-Lilly, it was stated clearly within this
study that the company was not involved in the design of the
study, analyses or interpretation of results and therefore the risk
of bias here was considered to be low. The risk of bias in Brunette
2011 was also found to be low as the authors reported no financial
relationships or commercial interest with regard to the present
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study. In all of the other included studies there were no allusions
to other potential sources of bias, thus the risk of bias was deemed
to be unclear.
Effects of interventions
See: Summary of findings for the main comparison
CANNABIS REDUCTION: ADJUNCT PSYCHOLOGICAL
THERAPY versus TREATMENT AS USUAL for schizophrenia;
Summary of findings 2 CANNABIS REDUCTION:
PSYCHOLOGICAL THERAPY (SPECIFICALLY ABOUT
CANNABIS AND PSYCHOSIS) versus NON-SPECIFIC
PSYCOEDUCTION for schizophrenia; Summary of findings
3 CANNABIS REDUCTION: ANTIPSYCHOTIC ’A’
versus ANTIPSYCHOTIC ’B’ for; Summary of findings
4 CANNABINOID AS TREATMENT: CANNABIDIOL
compared with AMISULPRIDE for SCHIZOPHRENIA
We calculated risk ratios (RR) for dichotomous data and estimated
mean differences (MD) for continuous data, with their respective
95% confidence intervals (CIs) throughout.
COMPARISON 1: CANNABIS REDUCTION:
ADJUNCT PSYCHOLOGICAL THERAPY versus
TREATMENT AS USUAL
1.1 Behaviour: Cannabis use: 1. Frequency of use (ASI,
group-based therapy, high = bad)
1.1.1 in past 30 days - by medium term
One relevant trial (n = 54) (Madigan 2012) provided data. There
was no significant difference between reduction in ASI for treat-
ment as usual and psychological therapy and treatment as usual (1
RCT n = 54, MD -0.10 CI -2.44 to 2.24, Analysis 1.1).
1.2 Behaviour: Cannabis use: 2. Number of joints of cannabis
in preceding month (skewed data)
One relevant trial (Hjorthoj 2013) reported data for this outcome.
However, these data were heavily skewed and are best inspected
by viewing Analysis 1.2.
1.3 Behaviour: Cannabis use: 3. Number of days abstinent
/last month (skewed data)
One relevant trial (Bonsack 2011) reported data for this outcome.
However, these data were heavily skewed and are best inspected
by viewing Analysis 1.3
1.4 Behaviour: Cannabis use: 4. Number of days binge use
(skewed data)
One relevant trial (Bonsack 2011) reported data for this outcome.
However, these data were heavily skewed and are best inspected
by viewing Analysis 1.4
1.5 Mental state: 1. Average depressive symptom score
(CDSS, skewed data)
One relevant trial (Madigan 2012) reported data for this outcome.
However these data were heavily skewed and are best inspected by
viewing Analysis 1.5.
1.6 Mental state: 2. Average insight score (Birchwood Insight
Scale, higher = better)
1.6.1 medium term
One relevant trial (n = 58) (Madigan 2012) provided data. There
was no significant difference between Birchwood Insight Scale for
treatment as usual and psychological therapy and treatment as
usual (1 RCT n = 58, MD 1.10 CI -0.18 to 2.38, Analysis 1.6).
1.6.2 long term
One relevant trial (n = 46) (Madigan 2012) provided data. There
was no significant difference between Birchwood Insight Scale for
treatment as usual and psychological therapy and treatment as
usual (1 RCT n = 46, MD 0.40 CI -0.88 to 1.68, Analysis 1.6).
1.7 Mental state: 3. Average negative symptom score
(PANSS, higher score = poor)
1.7.1 medium term - three months
Data from one relevant trial (n = 62) (Bonsack 2011) showed no
significant difference between reduction in PANSS for treatment
as usual and psychological therapy and treatment as usual (1 RCT
n = 62, MD -0.10 CI -2.06 to 1.86, Analysis 1.7).
1.7.2 medium term - six months
Data from one relevant trial (n = 62) (Bonsack 2011) showed no
significant difference between reduction in PANSS for treatment
as usual and psychological therapy and treatment as usual (1 RCT
n = 62, MD 0.00 CI -1.80 to 1.80, Analysis 1.7).
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1.7.3 long term - 12 months
Data from one relevant trial (n = 62) (Bonsack 2011) showed
no statistically significant difference between reduction in PANSS
for treatment as usual and psychological therapy and treatment as
usual (1 RCT n = 62, MD -1.20 CI -3.19 to 0.79, Analysis 1.7).
1.8 Mental state: 4.a. Average positive symptom score
(SAPS, skewed data)
One relevant trial (1 RCT n = 49) (Madigan 2012) reported data
for this outcome. However, these data were heavily skewed and
are best inspected by viewing Analysis 1.8.
1.9 Mental state: 4.b. Average positive symptom score
(SANS, skewed data)
One relevant trial (1 RCT n = 49) (Madigan 2012) reported data
for this outcome. However, these data were heavily skewed and
are best inspected by viewing Analysis 1.9.
1.10 Mental state: 4.c. Average positive symptom score
(PANSS, higher score = poor)
1.10.1 medium term - three months
One relevant trial (n = 62) (Bonsack 2011) provided data. There
was no significant difference between reduction in PANSS for
treatment as usual and psychological therapy and treatment as
usual (1 RCT n = 62, MD -0.30 CI -2.55 to 1.95, Analysis 1.10).
1.10.2 medium term - six months
Data from one relevant trial (n = 62) (Bonsack 2011) showed no
significant difference between reduction in PANSS for treatment
as usual and psychological therapy and treatment as usual (1 RCT
n = 62, MD -0.10 CI -2.58 to 2.38, Analysis 1.10).
1.10.3 long term - 12 months
Data from one relevant trial (n = 62) (Bonsack 2011) showed
no statistically significant difference between reduction in PANSS
for treatment as usual and psychological therapy and treatment as
usual (1 RCT n = 62, MD -1.20 CI -3.32 to 0.92, Analysis 1.10).
1.11 General functioning: 1. Subjective quality of life (WHO
QOL, brief, higher = better)
1.11.1 medium term
Data from one relevant trial (n = 49) (Madigan 2012) showed no
significant difference betweenWHOQOL for treatment as usual
and psychological therapy and treatment as usual (1 RCT n = 49,
MD 0.90 CI -1.15 to 2.95, Analysis 1.11).
1.11.2 long term
Data from one relevant trial (n = 48) (Madigan 2012) showed no
significant difference betweenWHOQOL for treatment as usual
and psychological therapy and treatment as usual (1 RCT n = 48,
MD 1.50 CI -0.40 to 3.40, Analysis 1.11).
1.12 General functioning: 3. Global functioning (GAF, higher
= better)
1.12.1 medium term - three months
Two relevant trials (n = 120) provided data. There was no signif-
icant difference between GAF for treatment as usual and psycho-
logical therapy and treatment as usual (2 RCTs n = 120, MD -
0.11 CI -2.57 to 2.36, Heterogeneity: Chi² = 0.17, df = 1 (P =
0.68); I² = 0%, Analysis 1.12).
1.12.2 medium term - six months
Data from one relevant trial (n = 62) (Bonsack 2011) showed
no significant difference between GAF for treatment as usual and
psychological therapy and treatment as usual (1 RCT n = 62, MD
-1.00 CI -4.40 to 2.40 Analysis 1.12).
1.12.3 long term
Two relevant trials (n = 109) provided data. There was no signifi-
cant difference between reduction in GAF for treatment as usual
and psychological therapy and treatment as usual (2 RCTs n =
109, MD 1.88 CI -1.09 to 4.85, Heterogeneity: Chi² = 0.27, df
= 1 (P = 0.60); I² = 0%, Analysis 1.12).
1.13 General functioning: 2. Attitude to treatment (DAI,
medium term, skewed data)
One relevant trial (1 RCT n = 49) (Madigan 2012) reported data
for this outcome. However, these data were heavily skewed and
are best inspected by viewing Analysis 1.13
1.14 General functioning: 4. Global functioning (SOFAS,
higher = better)
2.14.1 medium term - three months
Data from one relevant trial (n = 62) (Bonsack 2011) showed no
significant difference between in SOFAS: treatment as usual and
psychological therapy and treatment as usual (1 RCT n = 62, MD
0.10 CI -3.02 to 3.22, Analysis 1.14).
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1.14.2 medium term six months
Data from one relevant trial (n = 62) (Bonsack 2011) showed
no significant difference between SOFAS: treatment as usual and
psychological therapy and treatment as usual (1 RCT n = 62, MD
-0.10 CI -3.63 to 3.43, Analysis 1.14).
1.14.3 long term
Data from one relevant trial (n = 62) (Bonsack 2011) showed
no significant difference between SOFAS: treatment as usual and
psychological therapy and treatment as usual (1 RCT n = 62, MD
2.70 CI -1.08 to 6.48, Analysis 1.14).
COMPARISON 2: CANNABIS REDUCTION:
PSYCHOLOGICAL THERAPY (SPECIFCALLY
ABOUT CANNABIS AND PSYCHOSIS) versus
NON-SPECIFIC PSYCHOEDUCATION
2.1 Behaviour: Cannabis use: 1. Used cannabis in last four
weeks
2.1.1 by three months - end of treatment
One relevant trial (n = 47) (Edwards 2006) provided data. There
was no significant difference between cannabis use: cannabis and
psychosis therapy and psychoeducation (1 RCT n = 47, RR 1.04
CI 0.62 to 1.74, Analysis 2.1).
2.1.2 by nine months - six months after end of treatment
One relevant trial (n = 47) (Edwards 2006) provided data. There
was no significant difference between cannabis use: cannabis and
psychosis therapy and psychoeducation (1 RCT n = 47, RR 1.30
CI 0.79 to 2.15, Analysis 2.1).
2.2 Behaviour: Cannabis use: 2. Percentage days used
cannabis in last four weeks (skewed data)
2.2.1 by three months
Data for this outcome were heavily skewed and are best inspected
by viewing Analysis 2.2.
2.2.2 by nine months
Data for this outcome were heavily skewed and are best inspected
by viewing Analysis 2.2.
2.3 Mental state: 1. Average overall score (BPRS-E total
endpoint, higher scores = poor)
2.3.1 by three months - end of treatment
Data from one relevant trial (n = 47) (Edwards 2006) showed no
significant difference between reduction in average overall BPRS
scores: cannabis and psychosis therapy and psychoeducation (1
RCT n = 47, MD 3.60 CI -5.61 to 12.81, Analysis 2.3).
2.3.2 by nine months - six months after end of treatment
Data from one relevant trial (n = 47) (Edwards 2006) showed no
significant difference between reduction in average overall BPRS
scores: cannabis and psychosis therapy and psychoeducation (1
RCT n = 47, MD -0.80 CI -9.07 to 7.47, Analysis 2.3).
2.4 Mental state: 2. Average overall score (BPRS-PS total
endpoint, higher scores = poor, skewed data)
2.4.1 by three months - end of treatment
Data for this outcome were heavily skewed and are best inspected
by viewing Analysis 2.4.
2.4.2 by nine months - six months after end of treatment
Data for this outcome were heavily skewed and are best inspected
by viewing Analysis 2.4.
2.5 Mental state: 3. Average depression score (BDI-SF total
endpoint , higher scores = poorer, skewed data)
2.5.1 by three months - end of treatment
Data for this outcome were heavily skewed and are best inspected
by viewing Analysis 2.5.
1.3.2 by nine months - six months after end of treatment
Data for this outcome were heavily skewed and are best inspected
by viewing Analysis 2.5.
2.6 Mental state: 4. Average negative symptom score (SANS
endpoint, higher scores = poor, skewed data)
2.6.1 by three months - end of treatment
Data for this outcome were heavily skewed and are best inspected
by viewing Analysis 2.6.
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2.6.2 by nine months - six months after end of treatment
Data for this outcome were heavily skewed and are best inspected
by viewing Analysis 2.6.
2.7 Global state: Average overall score (KAPQ total
endpoint, higher = good)
2.7.1 by three months - end of treatment
Data from one relevant trial (n = 47) (Edwards 2006) showed
no significant difference between KAPQ scores for cannabis and
psychosis therapy and psychoeducation (1 RCT n = 47,MD -0.80
CI -3.38 to 1.78, Analysis 2.7).
2.7.2 by nine months - six months after end of treatment
Data from one relevant trial (n = 47) (Edwards 2006) showed no
significant difference between KAPQ scores: cannabis and psy-
chosis therapy and psychoeducation (1 RCT n = 47, MD -0.90
CI -3.22 to 1.42, Analysis 2.7).
2.8 General functioning: Average score (SOFAS total
endpoint, higher scores = good)
2.8.1 by three months - end of treatment
Data from one relevant trial (n = 47) (Edwards 2006) showed
no significant difference between SOFAS: cannabis and psychosis
therapy and psychoeducation (1 RCT n = 47, MD -0.80 CI -9.95
to 8.35, Analysis 2.8).
2.8.2 by nine months - six months after end of treatment
Data from one relevant trial (n = 47) (Edwards 2006) showed
no significant difference between SOFAS: cannabis and psychosis
therapy and psychoeducation (1 RCT n = 47, MD -4.70 CI -
14.52 to 5.12, Analysis 2.8).
COMPARISON 3: CANNABIS REDUCTION -
ANTIPSYCHOTIC ’A’ versus ANTIPSYCHOTIC ’B’
3.1 Behaviour: Cannabis use: 1. Traces of cannabis
breakdown products in urine (number of patients positive
above threshold level - 100 nanograms, olanzapine versus
risperidone)
One trial (n = 16) (Akerele 2007) provided data.There was no
significant difference between reduction in cannabis use: antipsy-
chotic and antipsychotic (1 RCT n = 16, RR 1.80 CI 0.52 to 6.22,
Analysis 3.1).
3.2 Behaviour: Cannabis use: 2. As defined in each study
(skewed data)
In this outcome we found all three trials relevant to comparison
three to be pertinent (3 RCTs) : van Nimwegen 2008 (n = 41),
Brunette 2011 (n = 31) and Akerele 2007 (n = 16)
3.2.1 Average score per week (Marijuana Craving Report,
high score = poor, olanzapine versus risperidone)
Data for this outcome were heavily skewed and are best inspected
by viewing Analysis 3.2
3.2.2 Self-report scores, joints per week (short term) -
olanzapine versus risperidone
Data for this outcome were heavily skewed and are best inspected
by viewing Analysis 3.2
3.2.3 Intensity of cannabis use (joints per week) - clozapine
versus other antipsychotics
Data for this outcome were heavily skewed and are best inspected
by viewing Analysis 3.2
3.3 Behaviour: Cannabis use: 3. Average score per week
(Marijuana Craving Report, skewed data - olanzapine versus
risperidone)
In this outcome we found only one trial to be relevant (1 RCT):
Akerele 2007 (n = 16). Data for this outcome were heavily skewed
and are best inspected by viewing Analysis 3.3.
3.4 Mental state: Average score (OCDUS, short-term, high
= poor - olanzapine versus risperidone)
In this subgroup we only found one relevant trial (n = 41) (van
Nimwegen 2008). There was no significant difference between
OCDUS for antipsychotic and antipsychotic (1 RCT n = 41, MD
-1.30 CI -6.11 to 3.51, Analysis 3.4).
3.5 Adverse effects: 1. Anticholinergic - various (clozapine
versus other antipsychotic)
3.5.1 constipation
In this subgroupwe only foundone relevant trial (n =30) (Brunette
2011). There was no significant difference in constipation: an-
tipsychotic and antipsychotic (1 RCT n = 30, RR 9.00 CI 0.53 to
153.79, Analysis 3.5).
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3.5.2 nasal congestion
In this subgroupwe only foundone relevant trial (n =31) (Brunette
2011). There was no significant difference in nasal congestion:
antipsychotic and antipsychotic (1 RCT n = 31, RR 0.21 CI 0.01
to 4.1, Analysis 3.5).
3.5.3 salivation - too much
In this subgroupwe only foundone relevant trial (n =31) (Brunette
2011). There no was a statistically significant difference in saliva-
tion: antipsychotic and antipsychotic (1 RCT n = 31, RR 22.31
CI 1.42 to 350.31, Analysis 3.5).
3.5.4 salivation - too little
In this subgroupwe only foundone relevant trial (n =31) (Brunette
2011). There was no significant difference in salivation: antipsy-
chotic and antipsychotic (1 RCT n = 31, RR 1.07 CI 0.17 to 6.64,
Analysis 3.5).
3.5.5 urinary incontinence
In this subgroupwe only foundone relevant trial (n =31) (Brunette
2011). Therewas no significant difference in urinary incontinence:
antipsychotic and antipsychotic (1 RCT n = 31, RR 5.31 CI 0.28
to 102.38, Analysis 3.5).
3.6 Adverse effects: 2. Cardiac - various (clozapine versus
other antipsychotic)
3.6.1 hypertension
In this subgroupwe only foundone relevant trial (n =30) (Brunette
2011). There was no significant difference between hypertension:
antipsychotic and antipsychotic (1 RCT n = 30, RR 1.00 CI 0.16
to 6.20, Analysis 3.6).
3.7 Adverse effects: 3. Central nervous system/higher
functions - various (clozapine versus other antipsychotic,
number of events)
3.7.1 agitation - increased
In this subgroupwe only foundone relevant trial (n =30) (Brunette
2011). There was no significant difference in agitation antipsy-
chotic and antipsychotic (1 RCT n = 30, RR 1.00 CI 0.07 to
14.55, Analysis 3.7).
3.7.2 depression
In this subgroupwe only foundone relevant trial (n =30) (Brunette
2011). There was no significant difference in depression: antipsy-
chotic and antipsychotic (1 RCT n = 30, RR 2.00 CI 0.20 to
19.78, Analysis 3.7).
3.7.3 dizziness
In this subgroupwe only foundone relevant trial (n =31) (Brunette
2011). There was no significant difference in dizziness: antipsy-
chotic and antipsychotic (1 RCT n = 31, RR 5.33 CI 0.70 to
40.54, Analysis 3.7).
3.7.4 dreams - unusual dream activity
In this subgroupwe only foundone relevant trial (n =31) (Brunette
2011). There was no significant difference between in unusual
dream activity: antipsychotic and antipsychotic (1 RCT n = 31,
RR 0.21 CI 0.01 to 4.10, Analysis 3.7).
3.7.5 fatigue
In this subgroupwe only foundone relevant trial (n =31) (Brunette
2011). There was no significant difference between reduction in
cannabis use: antipsychotic and antipsychotic (1 RCT n = 31, RR
7.44 CI 0.42 to 132.95, Analysis 3.7).
3.7.6 irritability
In this subgroupwe only foundone relevant trial (n =31) (Brunette
2011). There was no significant difference between reduction in
cannabis use: antipsychotic and antipsychotic (1 RCT n = 31, RR
1.07 CI 0.07 to 15.57, Analysis 3.7).
3.7.7 libido - decreased
One relevant trial (n = 31) (Brunette 2011) provided data. There
was no significant difference between reduction in cannabis use:
antipsychotic and antipsychotic (1 RCT n = 31, RR 1.07 CI 0.07
to 15.57, Analysis 3.7).
3.7.8 sleep - too much
One relevant trial (n = 31) (Brunette 2011) provided data. There
was a statistically significant difference between reduction in
cannabis use: antipsychotic and antipsychotic (1 RCT n = 31, RR
4.80 CI 1.23 to 18.71, Analysis 3.7).
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3.7.9 sleep - insomnia
One relevant trial (n = 31) (Brunette 2011) provided data. There
was no significant difference in insomnia: antipsychotic and an-
tipsychotic (1 RCT n = 31, RR 2.13 CI 0.22 to 21.17, Analysis
3.7).
3.7.10 suicide attempt
One relevant trial (n = 31) (Brunette 2011) provided data. There
was no significant difference in suicide attempts: antipsychotic and
antipsychotic (1 RCT n = 31, RR 1.07 CI 0.07 to 15.57, Analysis
3.7).
3.8 Adverse effects: 4. Gastrointestinal - various (clozapine
versus ’other antipsychotic’, number of events)
3.8.1 nausea
Data from one relevant trial (n = 31) (Brunette 2011) showed no
significant difference in nausea: antipsychotic and antipsychotic
(1 RCT n = 31, RR 2.13 CI 0.22 to 21.17, Analysis 3.8).
3.8.2 vomiting
Data from one relevant trial (n = 31) (Brunette 2011) showed no
significant difference vomiting in cannabis use: antipsychotic and
antipsychotic (1 RCT n = 31, RR 1.07 CI 0.25 to 4.49, Analysis
3.8).
3.9 Adverse effects: 5. Metabolic - weight gain (clozapine
versus ’other antipsychotic’, number of events)
One relevant trial (Brunette 2011) provided data. There was no
significant difference in weight gain cannabis use: antipsychotic
and antipsychotic (1 RCT n = 31, RR 3.20 CI 0.76 to 13.46,
Analysis 3.9).
3.10 Adverse effects: 6. a. Movement disorders - various
(clozapine versus ’other antipsychotic’, number of events)
3.10.1 agitation - increased
One relevant trial (n = 30) (Brunette 2011) provided data. There
was no significant difference in agitation: antipsychotic and an-
tipsychotic (1 RCT n = 30, RR 1.00 CI 0.07 to 14.55, Analysis
3.10).
3.10.2 akathisia
One relevant trial (n = 31) (Brunette 2011) provided data. There
was no significant difference in akathisia: antipsychotic and an-
tipsychotic (1 RCT n = 31, RR 1.07 CI 0.07 to 15.57, Analysis
3.10).
3.10.3 muscle spasms
One relevant trial (n = 31) (Brunette 2011) provided data. There
was no significant difference in muscle spasms: antipsychotic and
antipsychotic (1 RCT n = 31, RR 5.31 CI 0.28 to 102.38, Analysis
3.10).
3.11 Adverse events: 6. b. Movement disorders - average
score (Simpson scale, high score = poor)
3.11.1 olanzapine versus risperidone
Data from one relevant trial (n = 16) (Akerele 2007) showed no
significant difference in Simpson scale: antipsychotic and antipsy-
chotic (1 RCT n = 16, MD 0.08 CI -1.06 to 1.22, Analysis 3.11).
3.12 Adverse effects: 7. Others - various (clozapine versus
’other antipsychotic’, number of events)
3.12.1 chest pain - non-cardiac
Data from one relevant trial (n = 31) (Brunette 2011) showed
no significant difference in chest pain: antipsychotic and antipsy-
chotic (1 RCT n = 31, RR 0.53 CI 0.05 to 5.29, Analysis 3.12).
3.12.2 flu-like symptoms
One relevant trial (n = 31) (Brunette 2011) provided data. There
was no significant difference reduction in flu like symptoms: an-
tipsychotic and antipsychotic (1 RCT n = 31, RR 0.21 CI 0.01 to
4.10, Analysis 3.12).
3.12.3 headache
One relevant trial (n = 31) (Brunette 2011) provided data. There
was no significant difference in headache: antipsychotic and an-
tipsychotic (1 RCT n = 31, RR 2.13 CI 0.22 to 21.17, Analysis
3.12).
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3.13 Leaving the study early: 1. Reasons - Olanzapine versus
Risperidone (number of patients leaving)
3.13.1 admission
One relevant trial (n = 28) (Akerele 2007) provided data. There
was no significant difference in hospital admission: antipsychotic
and antipsychotic (1 RCT n = 28, RR 1.00 CI 0.07 to 14.45,
Analysis 3.13).
3.13.2 any
Data from one relevant trial (n = 28) (Akerele 2007) showed no
significant difference leaving the study for any reason cannabis
use: antipsychotic and antipsychotic (1 RCT n = 28, RR 0.50 CI
0.19 to 1.29, Analysis 3.13).
3.13.3 intolerable adverse effects
Data from one relevant trial (n = 28) (Akerele 2007) showed there
was a statistically significant difference between intolerable adverse
effects: antipsychotic and antipsychotic (1 RCT n = 28, RR 0.00
CI 0.00 to 0.00, Analysis 3.13).
3.13.4 not interested
Data from one relevant trial (n = 28) (Akerele 2007) showed there
was no significant difference between leaving the study due to be
not being interested: antipsychotic and antipsychotic (1 RCT n =
28, RR 0.43 CI 0.14 to 1.33, Analysis 3.13).
3.14 Leaving the study early: 2. Time in treatment (weeks)
3.14.1 olanzapine versus risperidone
Data from one relevant trial (n = 28) (Akerele 2007) showed there
was no significant difference between time in treatment: antipsy-
chotic and antipsychotic (1 RCT n = 28, MD 0.00 CI -3.35 to
3.35, Analysis 3.14).
COMPARISON 4: CANNABINOID AS TREATMENT
- CANNABIDIOL versus AMISULPRIDE
4.1 Mental state: 1. a. Average overall score (BPRS, total
endpoint, higher scores = poor)
4.1.1 Day 7 - short term
In this subgroup we only found one relevant trial (n = 39) (Leweke
2012). Therewas no significant difference inBPRS for cannabidiol
and amisulpride (1 RCT n = 39, MD -1.50 CI -6.54 to 3.54,
Analysis 4.1).
4.1.2 Day 14 - short term
In this subgroup we only found one relevant trial (n = 39) (Leweke
2012). There was no significant difference between in BPRS for
cannabidiol and amisulpride (1 RCT n = 39, MD 1.80 CI -4.61
to 8.21, Analysis 4.1).
4.1.3 Day 21 - short term
In this subgroup we only found one relevant trial (n = 34) (Leweke
2012). There was no significant difference in BPRS between
cannabidiol and amisulpride (1 RCT n = 34, MD 4.20 CI -4.24
to 12.64, Analysis 4.1).
4.1.4 Day 28 - short term
In this subgroup we only found one relevant trial (n = 35) (Leweke
2012). There was no significant difference in BPRS between
cannabidiol and amisulpride (1 RCT n = 35, MD 1.10 CI -8.18
to 10.38, Analysis 4.1).
4.2 Mental state: 1. b. Average overall score (PANSS, total
endpoint, higher scores = poor)
4.2.1 day 14 (short term)
In this subgroup we only found one relevant trial (n = 39) (Leweke
2012). There was no significant difference in PANSS between
cannabidiol and amisulpride (1 RCT n = 39, MD 0.00 CI -10.10
to 10.10, Analysis 4.2).
4.2.2 day 28 (short term)
In this subgroup we only found one relevant trial (n = 35) (Leweke
2012). There was no significant difference in PANSS between
cannabidiol and amisulpride (1 RCT n = 35, MD 0.40 CI -13.42
to 14.22, Analysis 4.2).
4.3 Mental state: 2. Average negative symptom score
(PANSS, higher score = poor)
4.3.1 Day 14 - short term
In this subgroup we only found one relevant trial (n = 39) (Leweke
2012). There was no significant difference in PANSS between
cannabidiol and amisulpride (1 RCT n = 39, MD 1.20 CI -2.13
to 4.53, Analysis 4.3).
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4.3.2 Day 28 - short term
In this subgroup we only found one relevant trial (n = 35) (Leweke
2012). There was no significant difference in PANSS between
cannabidiol and amisulpride (1 RCT n = 35, MD 2.70 CI -0.92
to 6.32, Analysis 4.3).
4.4 Mental state: 3. Average positive symptom score
(PANSS, higher score = poor)
4.4.1 Day 14 - short term
In this subgroup we only found one relevant trial (n = 39) (Leweke
2012). There was no significant difference in PANSS between
cannabidiol and amisulpride (1 RCT n = 39, MD 1.20 CI -1.85
to 4.25, Analysis 4.4).
4.4.2 Day 28 - short term
In this subgroup we only found one relevant trial (n = 35) (Leweke
2012). There was no significant difference in PANSS between:
cannabidiol and amisulpride (1 RCT n = 35, MD 0.60 CI -3.92
to 5.12, Analysis 4.4).
4.5 Adverse effects: 1. Endocrine - prolactin (µg/L, short
term)
Data for this outcome were heavily skewed and are best inspected
by viewing Analysis 4.5.
4.6 Adverse effects: 2. Metabolic - weight gain (kg, short
term)
Data for this outcome were heavily skewed and are best inspected
by viewing Analysis 4.6.
4.7 Adverse effects: 3. Movement disorders - change in
extrapyramidal symptoms (EPS, short term)
Data for this outcome were heavily skewed and are best inspected
by viewing Analysis 4.7.
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A D D I T I O N A L S U M M A R Y O F F I N D I N G S [Explanation]
REDUCTION IN CANNABIS USE: ‘‘CANNABIS AND PSYCHOSIS THERAPY’’ versus PSYCHOEDUCATION
Patient or population: pat ients with SCHIZOPHRENIA AND CANNABIS USE
Settings: Outpat ient
Intervention: CANNABIS AND PSYCHOSIS THERAPY
Comparison: PSYCHOEDUCATION
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of Participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
PSYCHOEDUCATION CANNABIS
WITHDRAWAL:
CANNABIS AND PSY-
CHOSIS THERAPY
Behaviour: Cannabis
use: Used cannabis in
last 4 weeks - medium
term
Cannabis use
Follow-up: 6 months
Study population RR 1.04
(0.62 to 1.74)
47
(1 study)
⊕⊕⊕©
moderate1
542 per 1000 563 per 1000
(336 to 943)
M oderate
542 per 1000 564 per 1000
(336 to 943)
M ental state: 1. Av-
erage score (BPRS-E
total endpoint, higher
scores = poor) -
medium term
BPRS-E. Scale f rom: 0
to 168.
Follow-up: mean 6
months
The mean mental state:
1. average score (BPRS-
E total endpoint, higher
scores = poor) -
medium term in the
control groups was
47.7 Points
The mean mental state:
1. average score (BPRS-
E total endpoint, higher
scores = poor) -
medium term in the in-
tervent ion groups was
3.60 lower
(12.81 lower to 5.61
higher)
47
(1 study)
⊕⊕⊕©
moderate1
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Global state: relapse -
medium term - not re-
ported
See comment See comment Not est imable - See comment
General functioning:
no clinically impor-
tant change in general
functioning - medium
term - not reported
See comment See comment Not est imable - See comment
Adverse effects: no
clinically important ad-
verse effects - medium
term - not measured
See comment See comment Not est imable - See comment
Leaving the study early
- medium term - not re-
ported
See comment See comment Not est imable - See comment
Satisfaction with treat-
ment - medium term -
not measured
See comment See comment Not est imable - See comment
* The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% conf idence interval) is
based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95% CI).
CI: Conf idence interval; RR: Risk rat io;
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our conf idence in the est imate of ef fect.
M oderate quality: Further research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: Further research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: We are very uncertain about the est imate.
1 Imprecision: rated ’serious’ - only one study included with few part icipants, few events and wide conf idence intervals.
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REDUCTION IN CANNABIS USE: ANTIPSYCHOTIC compared with ANTIPSYCHOTIC
Patient or population: pat ients with SCHIZOPHRENIA.
Settings: Inpat ient, outpat ient.
Intervention: ANTIPSYCHOTIC versus ANTIPSYCHOTIC
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of Participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
RISPERIDONE vs
CLOZAPINE
OLANZAPINE
Behaviour: Cannabis
use 3: Traces of
cannabis breakdown
products in urine -
medium term
Follow-up: 14 weeks
Study population RR 1.8
(0.52 to 6.22)
16
(1 study)
⊕⊕⊕©
moderate1
333 per 1000 600 per 1000
(173 to 1000)
M oderate
333 per 1000 599 per 1000
(173 to 1000)
* * M ental state: Obses-
sive-Compulsive Drug
Use Scale (OCDUS)
(short- term, higher=
bad) - short term
Scale f rom: 0 to 44.
Follow-up: 6 weeks
2 The mean mental
state: obsessive-com-
pulsive drug use scale
(OCDUS) (short term,
higher = bad) - medium
term in the intervent ion
groups was
1.3 lower
(6.11 lower to 3.51
higher)
41
(1 study)
⊕⊕⊕©
moderate1
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Global state: relapse -
medium term - not mea-
sured
See comment See comment Not est imable - See comment
General functioning:
no clinically impor-
tant change in general
functioning - medium
term - not measured
See comment See comment Not est imable - See comment
Adverse effects: mea-
sured adverse events
- Simpson scale -
medium term
Scale f rom: 0 to 40.
Follow-up: 14 weeks
2 The mean adverse ef -
fects: measured ad-
verse events - Simpson
scale - medium term in
the intervent ion groups
was
0.08 higher
(1.06 lower to 1.22
higher)
2
(1 study)
⊕⊕⊕©
moderate1
Leaving the study
early: any reason -
medium term
Follow-up: 14 weeks
Study population RR 0.5
(0.19 to 1.29)
28
(1 study)
⊕⊕⊕©
moderate1
571 per 1000 286 per 1000
(109 to 737)
M oderate
571 per 1000 285 per 1000
(108 to 737)
Satisfaction with treat-
ment - medium term -
not measured
See comment See comment Not est imable - See comment
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* The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% conf idence interval) is
based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95% CI).
* * Main outcome was specif ied as medium term, however no data was available at this t ime point, and so short term was used instead.
CI: Conf idence interval; RR: Risk rat io;
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our conf idence in the est imate of ef fect.
M oderate quality: Further research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: Further research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: We are very uncertain about the est imate.
1 Imprecision: rated ’serious’ - only one study included with few part icipants, few events and wide conf idence intervals.
2 No control arm - comparison between two antipsychot ics.
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CANNABINOID AS TREATM ENT: CANNABIDIOL compared with AM ISULPRIDE for SCHIZOPHRENIA
Patient or population: pat ients with SCHIZOPHRENIA
Settings: Inpat ient
Intervention: CANNABIDIOL
Comparison: AMISULPRIDE
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of Participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
AM ISULPRIDE CANNABIDIOL
Behaviour: Cannabis
use: 1. frequency of
use (group-based ther-
apy) (high = bad) -
medium term - not mea-
sured
See comment See comment Not est imable - See comment not measured
M ental state: PANSS
total (high = bad) -
medium term - not mea-
sured
See comment See comment Not est imable - See comment not measured
Global state: relapse -
medium term - not mea-
sured
See comment See comment Not est imable - See comment not measured
General functioning:
no clinically impor-
tant change in general
functioning - medium
term - not measured
See comment See comment Not est imable - See comment not measured
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Adverse effects: mea-
sured adverse events -
medium term - not mea-
sured
See comment See comment Not est imable - See comment not measured
Leaving the study
early: any reason -
medium term - not mea-
sured
See comment See comment Not est imable - See comment not measured
Satisfaction with treat-
ment - medium term -
not measured
See comment See comment Not est imable - See comment not measured
* The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% conf idence interval) is
based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95% CI).
CI: Conf idence interval;
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our conf idence in the est imate of ef fect.
M oderate quality: Further research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: Further research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: We are very uncertain about the est imate.
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D I S C U S S I O N
1. The search
The Cochrane Schizophrenia Group’s register of trials is the most
comprehensive register of its kind. It is compiled by searching
mainstream and less well known bibliographic databases and from
manual searches of key journals and conference proceedings. We
were able to include eight studies and found one additional study
(D’Souza 2005), which was added to awaiting assessment whilst
further information is sought. Trials published in languages other
than English (we found no studies published in any language other
than English), and those with equivocal results are often difficult
to find, and our search relied heavily on English phrases. However,
it seems unlikely that well designed and reported randomised trials
went unnoticed.
Summary of main results
1. COMPARISON 1: CANNABIS REDUCTION:
ADJUNCT PSYCHOLOGICAL THERAPY versus
TREATMENT AS USUAL
This section of the review compared treatment as usual versus
psychological intervention specifically targeted at cannabis use (to
encourage reduction in cannabis consumption) combined with
treatment as usual. For a summary of the primary outcomes of
interest and ratings of the quality of the evidence for each com-
parison, view Summary of findings for the main comparison.
1.1 Behaviour: Cannabis use
The main aim of the three studies selected was to see if there was a
decrease in cannabis consumption and if there was any subsequent
improvement in schizophrenia symptoms, however the compari-
son suffered due to the trials being small and little data were di-
rectly comparable. None of the studies demonstrate any signifi-
cant difference between treatment as usual and the psychological
intervention being tested for outcomes of cannabis use; mental
state or general functioning.
The majority of the data for this outcome was skewed.
1.2 General functioning
For one of the four subgroup outcomes the data were skewed. Each
outcome was reported by a single paper, as such it is difficult to
make any meaningful conclusion. None of the outcomes showed a
significant difference in general functioningbetweenpsychological
intervention and treatment as usual.
1.3 Mental state
All the data for mental state from Bonsack 2011 was skewed; the
remaining data were from Madigan 2012. Again, no significant
difference was found between the two treatments.
The studies ranged in size from n = 103 to n = 44; and only three
could be included, the small size and small number of studies
means that it is difficult to draw meaningful conclusions from the
studies
There were seven other studies that could have been included on
the basis of our inclusion criteria, but they could not be included
as the data were not provided in time for publication of the re-
view. Several of the trials involved people with schizophrenia with
multiple drug consumption, and although they were stratified for
cannabis use, the stratified data were not available at time of pub-
lication.
More research needs to be conducted to see if the extra psycho-
logical interventions improve outcomes, as the data stand at the
moment, they provide no evidence of improvement.
2. COMPARISON 2: CANNABIS REDUCTION:
PSYCHOLOGICAL THERAPY (SPECIFICALLY
ABOUT CANNABIS AND PSYCHOSIS) versus
NON-SPECIFIC PSYCHOEDUCATION
This section of the review compared cannabis and psychosis ther-
apy versus psychoeducation. For a summary of the primary out-
comes of interest and ratings of the quality of the evidence for each
comparison, view Summary of findings 2.
2.1 Cannabis use
The key aim of this study was to minimise the usage of cannabis
in people with first episode psychosis. None of the outcomes re-
vealed any significant difference between groups. Had the study
been larger, differences may have emerged. Given the lack of trial-
based data in this area this study provides a welcome appraisal, and
hopefully more studies will shed light on the impact of cannabis
in people with psychoses.
2.2 Global state
The Knowledge About Psychosis Questionnaire (KAPQ) ques-
tionnaire was used to inform participants about psychosis, but did
not reveal any differences in the groups understanding at the three-
and nine-month assessment points. It is possible that the lack of
significant differences to emerge may, in part, have been due to
using an active control group.
2.3 Mental state
From the available data on the positive symptoms of psychosis
measured with the Brief Psychiatric Rating Scale (BPRS) scale,
no differences emerged that demonstrated an overall benefit for
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Cannabis and Psychosis (CAP) therapy compared with psychoe-
ducation. Other scales were used but these reported skewed data
which we had pre-stated we would not use due to too much in-
consistency.
2.4 Social functioning
The participants’ social functioning did not improve in either
group during the trial whilst interventions were given for three
months, or at the follow-up stage six months later.
3. COMPARISON 3: CANNABIS REDUCTION -
ANTIPSYCHOTIC ’A’ versus ANTIPSYCHOTIC ’B’
This section of the review compared antipsychotic medication in
those with schizophrenia and who used cannabis, comparing the
ability to alter the amount of cannabis consumed, and compar-
ing antipsychotic side-effect profile in specifically that group of
patients. For a summary of the primary outcomes of interest and
ratings of the quality of the evidence for each comparison, view
Summary of findings 3.
3.1 Cannabis use
The objective of the three trials that measured the impact of an-
tipsychotics on cannabis usage was to deduce whether use and/or
cravings subsided differentially when comparing exposure to cer-
tain drugs. In none of the outcomes did any study provide evidence
for significant differences between groups. Each trial was limited
by a small sample size and skewed data, therefore reliable con-
clusions regarding the comparative effect of antipsychotics cannot
be drawn. In Brunette 2011, data suggest therapy with clozapine
may reduce cannabis use more than treatment as usual among pa-
tients with schizophrenia and co-occurring cannabis use disorder,
however data are skewed and the sample size small. There appears
to be scope for further exploration of the comparative utility of
antipsychotics in future trials with larger sample sizes.
3.2 Adverse events
Two trials recorded the adverse effects of interventions that relate
to this comparison. In Brunette 2011, significant differences in
somnolence and hypersalivation were observed that suggest cloza-
pine associates with better outcomes here. In all other adverse ef-
fects measured in Brunette 2011 there were no significant differ-
ences between groups, however in several instances (including con-
stipation, weight gain and dizziness), the differences were almost
significant. In Akerele 2007, there was no significant difference in
terms of movement disorders between groups using the Simpson-
Angus Scale; the study noted that sedation was reported as the
most common side effect by both groups; however no patient was
withdrawn due to side effects, suggesting a limited need for future
investigations into the comparative side effects of olanzapine and
risperidone in this context.
3.3 Leaving the study early
There were no significant differences in time until dropout in
the olanzapine and risperidone groups in Akerele 2007, and nor
were there any significant differences in the reasons for dropout
between participants across the two groups. In neither group were
intolerable side effects cited by participants as a reason for dropping
out. Future trialswith larger sample sizesmay be better able to elicit
differences in motivations for dropping out amongst participants.
3.4 Mental state
In vanNimwegen 2008 there were no significant differences found
between groups relating to the Obsessive-Compulsive Drug Use
Scale (OCDUS),which pertains to craving for cannabis. The study
noted that most of the changes associated with the scale took place
in the first week of the trial, thus a trial extension is unlikely to have
uncovered further changes. Measures of changes in mental state
relating to cannabis craving that affects usage would be welcome
in future studies.
4. COMPARISON 4: CANNABINOID AS
TREATMENT - CANNABIDIOL versus
AMISULPRIDE
This section of the review compared treatment of schizophrenia
with cannabidiol versus amisulpride. For a summary of the primary
outcomes of interest and ratings of the quality of the evidence for
each comparison, view Summary of findings 4.
4.1 Mental state
Leweke 2012 recorded data relating to mental state outcomes.
BPRS total endpoint scores appear to favour cannabinoid com-
pared to amisulpride at 7 days, however the difference in scores was
not significant and this slight advantage for cannabinoid was not
apparent at day 14, 21 and 28. Leweke 2012 also measuredmental
state using the PANSS and found no found differences in mental
state using this scale. The apparent difference in mental state at
7 days is an interesting finding, as there is some slight suggestion
that cannabidiol may be have some antipsychotic characteristics,
however this result is based on one short term follow-up and from
a very small trial, this overall lack of effect may have been because
there was a lack of power to detect a difference in this one very
small study. Future studies into its mechanism, efficacy and clin-
ical viability could be of great benefit regarding its potential role
as an antipsychotic. Furthermore, research into its antipsychotic
role within cannabis could help explain more about associations
between cannabis and schizophrenia.
4.2 Adverse effects
In relation to adverse effects, (Leweke 2012) the side-effect profile
for cannabidiol appears to be superior to that of amisulpride. The
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data are heavily skewed however, thus future studies would be
required to clarify whether this is the case.
Overall completeness and applicability of
evidence
1. Completeness
Overall, the completeness of evidence was poor; for two compar-
isons only three of the seven main outcomes were reported, one
comparison had two outcomes, and one comparison had no data
for any of the seven main outcomes.
There was also a lack of trials for each comparison and for each
main outcome; generally there was only one trial for each outcome.
The trials were all of moderate quality.
2. Applicability of evidence
Generally the evidence was applicable, all the trials involved pa-
tients who were diagnosed on the basis of international standard-
ised diagnostic criteria. All trials took place in developed countries.
It is assumed that the healthcare standard amongst these countries
is broadly similar; however there are differences in funding struc-
ture of health care within these group of countries (private versus
publicly funding health care), the main divide being between tri-
als conducted within the United States of America and Western
Europe. It is unclear whether these differences in funding would
make comparison between trials more difficult. However the lack
of comparable data limited the applicability of the evidence to
consumers, health professionals and policy makers.
Quality of the evidence
In general, the quality of the evidence was moderate: the main
issue with the data were lack of multiple studies, there was usually
only one randomised controlled trial (RCT) for each analysis, thus
reducing the ability to draw a conclusion. There was also an issue
with skewed data. The lack of data are the main limitation with
this review.
Generally the trials did attempt to follow the CONSORT state-
ment, however none of the trials adhered very well to the state-
ment, and as a result there was a lack of transparency in several
studies, where certain steps or processes within the trial were not
clear to the reader. Some trials were excluded due to this lack of
transparency, we attempted to contact the authors in order to clar-
ify data or methodology but in several cases no reply was given.
Overall, this review encountered low levels of bias in the studies
fit for inclusion. (See Figure 4 and Figure 5.) Potential exceptions
occurred in one trial that was funded by a company with pecuniary
interest in the result.The only other notable area of bias came
where blinding was disrupted or not carried out, this occurred in
two trials. Please see the GRADE rating in Summary of findings
for the main comparison; Summary of findings 2; Summary of
findings 3; Summary of findings 4.
Potential biases in the review process
There were changes between the first published protocol and the
protocol we published above. The key differences were that we
partially changed the primary outcomes: we kept relapse and clin-
ically important mental state change; but we did remove hospital-
isation. We did this before conducting the review, so any potential
bias would be considered unlikely: it would not have affected the
selection process of the trials, but it will have changed the results
in the discussion. We did not remove or add any main outcomes,
however we reordered them, and reclassified death under adverse
events,. We also changed the time period for the primary out-
comes so that they were all medium term - this was to avoid any
ambiguity and to reduce the risk of bias in carrying out the review.
Further, we grouped the outcomes within different timeframes of
short, medium and long term; this was to ensure applicability of
data, and to ensure fair comparison.
We reworded the comparisons, again to avoid ambiguity and re-
duce risk of bias. In the original protocol, four types of interven-
tion including placebo, cannabinoids, and any other intervention
were simply listed; the updated protocol reorganised those four
interventions into two specific comparisons: firstly: looking into
interventions which affected cannabis use and secondly interven-
tion which involved giving any form of cannabinoids. We believe
that did not affect which papers were included in the study, al-
though we did remove the vague intervention of “any other”; there
were no papers which we screened that would have come under
this category.
There are noknownconflicts of interest amongst the authors, none
of the authors received any direct funding for the completion of
this review.
Agreements and disagreements with other
studies or reviews
The scope of this review focuses specifically on schizophrenia and
cannabis, an area not directly dealt with by any other reviews. One
key review that demonstrates some overlap in findings is Hunt
2013, which agrees overall with the conclusions made in Com-
parison 2 of this review: that not any one psychosocial treatment
is favourable in reducing substance abuse or mental state in peo-
ple with severe mental illnesses. The specific nature of this review
means that there is little wider overlap with other studies and re-
views.
A U T H O R S ’ C O N C L U S I O N S
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Implications for practice
The question most frequently asked in reference to the relation-
ship between cannabis and schizophrenia is that of whether using
cannabis increases the chance of suffering the disorder. However,
due to the nature of data available at the time of writing, this review
focusses primarily on interventions directed at reducing cannabis
use in people with schizophrenia and whether cannabinoids re-
duce symptoms. There are not enough data to answer these ques-
tions.
1. For people with schizophrenia
Cannabis could relieve some of the psychological difficulties that
come as part of the illness of schizophrenia, or as reaction to having
schizophrenia. However, taking this compound could also make
things worse. The evidence is just not clear from the trials. It would
seem reasonable that people with schizophrenia who are being
advised to stop their cannabis use, when no clear detrimental effect
is evident, require better evidence from researchers. People who
have schizophrenia and want to stop their cannabis use should also
expect better evidence around techniques by which this is assisted.
2. For clinicians
For some people with schizophrenia, cannabis use clearly makes
’positive’ symptoms worse. For many, however, using cannabis
seems only to have the expected mild soporific effects that prob-
ably compound ’negative’ symptom languor. Trial-based research
is so limited that it is uninformative. Whether adding the drug is
harmful - or helpful is unclear. How best to help people stop when
they ask for help in doing so is not well-researched. There is much
work to be done.
3. For policy makers
Adjunctive use of cannabinoid drugs for peoplewith schizophrenia
is experimental. Techniques to help people reduce or stop the
cannabis are poorly tested.
Implications for research
1. General
Public registration of a study before participants are randomised
would ensure that participants could be confident that people
would know that the study had at least taken place. Strict com-
pliance with CONSORT (Moher 2001), both on the part of au-
thors and editors, would help to clarify methodology and ensure
outcomes are reported in a manner that is accessible and usable
to others. Failure to comply with CONSORT guidelines results
in loss of data and confusion in results, neither of which helps
clinicians, patients, managers or researchers.
2. Methods
Future trials should ensure that a clear description of the inter-
ventions are given. Such a study would only be meaningful if un-
dertaken within usual resources available to routine care and mea-
sured outcomes of relevance to clinicians and recipients of care
as well as researchers. Study samples should include people with
schizophrenia and closely related disorders, or at least allow data
on this group of people to be extracted from the paper. Trials con-
ducted in the future would also benefit from increased sample sizes
to corroborate study findings.
3. Data
Future trials should ensure that data are presented clearly and
thoroughly, which would ensure that it was available for analysis
and interpretation. Often data have been inconsistent and miss-
ing, which results in difficulty reaching meaningful conclusions;
reduced clarity and raises suspicion of bias, when perhaps there is
none. We reiterate the importance of researchers to adhere to the
Consort Statement, and support the All Trials campaign to ensure
all data are published.
4. Suggestions for future reviews
See Characteristics of excluded studies and Characteristics of
studies awaiting classification. All studies described within these
tables could be possibly included in future reviews as they match
inclusion criteria, however at the time of review, no usable data
were received and therefore they could not be included.
5. Suggestions for future trials
We recognise that much planning must go into production of a
trial protocol but we have now looked at existing evidence is some
detail and suggest designs for trials to help people with schizophre-
nia stop cannabis (Table 2), and, if intent on continuing to use we
think that investigating the best antipsychotic to employ (specifi-
cally clozapine) could be justified (Table 3).
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Akerele 2007
Methods Allocation: randomised.
Blinding: double blind.
Duration: 14 weeks.
Setting: Harlem Hospital, New York, USA.
Design: randomised controlled trial, parallel.
Funding: National Institute on Drug Abuse, Brain and Behaviour Research Foundation,
Eli Lily
Participants Diagnosis: schizophrenia/schizoaffective disorder plus current co-morbid substance use
problems (DSM-IV).*
N = 28.
Age: mean ~36 years (SD ~10).
Sex: 25 M, 3 F.
Ethnicity: African American (n = 15), White (n = 4), Hispanic (n = 9).
History: not stated.
Included: met DSM-IV criteria for schizophrenia or schizoaffective disorder; met DSM-
IV criteria for current cocaine and/or marijuana abuse or dependence and were using
marijuana at least twice/week, or cocaine at least once/week on average during past 3
months prior to enrolment in study
Excluded: i. pregnant; ii. currently physiologically dependent on alcohol or other drugs;
iii. unstable psychiatric symptomatology; iv. unstable medical condition; v. enzyme func-
tion tests > 3 times upper limit of normal; vi. history of seizures or neuroleptic malignant
syndrome; vii. committed violent crime within past 2 years; viii. not responded to either
olanzapine or risperidone in past; ix. had score > 30 on positive and negative subscales
of PANSS
Consent: written informed consent.
Interventions 1. Olanzapine: dose 5-20 mg/day + 3 visits per week by specialist worker, n = 14
2. Risperidone: dose 3-9 mg/day + 3 visits per week by specialist worker, n = 14
Outcomes Behaviour: Cannabis use - Marijuana Craving Report, cannabis breakdown products
in urine (week 1-6, weekly measurement, proportion of positive patients - above 100
nanograms/mL)
Leaving the study early: time in treatment, reason for attrition
Adverse effects:Movement disorders: Simpson scale (week 6).
Unable to use -
Drug usage: self-report - any drug use (not reported), days of use (no SD), Cocaine
Craving Report (not relevant). Quantitative Substance Use Inventory (no data, not
validated scale)
Mental state: CGI, HAM-D, PANSS (no scores reported).
Compliance with medication: self-report, riboflavin fluorescence (reported as % of dose
omitted, not by person)
Adverse effects: AIMS (not reported by group).
Leaving the study early: time to dropout (not reported).
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Akerele 2007 (Continued)
Notes *Highly screened: complete history and physical examinations, electrocardiogram, lab-
oratory tests (haematology, blood chemistry - including liver function, and blood preg-
nancy test for women); further data were requested, but none received
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Not stratified, 50:50 uniform distribution
of groups of 4” - unclear exactly how ran-
domised
Allocation concealment (selection bias) Unclear risk Not mentioned.
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk Risperidone and olanzapine in gelatin cap-
sules containing riboflavin - unclear if suc-
cessful - not tested
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Unclear if successful - not tested.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Unclear if successful - not tested.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk No indication in report how managed
losses to follow-up.
Selective reporting (reporting bias) High risk Some outcomes reported by group, others
not.
Other bias Unclear risk Funded by company with pecuniary inter-
est in result (Eli Lilly - producers of olan-
zapine)
Bonsack 2011
Methods Allocation: randomised.
Blinding: double blind.
Duration: 12 months.
Setting: University Department of Psychiatry, Lausanne, Switzerland
Design: randomised controlled trial, parallel.
Funding: Swiss Research National.
Participants Diagnosis: DSM IV schizophrenia, schizophreniform disorder, bipolar disorder with
psychotic features, schizoaffective disorder, psychosis not otherwise specified
N = 62.
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Bonsack 2011 (Continued)
Age: range 18 - 35 years; mean ~ 23 years.
Sex: 54 M, 8 F.
Ethnicity: not stated.
History: smoked at least 3 joints/week during the month preceding inclusion
Inclusion: psychosis as specified under diagnosis.
Exclusion: organic brain disease, poor command of French, current alcohol or any other
substance dependence (except nicotine and alcohol)
Consent: Informed consent obtained.
Interventions 1.Treatment as usual (TAU),TAUconsisted of psychiatricmanagement by a clinical team
consisting of a psychiatrist and a nurse/clinical psychologist, with access to community
or inpatient treatment. Treatment included medication, regular visits and rehabilitation,
and standard psychoeducation on substance abuse n = 32
2. Motivational Intervention (MI) + TAU: 4-6 MI sessions; first session consisted of 60
minutes, followed by a feedback session of 45-60 minutes within the next week. 2-4
booster sessions of 30-45 minutes took place during the first 6 months, these sessions
explored the connection between cannabis use and psychosis n = 30
Outcomes Mental State: PANSS score: positive symptoms (3, 6, 12 months); negative symptoms
(3, 6, 12 months)
Behaviour: Cannabis use: Number of days abstinent last month (3, 6, 12 months);
Number of days binge use (3, 6, 12 months)
General functioning: GAF (3, 6, 12 months); SOFAS (3, 6, 12 months)
Unable to use - Readiness to change (data not available).
Notes Further data were requested, full data and response to queries was received
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated allocation.
Allocation concealment (selection bias) Low risk Closed envelopes, kept by member of ad-
ministrative staff.
Blinding (performance bias and detection
bias)
All outcomes
Low risk Assessments by independent parties, par-
ticipants blind.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Assessments by independent parties, par-
ticipants blind.
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Assessments by independent parties, par-
ticipants blind.
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Bonsack 2011 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Low risk Missing data were handled using last obser-
vation carried forward
Selective reporting (reporting bias) Unclear risk Not specified.
Other bias Unclear risk Not specified.
Brunette 2011
Methods Allocation: randomised.
Blinding: single blind, raters blinded.
Duration: 12 weeks.
Setting: outpatients, New Hampshire and South Carolina, USA.
Design: randomised controlled trial, parallel.
Funding: National Institute on Drug Abuse.
Participants Diagnosis: Manual (DSM IV) diagnosis of schizophrenia or schizoaffective disorder and
current cannabis use disorder
N = 31.
Age: range 18 - 65 years; mean ~ 36 years.
Sex: 24 M, 7 F.
Ethnicty: not stated.
History: cannabis use on at least 5 days over the 3 weeks prior to screening
Inclusion: outpatient status prior to randomisation and current treatment with antipsy-
chotic medication other than clozapine
Exclusion: patients taking medication with possible effects on alcohol use; patients with
active, serious medical illness, suicidality, or severe psychiatric instability. Patients for
whom clozapine was contraindicated were also excluded
Consent: not stated.
Interventions 1. Clozapine; 400 mg daily (titrated over 4 weeks), n = 15.
2. Continue with current antipsychotic medication, n = 16.
Outcomes Behaviour: Cannabis use: Intensity of cannabis use (joints per week) (week 0-12, weekly
measurement).
Adverse effects: measured adverse events (% of patients reporting adverse events over 12
weeks)
Unable to use - urine drug (data not available); Substance abuse treatment scale (data not
available); motivation to stop cannabis contemplation ladder scale (data not available);
BPRS (data not available); SANS (data not available); SAS (data not available); AIMS
(data not available); Barnes Akathsia Rating Scale (data not available)
Notes Further data were requested, but none received.
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
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Brunette 2011 (Continued)
Random sequence generation (selection
bias)
Unclear risk Block randomisation by site, yet method
unclear.
Allocation concealment (selection bias) Unclear risk Not specified.
Blinding (performance bias and detection
bias)
All outcomes
High risk Clinicians and participants not blinded.
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Clinicians and participants not blinded.
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Raters making assessments were blinded.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Not specified.
Selective reporting (reporting bias) Unclear risk Not specified.
Other bias Low risk None of the authors report any financial
relationships with commercial interest with
regard to the present study
Edwards 2006
Methods Allocation: randomised, computer-generated, placed in sealed envelopes.
Blinding: single; attempts to maintain rater blindness included use of separate rooms
and admin procedures for staff.
Duration: 3 months intervention phase followed by 6 months of follow-up.
Setting: Early Psychosis Prevention and Intervention Centre (EPPIC) (youth mental
health service), Melbourne, Australia
Design: randomised controlled trial, parallel.
Funding: Victorian Government Department of Human Services.
Participants Diagnosis: first episode psychosis (DSM-IV).
N = 47.
Age: 15-29 years; mean ~ 20.9 years.
Sex: 34 M, 13 F.
Ethnicity: not stated.
History: patients continuing to use cannabis after initial treatment for first episode of
psychosis.
Inclusion criteria: DSM-IV diagnosis of a psychotic disorder (i.e. schizophrenia,
schizophreniform, schizoaffective, delusional disorder, bipolar disorder, major depressive
disorder with psychotic features, psychosis not otherwise stated, brief reactive psychosis.
Exclusion criteria: only participants with at least 10 weeks continuous cannabis usage
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Edwards 2006 (Continued)
prior to study were eligible for study inclusion
Consent: Not stated.
Interventions 1. “Cannabis and Psychosis Therapy”: mean no. of CAP sessions 8, CAP is an indi-
vidually delivered cognitive-behavioural-orientated program delivered in weekly sessions
by trained clinicians over 3 months, involving education about cannabis and psychosis,
motivational interviewing, goal setting, and relapse prevention, n = 23
2. Psychoeducation: mean no. of sessions 8, this was an active control, involving educa-
tion of psychosis,medication and relapse prevention but with no specific discussion of
cannabis, n = 24
Outcomes Mental state: BPRS-E, BPRS-PS, SANS, BDI-SF (measured at baseline, end of study -
3 months, 6 months after end of study).
Global state: KAPQ (measured at baseline, end of study - 3 months, 6 months after end
of study)
Behaviour: Cannabis use: in last 4 weeks; percentage used in last 4 weeks (measured at
baseline, end of study - 3 months, 6 months after end of study).
General functioning: SOFAS (measured at baseline, end of study - 3 months, 6 months
after end of study)
Notes Further data were requested, but none received.
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: ’Randomization codes were com-
puter generated and placed in sealed en-
velopes, managed by a nonclinical
member of the research team.’
Allocation concealment (selection bias) Low risk Quote: ’Attempts to maintain rater blind-
ness included use of separate rooms and
administrative procedures for project staff,
limiting information recorded in clinical
notes, and requesting participants and clin-
icians not to disclose treatment conditions
to raters.’
Blinding (performance bias and detection
bias)
All outcomes
Low risk Quote: ’A single-blind randomised con-
trolled trial.’
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: ’A single-blind randomised con-
trolled trial.’
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: ’Two-way random effects intra-
class correlation coefficients (ICC)with ab-
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Edwards 2006 (Continued)
solute agreement’ were derived at levels
’suggesting excellent reliability.’
Incomplete outcome data (attrition bias)
All outcomes
Low risk Quote: ’Follow-up rates were similar across
intervention conditions.’
Selective reporting (reporting bias) Unclear risk Not specified.
Other bias Unclear risk Not specified.
Hjorthoj 2013
Methods Allocation: Randomisation.
Blinding: single blind, assessor/rater blind.
Duration: 6 months.
Setting: outpatients, Copenhagen, Denmark.
Design: randomised controlled trial, parallel.
Funding: Lundbeck Foundation, Municipality of Copenhagen, Egmont Foundation,
Health Insurance Foundation, Ministry of Social Welfare, Aase and Ejnar Danielsen’s
Foundation, Worzner Foundation
Participants Diagnosis: ICD-10 schizophrenia spectrum psychosis and cannabis use
N = 103.
Age: range 18-35 (and subsequently during the study expanded to 17-42); mean ~ 26.9
Sex: 78 M, 25 F.
Ethnicity: not stated.
History: Cannabis primary substance of abuse.
Included: resident of Copenhagen, not requiring interpreter, able to give informed con-
sent
Excluded: not stated.
Consent: written informed consent obtained.
Interventions 1. CapOpus (motivational interviewing and CBT aimed at cannabis related problems)
and treatment as usual, n = 52
2. Treatment as usual - treatment available to patients had they not participated in the
trial (CBT, anti psychotic medication), n = 51
Outcomes Behaviour: Cannabis Use: Number of joints of cannabis in preceding month (baseline,
end of intervention: 6 months, 10 months)
Unable to use -
Number of days with cannabis use (no means)
PANSS (no means or SD)
Lab data (not per protocol).
Notes Further data were requested, but none received.
Risk of bias Risk of bias
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Hjorthoj 2013 (Continued)
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computerised central randomisation.
Allocation concealment (selection bias) Low risk Outcome assessor was kept blind to alloca-
tion.
Blinding (performance bias and detection
bias)
All outcomes
High risk Fourteen patients or managers accidentally
broke the blinding
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not specified.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not specified.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Not specified.
Selective reporting (reporting bias) Unclear risk Not specified.
Other bias Unclear risk Not specified.
Leweke 2012
Methods Allocation: randomised.
Blinding: double blind
Duration: 28 days.
Setting: Inpatients, Department of Psychiatry and Psychotherapy,University of Cologne,
Cologne, Germany
Design: randomised controlled trial, parallel.
Funding: Stanley Medical Research Institute, National Institute on Drug Abuse
Participants Diagnosis: Schizophrenia; schizophreniform psychosis (DSM-IV)
N = 42.
Age: range 18-50; mean ~ 30.15.
Sex: 32 M, 7 F.
Ethnicity: not stated.
History: acutely exacerbated schizophrenia.
Included: BPRS ≥ 36; BPRS thought disorders (THOT) ≥ 12.
Exclusion: Substance use disorders; depot antipsychotic in past 3 months; positive drug
urine; history of treatment resistance; relevant/unstable medical condition
Consent: informed consent obtained.
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Leweke 2012 (Continued)
Interventions 1. Amisulpride: start with 200 mg per day increasing stepwise to 200 mg four times a
day (total dose: 800 mg) within the first week; dose of 800 mg maintained for three
further weeks; a reduction to 600 mg in total per day was allowed for clinical reasons
such as side effects after week 2, n = 21
2. Cannabidiol: start with 200 mg per day increasing stepwise to 200 mg four times a
day (total dose: 800 mg) within the first week; dose of 800 mg maintained for three
further weeks; a reduction to 600 mg in total per day was allowed for clinical reasons
such as side effects after week 2, n = 21
Outcomes Mental State: PANSS (day 0, 14, 28); BPRS (day 0, 14, 28).
Adverse effects: weight gain (kg) (day 0, 14, 28); EPS (day 0, 14, 28); serum prolactin
(micrograms/L) (day 0, 14, 28);
Unable to use -
serum anandamide (not relevant to this review); serum oleoylethanolamide (not relevant
to this review); serum palmitoylethanolamide (not relevant to this review)
Notes Further data were requested, but none received.
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Prepared by person uninvolved in study.
Allocation concealment (selection bias) Low risk Prepared by person uninvolved in study.
Blinding (performance bias and detection
bias)
All outcomes
Low risk Prepared by person uninvolved in study.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Prepared by person uninvolved in study.
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Prepared by person uninvolved in study.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Last observation carried forward.
Selective reporting (reporting bias) Unclear risk Not specified.
Other bias Unclear risk Not specified.
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Madigan 2012
Methods Allocation: randomised.
Blinding: single blind.
Duration: one year.
Setting: multi-centre, inpatients/outpatients, Ireland.
Design: randomised controlled trial, parallel.
Funding: Health Research Board of Ireland.
Participants Diagnosis: psychosis with comorbid substance dependence (DSM-IV)
N = 88.
Age: range 16-65 years; mean: 27.9 years.
Sex: 69 M, 19 F.
Ethnicity: not stated.
History: first psychotic episode or within 3 years following onset of non-affective or
affective psychosis
Included: outpatients and inpatients, without learning disability; without organic brain
damage
Exclusion: failure to meet SCID criteria for psychosis.
Consent: written informed consent obtained.
Interventions 1. Treatment as usual (TAU), care from a multidisciplinary team including medication
and regular review n = 29
2. Group Psychological Intervention (plus TAU) once a week for twelve weeks plus one
session six weeks afterwards, provided by a clinical psychologist, they included anxiety
management, motivational interviewing and CBT, n = 59
Outcomes Mental State: SAPS (baseline, 3 months, 1 year); SANS (baseline, 3 months, 1 year);
CDSS (baseline, 3 months, 1 year); PANSS positive (baseline, 3 months, 1 year); PANSS
negative (baseline, 3 months, 1 year); BSI (baseline, 3 months, 1 year)
Behaviour: Cannabis use: frequency of use: ASI (baseline, 3 months, 1 year)
General functioning: World Health OrganiZation Quality of Life Assessment (
WHOQOL. BREF) (baseline, 3 months, 1 year); Drug Attitude Inventory (DAI-30)
(baseline, 3 months, 1 year); GAF (baseline, 3 months, 1 year)
Notes Further data were requested, but none received.
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk ComputeriSed randomisation.
Allocation concealment (selection bias) Low risk Single blind (uninvolved researcher respon-
sible for randomisation)
Blinding (performance bias and detection
bias)
All outcomes
Low risk Single blind (uninvolved researcher respon-
sible for randomisation)
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Madigan 2012 (Continued)
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Single blind (uninvolved researcher respon-
sible for randomisation); rater remained
blind until final assessment
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Single blind (uninvolved researcher respon-
sible for randomisation); rater remained
blind until final assessment
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Datawere analysed on an intention-to-treat
basis.
Selective reporting (reporting bias) Unclear risk No indication.
Other bias Unclear risk No indication.
van Nimwegen 2008
Methods Allocation: randomised.
Blinding: double blind.
Duration: 6 weeks.
Setting: outpatients, multi-centre, Netherlands.
Design: randomised controlled trial, parallel.
Funding: Eli Lily.
Participants Diagnosis: DSM-IV diagnosis of schizophrenia, schizophreniform or schizoaffective dis-
order.
N = 129.
Age: 18-30 years.
Sex: not stated.
Ethnicity: not stated.
History: DSM-IV diagnosis of schizophrenia, schizophreniform or schizoaffective dis-
order.
Inclusion criteria: DSM-IV-R criteria for schizophrenia, schizoaffective disorder, or
schizophreniform disorder based on the Structured Clinical Interview for the Diagnostic
and Statistical Manual of Mental Disorders, fourth edition,
patient version.
Exclusion criteria: the concomitant use of any other antipsychotic drug (not olanzapine
or risperidone), depot antipsychotic medications in the 3 months prior to inclusion, and
current use of other psychotropic medications other than oxazepam or biperiden
Consent: not stated.
Interventions 1. Olanzapine (5, 10, 15, or 20 mg/day), n = 66.
2. Risperidone (1.25, 2.5, 3.75, or 5 mg/day), n = 72.
Outcomes Mental State: OCDUS scores (baseline, 6 weeks).
Behaviour: Cannabis use: self-report scores, joints per week (baseline, 6 weeks)
Unable to use -
SWN (not relevant).
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van Nimwegen 2008 (Continued)
DDQ (validity unknown).
Notes Further data were requested, but none received.
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not specified.
Allocation concealment (selection bias) Low risk Double blind.
Blinding (performance bias and detection
bias)
All outcomes
Low risk Double blind.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double blind.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not specified.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Not specified.
Selective reporting (reporting bias) Unclear risk Not specified.
Other bias Low risk Eli-Lilly funded the trial, yet were not in-
volved in the design of the study, analyses,
or interpretation of results
CBT - cognitive behavioural therapy
BPRS-E - Brief Psychiatric Rating Scale-Expanded
BPRS - Brief Psychiatric Rating Scale
BPRS-PS - Brief Psychiatric Rating Scale-Positive Symptoms
BPRS THOT - Brief Psychiatric Rating Scale Thought Disorder
BDI-SF - Beck Depression Inventory - Short Form
ICD-10 - International Classification of Diseases, tenth revision
SAS - Simpson Angus Scale
SANS - Scale for the Assessment of Negative Symptoms
SOFAS - Social and Occupational Functioning Assessment Scale
KAPQ - Knowledge About Psychosis Questionnaire
CGI - Clinical Global Impression Scale
ASI - Addiction Severity Index
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HAM-D - Hamilton Depression Scale
AIMS - Abnormal Involuntary Movement Scale
PANSS - Positive and Negative Syndrome Scale
SCID - Structured Clincal Interview for Diagnosis
GAF - Global Assessment of Functoning Scale
DSM - The Diagnostic and Statistical Manual of Mental Disorders
TAU - Treatment as Usual
MI - Motivational Intervention
SAPS - Scale for the assessment of positive symptoms
CDSS - Calgary Depression Scale for Schizophrenia
BSI - Birchwood Insight Scale
WHOQOLL. BREF - World Health Organisation Quality of Life Assessment
DAI-30 - Drug Attitude Inventory
OCDUS - Obsessive-Compulsive Drug Use Scale
DDQ - Drug Desire Questionnaire
SWN - Subjective Wellbeing Under Neuroleptics Scale
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Baker 2006 Allocation: randomised.
Participants: people with psychotic disorder and who reported hazardous alcohol, cannabis and/or am-
phetamine use in the previous month
Interventions: Standard care vs motivational interviewing/CBT
Outcomes: usable data were requested, but none received.
Barrowclough 2010 Allocation: randomised.
Participants: non-affective psychotic disorder, illicit drugs/alcohol dependence
Interventions: Standard care vs. MiCBT + standard care.
Outcomes: usable data were requested, but none received.
Bellack 2006 Allocation: randomised.
Participants: people meeting DSM criteria for drug dependence and serious mental illness
Interventions: BTSAS social learning intervention (includes motivational interviewing, a urinalysis contin-
gency, and social skills training) vs. STAR (a supportive group discussion treatment)
Outcomes: usable data were requested, but none received.
James 2004 Allocation: randomised.
Participants: axis I diagnosis of a non-organic psychotic disorder, currently using illicit drugs/alcohol
Interventions: group intervention - weekly 90-minute sessions over 6 weeks vs. single education session
Outcomes: usable data were requested, but none received.
Kemp 2007 Allocation: randomised.
Participants: young people with primary diagnosis of a psychotic illness
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(Continued)
Interventions: treatment as usual vs CBT: “Stop using stuff.”
Outcome: usable data were requested, but none received.
Martino 2006 Allocation: randomised.
Participants: Individuals with co-occurring psychotic and drug-related disorders
Interventions: two-session motivational interview adapted for dually diagnosed psychotic and drug-related
disordered patients vs. two-session standard psychiatric interview
Outcomes: usable data were requested, but none received.
CBT - cognitive behavioural therapy
MiCBT - Integrated Motivational Interviewing and Cognitive Behavioural Therapy
DSM - Diagnostic and Statistical Manual of Mental Disorders
BTSAS - Behavioural Treatment for Substance Abuse in Severe and Persistent Mental Illness
STAR - Supportive Treatment for Addiction Recovery
Characteristics of studies awaiting assessment [ordered by study ID]
D’Souza 2005
Methods Allocation: randomised.
Blindness: double blind.
Duration 3 days.
Setting: Neurobiological Studies Unit.
Design: parallel.
Funding: Department of Veterans Affairs.
Participants Diagnosis: schizophrenia or schizoaffective disorder (DSM-IV)
N = 13.
Age: 44.46 ±10.4 years.
Sex M:F 10:3.
History: clinically stable.
Included: at least one exposure to cannabis.
Exclusion: recent/current hospitalisation; homicidality; suicidality; grave disability; cannabis naive; lifetime cannabis
use disorder; recent abuse (within 3 months) or dependence (within a year) of any substance of abuse except nicotine
Consent: not known.
Interventions 1. THC: dose 2.5 mg.
2. THC: dose 5 mg.
3. Placebo.
Outcomes Mental state: PANSS.
Cannabis use: CADSS.
Adverse events: Extrapyramidal effects.
Notes Usable data requested, but none received.
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CADSS - Clinician-Administered Dissociative Symptom Scale
DSM - Diagnostic and Statistical Manual of Mental Disorders
PANSS - Positive and Negative Syndrome Scale
THC - delta-9-tetrahydrocannabinol
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D A T A A N D A N A L Y S E S
Comparison 1. CANNABIS REDUCTION: ADJUNCT PSYCHOLOGICAL THERAPY versus TREATMENT
AS USUAL
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Behaviour: Cannabis use:
1. Frequency of use (ASI,
group-based therapy, high =
bad)
1 Mean Difference (IV, Fixed, 95% CI) Subtotals only
1.1 in past 30 days - by
medium term
1 54 Mean Difference (IV, Fixed, 95% CI) -0.10 [-2.44, 2.24]
2 Behaviour: Cannabis use: 2.
Number of joints of cannabis
in preceding month (skewed
data)
Other data No numeric data
2.1 medium term Other data No numeric data
2.2 long term Other data No numeric data
3 Behaviour: Cannabis use: 3.
Number of days abstinent /last
month (skewed data)
Other data No numeric data
3.1 medium term - 3 months Other data No numeric data
3.2 medium term - 6 months Other data No numeric data
3.3 long term - 12 months Other data No numeric data
4 Behaviour: Cannabis use: 4.
Number of days of binge use
(skewed data)
Other data No numeric data
4.1 medium term - 3 months Other data No numeric data
4.2 medium term - 6 months Other data No numeric data
4.3 long term - 12 months Other data No numeric data
5 Mental state: 1. Average
depressive symptom score
(CDSS, skewed data)
Other data No numeric data
5.1 medium term Other data No numeric data
5.2 long term Other data No numeric data
6 Mental state: 2. Average insight
score (Birchwood Insight Scale,
high score = better)
1 Mean Difference (IV, Fixed, 95% CI) Subtotals only
6.1 medium term 1 58 Mean Difference (IV, Fixed, 95% CI) 1.10 [-0.18, 2.38]
6.2 long term 1 46 Mean Difference (IV, Fixed, 95% CI) 0.40 [-0.88, 1.68]
7 Mental state: 3. Average negative
symptom score (PANSS, high
score = poor)
1 186 Mean Difference (IV, Fixed, 95% CI) -0.40 [-1.50, 0.70]
7.1 medium term - 3 months 1 62 Mean Difference (IV, Fixed, 95% CI) -0.10 [-2.06, 1.86]
7.2 medium term - 6 months 1 62 Mean Difference (IV, Fixed, 95% CI) 0.0 [-1.80, 1.80]
7.3 long term - 12 months 1 62 Mean Difference (IV, Fixed, 95% CI) -1.20 [-3.19, 0.79]
64Cannabis and schizophrenia (Review)
Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
8Mental state: 4a. Average positive
symptom score (SAPS, skewed
data)
Other data No numeric data
8.1 medium term Other data No numeric data
8.2 long term Other data No numeric data
9 Mental state: 4b. Average
positive symptom score (SANS,
skewed data)
Other data No numeric data
9.1 medium term Other data No numeric data
9.2 long term Other data No numeric data
10 Mental state: 4c. Average
positive symptom score
(PANSS, high score = poor)
1 Mean Difference (IV, Fixed, 95% CI) Subtotals only
10.1 medium term - 3 months 1 62 Mean Difference (IV, Fixed, 95% CI) -0.30 [-2.55, 1.95]
10.2 medium term - 6 months 1 62 Mean Difference (IV, Fixed, 95% CI) -0.10 [-2.58, 2.38]
10.3 long term - 12 months 1 62 Mean Difference (IV, Fixed, 95% CI) -1.20 [-3.32, 0.92]
11 General functioning: 1.
Subjective quality of life
(WHO QOL, brief, high score
= better)
1 Mean Difference (IV, Fixed, 95% CI) Subtotals only
11.1 medium term 1 49 Mean Difference (IV, Fixed, 95% CI) 0.90 [-1.15, 2.95]
11.2 long term 1 48 Mean Difference (IV, Fixed, 95% CI) 1.5 [-0.40, 3.40]
12 General functioning: 3. Global
functioning (GAF, high score =
better)
2 Mean Difference (IV, Fixed, 95% CI) Subtotals only
12.1 medium term - 3 months 2 120 Mean Difference (IV, Fixed, 95% CI) -0.11 [-2.57, 2.36]
12.2 medium term 6 months 1 62 Mean Difference (IV, Fixed, 95% CI) -1.0 [-4.40, 2.40]
12.3 long term 2 109 Mean Difference (IV, Fixed, 95% CI) 1.88 [-1.09, 4.85]
13 General functioning: 2.
Attitude to treatment (DAI,
medium term, skewed data)
Other data No numeric data
13.1 medium term Other data No numeric data
14 General functioning: 4. Global
functioning (SOFAS, high
score = better)
1 Mean Difference (IV, Fixed, 95% CI) Subtotals only
14.1 medium term - 3 months 1 62 Mean Difference (IV, Fixed, 95% CI) 0.10 [-3.02, 3.22]
14.2 medium term 6 months 1 62 Mean Difference (IV, Fixed, 95% CI) -0.10 [-3.63, 3.43]
14.3 long term 1 62 Mean Difference (IV, Fixed, 95% CI) 2.70 [-1.08, 6.48]
Comparison 2. CANNABIS REDUCTION: PSYCHOLOGICAL THERAPY (SPECIFICALLY ABOUT
CANNABIS AND PSYCHOSIS) versus NON-SPECIFIC PSYCHOEDUCATION
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Behaviour: Cannabis use: 1.
Used cannabis in last 4 weeks
1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
1.1 by 3 months - end of
treatment
1 47 Risk Ratio (M-H, Fixed, 95% CI) 1.04 [0.62, 1.74]
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1.2 by 9 months - 6 months
after end of treatment
1 47 Risk Ratio (M-H, Fixed, 95% CI) 1.30 [0.79, 2.15]
2 Behaviour: Cannabis use: 2.
Percentage days used cannabis
in last 4 weeks (skewed data)
Other data No numeric data
2.1 by 3 months - end of
treatment
Other data No numeric data
2.2 by 9 months - 6 months
after end of treatment
Other data No numeric data
3 Mental state: 1. Average overall
score (BPRS-E total endpoint,
high score = poor)
1 Mean Difference (IV, Fixed, 95% CI) Subtotals only
3.1 by 3 months - end of
treatment
1 47 Mean Difference (IV, Fixed, 95% CI) 3.60 [-5.61, 12.81]
3.2 by 9 months - 6 months
after end of treatment
1 47 Mean Difference (IV, Fixed, 95% CI) -0.80 [-9.07, 7.47]
4 Mental state: 2. Average overall
score (BPRS-PS total endpoint,
skewed data)
Other data No numeric data
4.1 by 3 months - end of
treatment
Other data No numeric data
4.2 by 9 months - 6 months
after end of treatment
Other data No numeric data
5 Mental state: 3. Average
depression score (BDI-SF total
endpoint, skewed data)
Other data No numeric data
5.1 by 3 months - end of
treatment
Other data No numeric data
5.2 by 9 months - 6 months
after end of treatment
Other data No numeric data
6 Mental state: 4. Average
negative symptom score (SANS
endpoint, skewed data)
Other data No numeric data
6.1 by 3 months - end of
treatment
Other data No numeric data
6.2 by 9 months - 6 months
after end of treatment
Other data No numeric data
7 Global state: Average overall
score (KAPQ total endpoint,
high score = good)
1 Mean Difference (IV, Fixed, 95% CI) Subtotals only
7.1 by 3 months - end of
treatment
1 47 Mean Difference (IV, Fixed, 95% CI) -0.80 [-3.38, 1.78]
7.2 by 9 months - 6 months
after end of treatment
1 47 Mean Difference (IV, Fixed, 95% CI) -0.90 [-3.22, 1.42]
8 General functioning: Average
score (SOFAS total endpoint,
high score = good)
1 Mean Difference (IV, Fixed, 95% CI) Subtotals only
8.1 by 3 months - end of
treatment
1 47 Mean Difference (IV, Fixed, 95% CI) -0.80 [-9.95, 8.35]
66Cannabis and schizophrenia (Review)
Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
8.2 by 9 months - 6 months
after end of treatment
1 47 Mean Difference (IV, Fixed, 95% CI) -4.70 [-14.52, 5.12]
Comparison 3. CANNABIS REDUCTION: ANTIPSYCHOTIC ’A’ versus ANTIPSYCHOTIC ’B’
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Behaviour: Cannabis use: 1.
Traces of cannabis breakdown
products in urine (number
of patients positive above
threshold level - 100 nanograms
- olanzapine versus risperidone)
1 16 Risk Ratio (M-H, Fixed, 95% CI) 1.8 [0.52, 6.22]
1.1 olanzapine vs risperidone 1 16 Risk Ratio (M-H, Fixed, 95% CI) 1.8 [0.52, 6.22]
2 Behaviour: Cannabis use: 2. As
defined in each study (skewed
data)
Other data No numeric data
2.1 average score per week
(Marijuana Craving Report -
olanzapine versus risperidone
Other data No numeric data
2.2 average self-report scores
of joints per week (short term)
- olanzapine versus risperidone
Other data No numeric data
2.3 average intensity of
cannabis use in joints per
week - clozapine versus other
antipsychotics
Other data No numeric data
3 Behaviour: Cannabis use:
3. Average score per week
(Marijuana Craving Report
skewed data - olanzapine versus
risperidone)
Other data No numeric data
4 Mental state: Average score
(OCDUS, short term, high
= poor) - olanzapine versus
risperdione
1 41 Mean Difference (IV, Fixed, 95% CI) -1.30 [-6.11, 3.51]
4.1 olanzapine vs risperidone 1 41 Mean Difference (IV, Fixed, 95% CI) -1.30 [-6.11, 3.51]
5 Adverse effects: 1.
Anticholinergic - various
(clozapine vs other
antipsychotic)
1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
5.1 constipation 1 30 Risk Ratio (M-H, Fixed, 95% CI) 9.0 [0.53, 153.79]
5.2 nasal congestion 1 31 Risk Ratio (M-H, Fixed, 95% CI) 0.21 [0.01, 4.10]
5.3 salivation - too much 1 31 Risk Ratio (M-H, Fixed, 95% CI) 22.31 [1.42, 350.31]
5.4 salivation - too little 1 31 Risk Ratio (M-H, Fixed, 95% CI) 1.07 [0.17, 6.64]
5.5 urinary incontinence 1 31 Risk Ratio (M-H, Fixed, 95% CI) 5.31 [0.28, 102.38]
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6 Adverse effects: 2. Cardiac -
various (clozapine vs other
antipsychotic)
1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
6.1 hypertension 1 30 Risk Ratio (M-H, Fixed, 95% CI) 1.0 [0.16, 6.20]
7 Adverse effects: 3. Central
nervous system / higher
functions - various (clozapine
vs other antipsychotic)
1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
7.1 agitation - increased 1 30 Risk Ratio (M-H, Fixed, 95% CI) 1.0 [0.07, 14.55]
7.2 depression 1 30 Risk Ratio (M-H, Fixed, 95% CI) 2.0 [0.20, 19.78]
7.3 dizziness 1 31 Risk Ratio (M-H, Fixed, 95% CI) 5.33 [0.70, 40.54]
7.4 dreams - unusual dream
activity
1 31 Risk Ratio (M-H, Fixed, 95% CI) 0.21 [0.01, 4.10]
7.5 fatigue 1 31 Risk Ratio (M-H, Fixed, 95% CI) 7.44 [0.42, 132.95]
7.6 irritability 1 31 Risk Ratio (M-H, Fixed, 95% CI) 1.07 [0.07, 15.57]
7.7 libido - decreased 1 31 Risk Ratio (M-H, Fixed, 95% CI) 1.07 [0.07, 15.57]
7.8 sleep - too much 1 31 Risk Ratio (M-H, Fixed, 95% CI) 4.8 [1.23, 18.71]
7.9 sleep- insomnia 1 31 Risk Ratio (M-H, Fixed, 95% CI) 2.13 [0.22, 21.17]
7.10 suicide attempt 1 31 Risk Ratio (M-H, Fixed, 95% CI) 1.07 [0.07, 15.57]
8 Adverse effects: 4.
Gastrointestinal - various
(clozapine vs other
antipsychotic)
1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
8.1 nausea 1 31 Risk Ratio (M-H, Fixed, 95% CI) 2.13 [0.22, 21.17]
8.2 vomiting 1 31 Risk Ratio (M-H, Fixed, 95% CI) 1.07 [0.25, 4.49]
9 Adverse effects: 5. Metabolic -
weight gain (clozapine vs other
antipsychotic)
1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
10 Adverse effects: 6a. Movement
disorders - various (clozapine vs
other antipsychotic)
1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
10.1 agitation - increased 1 30 Risk Ratio (M-H, Fixed, 95% CI) 1.0 [0.07, 14.55]
10.2 akathisia 1 31 Risk Ratio (M-H, Fixed, 95% CI) 1.07 [0.07, 15.57]
10.3 muscle spasms 1 31 Risk Ratio (M-H, Fixed, 95% CI) 5.31 [0.28, 102.38]
11 Adverse events: 6b. Movement
disorders - average score
(Simpson scale, high score
= poor - olanzapine versus
risperidone)
1 Mean Difference (IV, Fixed, 95% CI) Subtotals only
11.1 olanzapine vs risperidone 1 16 Mean Difference (IV, Fixed, 95% CI) 0.08 [-1.06, 1.22]
12 Adverse effects: 7. Others -
various (clozapine vs other
antipsychotic)
1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
12.1 chest pain - non-cardiac 1 31 Risk Ratio (M-H, Fixed, 95% CI) 0.53 [0.05, 5.29]
12.2 flu-like symptoms 1 31 Risk Ratio (M-H, Fixed, 95% CI) 0.21 [0.01, 4.10]
12.3 headache 1 31 Risk Ratio (M-H, Fixed, 95% CI) 2.13 [0.22, 21.17]
13 Leaving the study early: 1.
Number leaving (olanzapine vs
risperidone)
1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
13.1 admission 1 28 Risk Ratio (M-H, Fixed, 95% CI) 1.0 [0.07, 14.45]
13.2 any 1 28 Risk Ratio (M-H, Fixed, 95% CI) 0.5 [0.19, 1.29]
13.3 intolerable adverse effects 1 28 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
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13.4 not interested 1 28 Risk Ratio (M-H, Fixed, 95% CI) 0.43 [0.14, 1.33]
14 Leaving the study early: 2.
Weeks in treatment (olanzapine
vs risperidone)
1 28 Mean Difference (IV, Fixed, 95% CI) 0.0 [-3.35, 3.35]
14.1 olanzapine vs risperidone 1 28 Mean Difference (IV, Fixed, 95% CI) 0.0 [-3.35, 3.35]
Comparison 4. CANNABINOID AS TREATMENT: CANNABIDIOL versus AMISULPRIDE
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Mental state: 1a. Average overall
score (BPRS, total endpoint,
high score = poor)
1 Mean Difference (IV, Fixed, 95% CI) Subtotals only
1.1 Day 7 - short term 1 39 Mean Difference (IV, Fixed, 95% CI) -1.5 [-6.54, 3.54]
1.2 Day 14 - short term 1 39 Mean Difference (IV, Fixed, 95% CI) 1.80 [-4.61, 8.21]
1.3 Day 21 - short term 1 34 Mean Difference (IV, Fixed, 95% CI) 4.20 [-4.24, 12.64]
1.4 Day 28 - short term 1 35 Mean Difference (IV, Fixed, 95% CI) 1.10 [-8.18, 10.38]
2 Mental state: 1b. Average overall
score (PANSS, total endpoint,
high score = poor)
1 Mean Difference (IV, Fixed, 95% CI) Subtotals only
2.1 day 14 (short term) 1 39 Mean Difference (IV, Fixed, 95% CI) 0.0 [-10.10, 10.10]
2.2 day 28 (short term) 1 35 Mean Difference (IV, Fixed, 95% CI) 0.40 [-13.42, 14.22]
3 Mental state: 2. Average negative
symptom score (PANSS, high
score = poor)
1 Mean Difference (IV, Fixed, 95% CI) Subtotals only
3.1 Day 14 - short term 1 39 Mean Difference (IV, Fixed, 95% CI) 1.20 [-2.13, 4.53]
3.2 Day 28 - short term 1 35 Mean Difference (IV, Fixed, 95% CI) 2.70 [-0.92, 6.32]
4 Mental state: 3. Average positive
symptom score (PANSS, high
score = poor)
1 Mean Difference (IV, Fixed, 95% CI) Subtotals only
4.1 Day 14 - short term 1 39 Mean Difference (IV, Fixed, 95% CI) 1.20 [-1.85, 4.25]
4.2 Day 28 - short term 1 35 Mean Difference (IV, Fixed, 95% CI) 0.60 [-3.92, 5.12]
5 Adverse effects: 1. Endocrine -
prolactin (µg/l, short term -
skewed data)
Other data No numeric data
6 Adverse effects: 2. Metabolic -
weight gain (kg, short term -
skewed data)
Other data No numeric data
7 Adverse effects: 3. Movement
disorders - change in
extrapyramidal symptoms
(EPS, short term - skewed data)
Other data No numeric data
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Analysis 1.1. Comparison 1 CANNABIS REDUCTION: ADJUNCT PSYCHOLOGICAL THERAPY versus
TREATMENT AS USUAL, Outcome 1 Behaviour: Cannabis use: 1. Frequency of use (ASI, group-based
therapy, high = bad).
Review: Cannabis and schizophrenia
Comparison: 1 CANNABIS REDUCTION: ADJUNCT PSYCHOLOGICAL THERAPY versus TREATMENT AS USUAL
Outcome: 1 Behaviour: Cannabis use: 1. Frequency of use (ASI, group-based therapy, high = bad)
Study or subgroup
Group
Psychological
intervention +TAU Treatment as usual
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 in past 30 days - by medium term
Madigan 2012 36 9.9 (4) 18 10 (4.2) 100.0 % -0.10 [ -2.44, 2.24 ]
Subtotal (95% CI) 36 18 100.0 % -0.10 [ -2.44, 2.24 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.08 (P = 0.93)
Test for subgroup differences: Not applicable
-2 -1 0 1 2
Favours GPI+TAU Favours TAU
Analysis 1.2. Comparison 1 CANNABIS REDUCTION: ADJUNCT PSYCHOLOGICAL THERAPY versus
TREATMENT AS USUAL, Outcome 2 Behaviour: Cannabis use: 2. Number of joints of cannabis in preceding
month (skewed data).
Behaviour: Cannabis use: 2. Number of joints of cannabis in preceding month (skewed data)
Study Intervention Mean SD N
medium term medium term
Hjorthoj 2013 CapOpus 27.2 52.8 52
Hjorthoj 2013 TAU 48.3 58.7 51
long term long term
Hjorthoj 2013 CapOpus 28.2 58.1 52
Hjorthoj 2013 TAU 41.8 59.0 51
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Analysis 1.3. Comparison 1 CANNABIS REDUCTION: ADJUNCT PSYCHOLOGICAL THERAPY versus
TREATMENT AS USUAL, Outcome 3 Behaviour: Cannabis use: 3. Number of days abstinent /last month
(skewed data).
Behaviour: Cannabis use: 3. Number of days abstinent /last month (skewed data)
Study Intervention Mean SD N
medium term - 3 months medium term - 3
Bonsack 2011 Treatment as usual (TAU)
+ Motivational interview-
ing (MI)
7.8 8.4 30
Bonsack 2011 TAU (control) 9.7 9.6 32
medium term - 6 months medium term - 6
Bonsack 2011 TAU + MI 9.7 9.9 30
Bonsack 2011 TAU 9.0 9.7 32
long term - 12 months long term - 12 months
Bonsack 2011 TAU + MI 9.9 10.6 30
Bonsack 2011 TAU 11.1 11.0 32
Analysis 1.4. Comparison 1 CANNABIS REDUCTION: ADJUNCT PSYCHOLOGICAL THERAPY versus
TREATMENT AS USUAL, Outcome 4 Behaviour: Cannabis use: 4. Number of days of binge use (skewed data).
Behaviour: Cannabis use: 4. Number of days of binge use (skewed data)
Study Intervention Mean SD N
medium term - 3 months medium term - 3
Bonsack 2011 Treatment as usual (TAU)
+ Motivational interview-
ing (MI)
1.5 1.9 30
Bonsack 2011 TAU 1.6 2.5 32
medium term - 6 months medium term - 6
Bonsack 2011 TAU + MI 1.0 1.9 30
Bonsack 2011 TAU 1.1 1.4 32
long term - 12 months long term - 12 months
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Behaviour: Cannabis use: 4. Number of days of binge use (skewed data) (Continued)
Bonsack 2011 TAU + MI 1.7 5.1 30
Bonsack 2011 TAU 1.7 3.9 32
Analysis 1.5. Comparison 1 CANNABIS REDUCTION: ADJUNCT PSYCHOLOGICAL THERAPY versus
TREATMENT AS USUAL, Outcome 5 Mental state: 1. Average depressive symptom score (CDSS, skewed
data).
Mental state: 1. Average depressive symptom score (CDSS, skewed data)
Study Intervention Mean SD N
medium term medium term
Madigan 2012 GPI + TAU 4.4 4.3 40
Madigan 2012 TAU 4.6 4.8 20
long term long term
Madigan 2012 GPI + TAU 4.3 4.4 33
Madigan 2012 TAU 4.3 4.2 11
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Analysis 1.6. Comparison 1 CANNABIS REDUCTION: ADJUNCT PSYCHOLOGICAL THERAPY versus
TREATMENT AS USUAL, Outcome 6 Mental state: 2. Average insight score (Birchwood Insight Scale, high
score = better).
Review: Cannabis and schizophrenia
Comparison: 1 CANNABIS REDUCTION: ADJUNCT PSYCHOLOGICAL THERAPY versus TREATMENT AS USUAL
Outcome: 6 Mental state: 2. Average insight score (Birchwood Insight Scale, high score = better)
Study or subgroup GPI+TAU TAU
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 medium term
Madigan 2012 39 7.7 (2.2) 19 6.6 (2.4) 100.0 % 1.10 [ -0.18, 2.38 ]
Subtotal (95% CI) 39 19 100.0 % 1.10 [ -0.18, 2.38 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.68 (P = 0.092)
2 long term
Madigan 2012 32 7 (2.9) 14 6.6 (1.5) 100.0 % 0.40 [ -0.88, 1.68 ]
Subtotal (95% CI) 32 14 100.0 % 0.40 [ -0.88, 1.68 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.61 (P = 0.54)
Test for subgroup differences: Chi2 = 0.58, df = 1 (P = 0.45), I2 =0.0%
-2 -1 0 1 2
Favours [TAU (control)] Favours [GPI + TAU]
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Analysis 1.7. Comparison 1 CANNABIS REDUCTION: ADJUNCT PSYCHOLOGICAL THERAPY versus
TREATMENT AS USUAL, Outcome 7 Mental state: 3. Average negative symptom score (PANSS, high score =
poor).
Review: Cannabis and schizophrenia
Comparison: 1 CANNABIS REDUCTION: ADJUNCT PSYCHOLOGICAL THERAPY versus TREATMENT AS USUAL
Outcome: 7 Mental state: 3. Average negative symptom score (PANSS, high score = poor)
Study or subgroup
Psychological
therapy +
TAU
Treatment as
usual
(Control)
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 medium term - 3 months
Bonsack 2011 30 18 (4.7) 32 18.1 (2.9) 31.7 % -0.10 [ -2.06, 1.86 ]
Subtotal (95% CI) 30 32 31.7 % -0.10 [ -2.06, 1.86 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.10 (P = 0.92)
2 medium term - 6 months
Bonsack 2011 30 17.4 (3.8) 32 17.4 (3.4) 37.6 % 0.0 [ -1.80, 1.80 ]
Subtotal (95% CI) 30 32 37.6 % 0.0 [ -1.80, 1.80 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
3 long term - 12 months
Bonsack 2011 30 16.3 (4.1) 32 17.5 (3.9) 30.6 % -1.20 [ -3.19, 0.79 ]
Subtotal (95% CI) 30 32 30.6 % -1.20 [ -3.19, 0.79 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.18 (P = 0.24)
Total (95% CI) 90 96 100.0 % -0.40 [ -1.50, 0.70 ]
Heterogeneity: Chi2 = 0.90, df = 2 (P = 0.64); I2 =0.0%
Test for overall effect: Z = 0.71 (P = 0.48)
Test for subgroup differences: Chi2 = 0.90, df = 2 (P = 0.64), I2 =0.0%
-2 -1 0 1 2
Favours [MI + TAU] Favours [TAU (control)]
Analysis 1.8. Comparison 1 CANNABIS REDUCTION: ADJUNCT PSYCHOLOGICAL THERAPY versus
TREATMENT AS USUAL, Outcome 8 Mental state: 4a. Average positive symptom score (SAPS, skewed data).
Mental state: 4a. Average positive symptom score (SAPS, skewed data)
Study Intervention Mean SD N
medium term medium term
Madigan 2012 GPI + TAU 4.8 3.7 42
Madigan 2012 TAU 5.1 4.1 22
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Mental state: 4a. Average positive symptom score (SAPS, skewed data) (Continued)
long term long term
Madigan 2012 GPI + TAU 4.9 4.0 32
Madigan 2012 TAU 5.1 4.2 17
Analysis 1.9. Comparison 1 CANNABIS REDUCTION: ADJUNCT PSYCHOLOGICAL THERAPY versus
TREATMENTAS USUAL, Outcome 9 Mental state: 4b. Average positive symptom score (SANS, skewed data).
Mental state: 4b. Average positive symptom score (SANS, skewed data)
Study Intervention Mean SD N
medium term medium term
Madigan 2012 GPI + TAU 3.8 2.4 40
Madigan 2012 TAU 3.2 2.3 20
long term long term
Madigan 2012 GPI + TAU 4.6 3.0 32
Madigan 2012 TAU 4.8 3.2 19
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Analysis 1.10. Comparison 1 CANNABIS REDUCTION: ADJUNCT PSYCHOLOGICAL THERAPY versus
TREATMENT AS USUAL, Outcome 10 Mental state: 4c. Average positive symptom score (PANSS, high score
= poor).
Review: Cannabis and schizophrenia
Comparison: 1 CANNABIS REDUCTION: ADJUNCT PSYCHOLOGICAL THERAPY versus TREATMENT AS USUAL
Outcome: 10 Mental state: 4c. Average positive symptom score (PANSS, high score = poor)
Study or subgroup
Psychological
therapy +
TAU
Treatment as
usual (TAU)
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 medium term - 3 months
Bonsack 2011 30 16.6 (4) 32 16.9 (5) 100.0 % -0.30 [ -2.55, 1.95 ]
Subtotal (95% CI) 30 32 100.0 % -0.30 [ -2.55, 1.95 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.26 (P = 0.79)
2 medium term - 6 months
Bonsack 2011 30 16.2 (5.3) 32 16.3 (4.6) 100.0 % -0.10 [ -2.58, 2.38 ]
Subtotal (95% CI) 30 32 100.0 % -0.10 [ -2.58, 2.38 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.08 (P = 0.94)
3 long term - 12 months
Bonsack 2011 30 15.2 (3.9) 32 16.4 (4.6) 100.0 % -1.20 [ -3.32, 0.92 ]
Subtotal (95% CI) 30 32 100.0 % -1.20 [ -3.32, 0.92 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.11 (P = 0.27)
Test for subgroup differences: Chi2 = 0.53, df = 2 (P = 0.77), I2 =0.0%
-2 -1 0 1 2
Favours Psychological therapy + TAU Favours TAU
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Analysis 1.11. Comparison 1 CANNABIS REDUCTION: ADJUNCT PSYCHOLOGICAL THERAPY versus
TREATMENT AS USUAL, Outcome 11 General functioning: 1. Subjective quality of life (WHO QOL, brief,
high score = better).
Review: Cannabis and schizophrenia
Comparison: 1 CANNABIS REDUCTION: ADJUNCT PSYCHOLOGICAL THERAPY versus TREATMENT AS USUAL
Outcome: 11 General functioning: 1. Subjective quality of life (WHO QOL, brief, high score = better)
Study or subgroup
Group Psychological
Intervention + TAU
Treatment as
usual (TAU)
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 medium term
Madigan 2012 34 13.5 (3.3) 15 12.6 (3.4) 100.0 % 0.90 [ -1.15, 2.95 ]
Subtotal (95% CI) 34 15 100.0 % 0.90 [ -1.15, 2.95 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.86 (P = 0.39)
2 long term
Madigan 2012 34 12.6 (3.4) 14 11.1 (2.9) 100.0 % 1.50 [ -0.40, 3.40 ]
Subtotal (95% CI) 34 14 100.0 % 1.50 [ -0.40, 3.40 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.55 (P = 0.12)
Test for subgroup differences: Chi2 = 0.18, df = 1 (P = 0.67), I2 =0.0%
-2 -1 0 1 2
Favours [TAU (control)] Favours [GPI + TAU]
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Analysis 1.12. Comparison 1 CANNABIS REDUCTION: ADJUNCT PSYCHOLOGICAL THERAPY versus
TREATMENT AS USUAL, Outcome 12 General functioning: 3. Global functioning (GAF, high score = better).
Review: Cannabis and schizophrenia
Comparison: 1 CANNABIS REDUCTION: ADJUNCT PSYCHOLOGICAL THERAPY versus TREATMENT AS USUAL
Outcome: 12 General functioning: 3. Global functioning (GAF, high score = better)
Study or subgroup intervention + TAU TAU
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 medium term - 3 months
Bonsack 2011 30 39.1 (4.8) 32 39.5 (6.5) 75.7 % -0.40 [ -3.23, 2.43 ]
Madigan 2012 39 37.4 (8) 19 36.6 (9.6) 24.3 % 0.80 [ -4.19, 5.79 ]
Subtotal (95% CI) 69 51 100.0 % -0.11 [ -2.57, 2.36 ]
Heterogeneity: Chi2 = 0.17, df = 1 (P = 0.68); I2 =0.0%
Test for overall effect: Z = 0.09 (P = 0.93)
2 medium term 6 months
Bonsack 2011 30 40.3 (5.9) 32 41.3 (7.7) 100.0 % -1.00 [ -4.40, 2.40 ]
Subtotal (95% CI) 30 32 100.0 % -1.00 [ -4.40, 2.40 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.58 (P = 0.56)
3 long term
Bonsack 2011 30 42.9 (6.5) 32 40.6 (7) 78.1 % 2.30 [ -1.06, 5.66 ]
Madigan 2012 31 37.6 (8.3) 16 37.2 (11.5) 21.9 % 0.40 [ -5.95, 6.75 ]
Subtotal (95% CI) 61 48 100.0 % 1.88 [ -1.09, 4.85 ]
Heterogeneity: Chi2 = 0.27, df = 1 (P = 0.60); I2 =0.0%
Test for overall effect: Z = 1.24 (P = 0.21)
Test for subgroup differences: Chi2 = 1.76, df = 2 (P = 0.41), I2 =0.0%
-4 -2 0 2 4
Favours [TAU (control)] Favours [intervention + TAU]
Analysis 1.13. Comparison 1 CANNABIS REDUCTION: ADJUNCT PSYCHOLOGICAL THERAPY versus
TREATMENT AS USUAL, Outcome 13 General functioning: 2. Attitude to treatment (DAI, medium term,
skewed data).
General functioning: 2. Attitude to treatment (DAI, medium term, skewed data)
Study Intervention Mean SD N
medium term medium term
Madigan 2012 GPI + TAU 8.1 9.9 33
Madigan 2012 TAU 5.9 9.6 15
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Analysis 1.14. Comparison 1 CANNABIS REDUCTION: ADJUNCT PSYCHOLOGICAL THERAPY versus
TREATMENT AS USUAL, Outcome 14 General functioning: 4. Global functioning (SOFAS, high score =
better).
Review: Cannabis and schizophrenia
Comparison: 1 CANNABIS REDUCTION: ADJUNCT PSYCHOLOGICAL THERAPY versus TREATMENT AS USUAL
Outcome: 14 General functioning: 4. Global functioning (SOFAS, high score = better)
Study or subgroup intervention +TAU TAU
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 medium term - 3 months
Bonsack 2011 30 40.5 (5.5) 32 40.4 (7) 100.0 % 0.10 [ -3.02, 3.22 ]
Subtotal (95% CI) 30 32 100.0 % 0.10 [ -3.02, 3.22 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.06 (P = 0.95)
2 medium term 6 months
Bonsack 2011 30 42.3 (6.8) 32 42.4 (7.4) 100.0 % -0.10 [ -3.63, 3.43 ]
Subtotal (95% CI) 30 32 100.0 % -0.10 [ -3.63, 3.43 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.06 (P = 0.96)
3 long term
Bonsack 2011 30 44.9 (7.2) 32 42.2 (8) 100.0 % 2.70 [ -1.08, 6.48 ]
Subtotal (95% CI) 30 32 100.0 % 2.70 [ -1.08, 6.48 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.40 (P = 0.16)
Test for subgroup differences: Chi2 = 1.41, df = 2 (P = 0.49), I2 =0.0%
-4 -2 0 2 4
Favours [TAU (control)] Favours [intervention]
79Cannabis and schizophrenia (Review)
Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 2.1. Comparison 2 CANNABIS REDUCTION: PSYCHOLOGICAL THERAPY (SPECIFICALLY
ABOUT CANNABIS AND PSYCHOSIS) versus NON-SPECIFIC PSYCHOEDUCATION, Outcome 1
Behaviour: Cannabis use: 1. Used cannabis in last 4 weeks.
Review: Cannabis and schizophrenia
Comparison: 2 CANNABIS REDUCTION: PSYCHOLOGICAL THERAPY (SPECIFICALLY ABOUT CANNABIS AND PSYCHOSIS) versus NON-SPECIFIC PSY-
CHOEDUCATION
Outcome: 1 Behaviour: Cannabis use: 1. Used cannabis in last 4 weeks
Study or subgroup CAP PE (control) Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 by 3 months - end of treatment
Edwards 2006 13/23 13/24 100.0 % 1.04 [ 0.62, 1.74 ]
Subtotal (95% CI) 23 24 100.0 % 1.04 [ 0.62, 1.74 ]
Total events: 13 (CAP), 13 (PE (control))
Heterogeneity: not applicable
Test for overall effect: Z = 0.16 (P = 0.87)
2 by 9 months - 6 months after end of treatment
Edwards 2006 15/23 12/24 100.0 % 1.30 [ 0.79, 2.15 ]
Subtotal (95% CI) 23 24 100.0 % 1.30 [ 0.79, 2.15 ]
Total events: 15 (CAP), 12 (PE (control))
Heterogeneity: not applicable
Test for overall effect: Z = 1.04 (P = 0.30)
Test for subgroup differences: Chi2 = 0.37, df = 1 (P = 0.54), I2 =0.0%
0.5 0.7 1 1.5 2
Favours CAP Favours PE
Analysis 2.2. Comparison 2 CANNABIS REDUCTION: PSYCHOLOGICAL THERAPY (SPECIFICALLY
ABOUT CANNABIS AND PSYCHOSIS) versus NON-SPECIFIC PSYCHOEDUCATION, Outcome 2
Behaviour: Cannabis use: 2. Percentage days used cannabis in last 4 weeks (skewed data).
Behaviour: Cannabis use: 2. Percentage days used cannabis in last 4 weeks (skewed data)
Study Intervention Mean SD N
by 3 months - end of treatment by 3 months - end
Edwards 2006 CAP 30.4 41.8 23
Edwards 2006 PE 18.8 30.6 24
by 9 months - 6 months after end of treatment by 9 months - 6
Edwards 2006 CAP 32.4 44.9 23
Edwards 2006 PE 19.3 30.4 24
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Analysis 2.3. Comparison 2 CANNABIS REDUCTION: PSYCHOLOGICAL THERAPY (SPECIFICALLY
ABOUT CANNABIS AND PSYCHOSIS) versus NON-SPECIFIC PSYCHOEDUCATION, Outcome 3 Mental
state: 1. Average overall score (BPRS-E total endpoint, high score = poor).
Review: Cannabis and schizophrenia
Comparison: 2 CANNABIS REDUCTION: PSYCHOLOGICAL THERAPY (SPECIFICALLY ABOUT CANNABIS AND PSYCHOSIS) versus NON-SPECIFIC PSY-
CHOEDUCATION
Outcome: 3 Mental state: 1. Average overall score (BPRS-E total endpoint, high score = poor)
Study or subgroup Favours CAP PE
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 by 3 months - end of treatment
Edwards 2006 24 47.7 (18.2) 23 44.1 (13.8) 100.0 % 3.60 [ -5.61, 12.81 ]
Subtotal (95% CI) 24 23 100.0 % 3.60 [ -5.61, 12.81 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.77 (P = 0.44)
2 by 9 months - 6 months after end of treatment
Edwards 2006 24 44.8 (15.4) 23 45.6 (13.5) 100.0 % -0.80 [ -9.07, 7.47 ]
Subtotal (95% CI) 24 23 100.0 % -0.80 [ -9.07, 7.47 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.19 (P = 0.85)
Test for subgroup differences: Chi2 = 0.49, df = 1 (P = 0.49), I2 =0.0%
-10 -5 0 5 10
Favours CAP Favours PE (control)
Analysis 2.4. Comparison 2 CANNABIS REDUCTION: PSYCHOLOGICAL THERAPY (SPECIFICALLY
ABOUT CANNABIS AND PSYCHOSIS) versus NON-SPECIFIC PSYCHOEDUCATION, Outcome 4 Mental
state: 2. Average overall score (BPRS-PS total endpoint, skewed data).
Mental state: 2. Average overall score (BPRS-PS total endpoint, skewed data)
Study Intervention Mean SD N
by 3 months - end of treatment by 3 months - end
Edwards 2006 CAP 8.9 4.8 23
Edwards 2006 PE 9.5 5.4 24
by 9 months - 6 months after end of treatment by 9 months - 6
Edwards 2006 CAP 9.4 4.6 23
Edwards 2006 PE 8.8 4.8 24
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Analysis 2.5. Comparison 2 CANNABIS REDUCTION: PSYCHOLOGICAL THERAPY (SPECIFICALLY
ABOUT CANNABIS AND PSYCHOSIS) versus NON-SPECIFIC PSYCHOEDUCATION, Outcome 5 Mental
state: 3. Average depression score (BDI-SF total endpoint, skewed data).
Mental state: 3. Average depression score (BDI-SF total endpoint, skewed data)
Study Intervention Mean SD N
by 3 months - end of treatment by 3 months - end
Edwards 2006 CAP 6.2 5.9 23
Edwards 2006 PE 7.8 8.1 24
by 9 months - 6 months after end of treatment by 9 months - 6
Edwards 2006 CAP 7.5 6.3 23
Edwards 2006 PE 6.3 7.2 24
Analysis 2.6. Comparison 2 CANNABIS REDUCTION: PSYCHOLOGICAL THERAPY (SPECIFICALLY
ABOUT CANNABIS AND PSYCHOSIS) versus NON-SPECIFIC PSYCHOEDUCATION, Outcome 6 Mental
state: 4. Average negative symptom score (SANS endpoint, skewed data).
Mental state: 4. Average negative symptom score (SANS endpoint, skewed data)
Study Intervention Mean SD N
by 3 months - end of treatment by 3 months - end
Edwards 2006 CAP 21.8 14.9 23
Edwards 2006 PE 23.5 14.0 24
by 9 months - 6 months after end of treatment by 9 months - 6
Edwards 2006 CAP 23.7 17.2 23
Edwards 2006 PE 19.4 13.5 24
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Analysis 2.7. Comparison 2 CANNABIS REDUCTION: PSYCHOLOGICAL THERAPY (SPECIFICALLY
ABOUT CANNABIS AND PSYCHOSIS) versus NON-SPECIFIC PSYCHOEDUCATION, Outcome 7 Global
state: Average overall score (KAPQ total endpoint, high score = good).
Review: Cannabis and schizophrenia
Comparison: 2 CANNABIS REDUCTION: PSYCHOLOGICAL THERAPY (SPECIFICALLY ABOUT CANNABIS AND PSYCHOSIS) versus NON-SPECIFIC PSY-
CHOEDUCATION
Outcome: 7 Global state: Average overall score (KAPQ total endpoint, high score = good)
Study or subgroup CAP PE
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 by 3 months - end of treatment
Edwards 2006 24 21.7 (5) 23 22.5 (4) 100.0 % -0.80 [ -3.38, 1.78 ]
Subtotal (95% CI) 24 23 100.0 % -0.80 [ -3.38, 1.78 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.61 (P = 0.54)
2 by 9 months - 6 months after end of treatment
Edwards 2006 24 21.5 (4.1) 23 22.4 (4) 100.0 % -0.90 [ -3.22, 1.42 ]
Subtotal (95% CI) 24 23 100.0 % -0.90 [ -3.22, 1.42 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.76 (P = 0.45)
Test for subgroup differences: Chi2 = 0.00, df = 1 (P = 0.95), I2 =0.0%
-2 -1 0 1 2
Favours PE (control) Favours CAP
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Analysis 2.8. Comparison 2 CANNABIS REDUCTION: PSYCHOLOGICAL THERAPY (SPECIFICALLY
ABOUT CANNABIS AND PSYCHOSIS) versus NON-SPECIFIC PSYCHOEDUCATION, Outcome 8 General
functioning: Average score (SOFAS total endpoint, high score = good).
Review: Cannabis and schizophrenia
Comparison: 2 CANNABIS REDUCTION: PSYCHOLOGICAL THERAPY (SPECIFICALLY ABOUT CANNABIS AND PSYCHOSIS) versus NON-SPECIFIC PSY-
CHOEDUCATION
Outcome: 8 General functioning: Average score (SOFAS total endpoint, high score = good)
Study or subgroup
Cannabis and
Psychosis
therapy
Pyschoeducation
(control)
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 by 3 months - end of treatment
Edwards 2006 23 50.5 (17) 24 51.3 (14.9) 100.0 % -0.80 [ -9.95, 8.35 ]
Subtotal (95% CI) 23 24 100.0 % -0.80 [ -9.95, 8.35 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.17 (P = 0.86)
2 by 9 months - 6 months after end of treatment
Edwards 2006 23 51.7 (18.3) 24 56.4 (15.9) 100.0 % -4.70 [ -14.52, 5.12 ]
Subtotal (95% CI) 23 24 100.0 % -4.70 [ -14.52, 5.12 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.94 (P = 0.35)
-10 -5 0 5 10
Favours PE Favours CAP
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Analysis 3.1. Comparison 3 CANNABIS REDUCTION: ANTIPSYCHOTIC ’A’ versus ANTIPSYCHOTIC
’B’, Outcome 1 Behaviour: Cannabis use: 1. Traces of cannabis breakdown products in urine (number of
patients positive above threshold level - 100 nanograms - olanzapine versus risperidone).
Review: Cannabis and schizophrenia
Comparison: 3 CANNABIS REDUCTION: ANTIPSYCHOTIC ’A’ versus ANTIPSYCHOTIC ’B’
Outcome: 1 Behaviour: Cannabis use: 1. Traces of cannabis breakdown products in urine (number of patients positive above threshold level - 100 nanograms - olanzapine
versus risperidone)
Study or subgroup Olanzapine Risperidone Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 olanzapine vs risperidone
Akerele 2007 6/10 2/6 100.0 % 1.80 [ 0.52, 6.22 ]
Total (95% CI) 10 6 100.0 % 1.80 [ 0.52, 6.22 ]
Total events: 6 (Olanzapine), 2 (Risperidone)
Heterogeneity: not applicable
Test for overall effect: Z = 0.93 (P = 0.35)
Test for subgroup differences: Not applicable
0.1 0.2 0.5 1 2 5 10
Olanzapine Risperidone
Analysis 3.2. Comparison 3 CANNABIS REDUCTION: ANTIPSYCHOTIC ’A’ versus ANTIPSYCHOTIC
’B’, Outcome 2 Behaviour: Cannabis use: 2. As defined in each study (skewed data).
Behaviour: Cannabis use: 2. As defined in each study (skewed data)
Study Intervention Mean Standard Deviation N
average score per week (Marijuana Craving Report - olanzapine versus risperidone average score per
Akerele 2007 Olanzapine 32.0 39.0 10
Akerele 2007 Risperidone 21.0 10.0 6
average self-report scores of joints per week (short term) - olanzapine versus risperidone average self-repor
van Nimwegen 2008 Olanzapine 1.6 2.6 20
van Nimwegen 2008 Risperidone 3.5 5.8 21
average intensity of cannabis use in joints per week - clozapine versus other antipsychotics average intensity
Brunette 2011 Treatment as usual
(TAU)
16 9.79 16
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Behaviour: Cannabis use: 2. As defined in each study (skewed data) (Continued)
Brunette 2011 Clozapine 8 5.14 15
Analysis 3.3. Comparison 3 CANNABIS REDUCTION: ANTIPSYCHOTIC ’A’ versus ANTIPSYCHOTIC
’B’, Outcome 3 Behaviour: Cannabis use: 3. Average score per week (Marijuana Craving Report skewed data -
olanzapine versus risperidone).
Behaviour: Cannabis use: 3. Average score per week (Marijuana Craving Report skewed data - olanzapine versus risperidone)
Study Intervention Mean SD N Notes
Akerele 2007 Olanzapine 32 39 10 Represented only in graph from which we have taken these estimates
Akerele 2007 Risperidone 21 10 6
Analysis 3.4. Comparison 3 CANNABIS REDUCTION: ANTIPSYCHOTIC ’A’ versus ANTIPSYCHOTIC
’B’, Outcome 4 Mental state: Average score (OCDUS, short term, high = poor) - olanzapine versus risperdione.
Review: Cannabis and schizophrenia
Comparison: 3 CANNABIS REDUCTION: ANTIPSYCHOTIC ’A’ versus ANTIPSYCHOTIC ’B’
Outcome: 4 Mental state: Average score (OCDUS, short term, high = poor) - olanzapine versus risperdione
Study or subgroup Olanzapine Risperidone
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 olanzapine vs risperidone
van Nimwegen 2008 20 20 (7.3) 21 21.3 (8.4) 100.0 % -1.30 [ -6.11, 3.51 ]
Total (95% CI) 20 21 100.0 % -1.30 [ -6.11, 3.51 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.53 (P = 0.60)
Test for subgroup differences: Not applicable
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Analysis 3.5. Comparison 3 CANNABIS REDUCTION: ANTIPSYCHOTIC ’A’ versus ANTIPSYCHOTIC
’B’, Outcome 5 Adverse effects: 1. Anticholinergic - various (clozapine vs other antipsychotic).
Review: Cannabis and schizophrenia
Comparison: 3 CANNABIS REDUCTION: ANTIPSYCHOTIC ’A’ versus ANTIPSYCHOTIC ’B’
Outcome: 5 Adverse effects: 1. Anticholinergic - various (clozapine vs other antipsychotic)
Study or subgroup Clozapine
Treatment as
usual (TAU) Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 constipation
Brunette 2011 4/15 0/15 100.0 % 9.00 [ 0.53, 153.79 ]
Subtotal (95% CI) 15 15 100.0 % 9.00 [ 0.53, 153.79 ]
Total events: 4 (Clozapine), 0 (Treatment as usual (TAU))
Heterogeneity: not applicable
Test for overall effect: Z = 1.52 (P = 0.13)
2 nasal congestion
Brunette 2011 0/15 2/16 100.0 % 0.21 [ 0.01, 4.10 ]
Subtotal (95% CI) 15 16 100.0 % 0.21 [ 0.01, 4.10 ]
Total events: 0 (Clozapine), 2 (Treatment as usual (TAU))
Heterogeneity: not applicable
Test for overall effect: Z = 1.03 (P = 0.30)
3 salivation - too much
Brunette 2011 10/15 0/16 100.0 % 22.31 [ 1.42, 350.31 ]
Subtotal (95% CI) 15 16 100.0 % 22.31 [ 1.42, 350.31 ]
Total events: 10 (Clozapine), 0 (Treatment as usual (TAU))
Heterogeneity: not applicable
Test for overall effect: Z = 2.21 (P = 0.027)
4 salivation - too little
Brunette 2011 2/15 2/16 100.0 % 1.07 [ 0.17, 6.64 ]
Subtotal (95% CI) 15 16 100.0 % 1.07 [ 0.17, 6.64 ]
Total events: 2 (Clozapine), 2 (Treatment as usual (TAU))
Heterogeneity: not applicable
Test for overall effect: Z = 0.07 (P = 0.94)
5 urinary incontinence
Brunette 2011 2/15 0/16 100.0 % 5.31 [ 0.28, 102.38 ]
Subtotal (95% CI) 15 16 100.0 % 5.31 [ 0.28, 102.38 ]
Total events: 2 (Clozapine), 0 (Treatment as usual (TAU))
Heterogeneity: not applicable
Test for overall effect: Z = 1.11 (P = 0.27)
Test for subgroup differences: Chi2 = 6.96, df = 4 (P = 0.14), I2 =43%
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Analysis 3.6. Comparison 3 CANNABIS REDUCTION: ANTIPSYCHOTIC ’A’ versus ANTIPSYCHOTIC
’B’, Outcome 6 Adverse effects: 2. Cardiac - various (clozapine vs other antipsychotic).
Review: Cannabis and schizophrenia
Comparison: 3 CANNABIS REDUCTION: ANTIPSYCHOTIC ’A’ versus ANTIPSYCHOTIC ’B’
Outcome: 6 Adverse effects: 2. Cardiac - various (clozapine vs other antipsychotic)
Study or subgroup Clozapine
Treatment as
usual (TAU) Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 hypertension
Brunette 2011 2/15 2/15 100.0 % 1.00 [ 0.16, 6.20 ]
Subtotal (95% CI) 15 15 100.0 % 1.00 [ 0.16, 6.20 ]
Total events: 2 (Clozapine), 2 (Treatment as usual (TAU))
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
Test for subgroup differences: Not applicable
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Analysis 3.7. Comparison 3 CANNABIS REDUCTION: ANTIPSYCHOTIC ’A’ versus ANTIPSYCHOTIC
’B’, Outcome 7 Adverse effects: 3. Central nervous system / higher functions - various (clozapine vs other
antipsychotic).
Review: Cannabis and schizophrenia
Comparison: 3 CANNABIS REDUCTION: ANTIPSYCHOTIC ’A’ versus ANTIPSYCHOTIC ’B’
Outcome: 7 Adverse effects: 3. Central nervous system / higher functions - various (clozapine vs other antipsychotic)
Study or subgroup Clozapine
Treatment as
usual (TAU) Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 agitation - increased
Brunette 2011 1/15 1/15 100.0 % 1.00 [ 0.07, 14.55 ]
Subtotal (95% CI) 15 15 100.0 % 1.00 [ 0.07, 14.55 ]
Total events: 1 (Clozapine), 1 (Treatment as usual (TAU))
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
2 depression
Brunette 2011 2/15 1/15 100.0 % 2.00 [ 0.20, 19.78 ]
Subtotal (95% CI) 15 15 100.0 % 2.00 [ 0.20, 19.78 ]
Total events: 2 (Clozapine), 1 (Treatment as usual (TAU))
Heterogeneity: not applicable
Test for overall effect: Z = 0.59 (P = 0.55)
3 dizziness
Brunette 2011 5/15 1/16 100.0 % 5.33 [ 0.70, 40.54 ]
Subtotal (95% CI) 15 16 100.0 % 5.33 [ 0.70, 40.54 ]
Total events: 5 (Clozapine), 1 (Treatment as usual (TAU))
Heterogeneity: not applicable
Test for overall effect: Z = 1.62 (P = 0.11)
4 dreams - unusual dream activity
Brunette 2011 0/15 2/16 100.0 % 0.21 [ 0.01, 4.10 ]
Subtotal (95% CI) 15 16 100.0 % 0.21 [ 0.01, 4.10 ]
Total events: 0 (Clozapine), 2 (Treatment as usual (TAU))
Heterogeneity: not applicable
Test for overall effect: Z = 1.03 (P = 0.30)
5 fatigue
Brunette 2011 3/15 0/16 100.0 % 7.44 [ 0.42, 132.95 ]
Subtotal (95% CI) 15 16 100.0 % 7.44 [ 0.42, 132.95 ]
Total events: 3 (Clozapine), 0 (Treatment as usual (TAU))
Heterogeneity: not applicable
Test for overall effect: Z = 1.36 (P = 0.17)
6 irritability
Brunette 2011 1/15 1/16 100.0 % 1.07 [ 0.07, 15.57 ]
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(. . . Continued)
Study or subgroup Clozapine
Treatment as
usual (TAU) Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Subtotal (95% CI) 15 16 100.0 % 1.07 [ 0.07, 15.57 ]
Total events: 1 (Clozapine), 1 (Treatment as usual (TAU))
Heterogeneity: not applicable
Test for overall effect: Z = 0.05 (P = 0.96)
7 libido - decreased
Brunette 2011 1/15 1/16 100.0 % 1.07 [ 0.07, 15.57 ]
Subtotal (95% CI) 15 16 100.0 % 1.07 [ 0.07, 15.57 ]
Total events: 1 (Clozapine), 1 (Treatment as usual (TAU))
Heterogeneity: not applicable
Test for overall effect: Z = 0.05 (P = 0.96)
8 sleep - too much
Brunette 2011 9/15 2/16 100.0 % 4.80 [ 1.23, 18.71 ]
Subtotal (95% CI) 15 16 100.0 % 4.80 [ 1.23, 18.71 ]
Total events: 9 (Clozapine), 2 (Treatment as usual (TAU))
Heterogeneity: not applicable
Test for overall effect: Z = 2.26 (P = 0.024)
9 sleep- insomnia
Brunette 2011 2/15 1/16 100.0 % 2.13 [ 0.22, 21.17 ]
Subtotal (95% CI) 15 16 100.0 % 2.13 [ 0.22, 21.17 ]
Total events: 2 (Clozapine), 1 (Treatment as usual (TAU))
Heterogeneity: not applicable
Test for overall effect: Z = 0.65 (P = 0.52)
10 suicide attempt
Brunette 2011 1/15 1/16 100.0 % 1.07 [ 0.07, 15.57 ]
Subtotal (95% CI) 15 16 100.0 % 1.07 [ 0.07, 15.57 ]
Total events: 1 (Clozapine), 1 (Treatment as usual (TAU))
Heterogeneity: not applicable
Test for overall effect: Z = 0.05 (P = 0.96)
Test for subgroup differences: Chi2 = 6.25, df = 9 (P = 0.72), I2 =0.0%
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Analysis 3.8. Comparison 3 CANNABIS REDUCTION: ANTIPSYCHOTIC ’A’ versus ANTIPSYCHOTIC
’B’, Outcome 8 Adverse effects: 4. Gastrointestinal - various (clozapine vs other antipsychotic).
Review: Cannabis and schizophrenia
Comparison: 3 CANNABIS REDUCTION: ANTIPSYCHOTIC ’A’ versus ANTIPSYCHOTIC ’B’
Outcome: 8 Adverse effects: 4. Gastrointestinal - various (clozapine vs other antipsychotic)
Study or subgroup Clozapine
Treatment as
usual (TAU) Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 nausea
Brunette 2011 2/15 1/16 100.0 % 2.13 [ 0.22, 21.17 ]
Subtotal (95% CI) 15 16 100.0 % 2.13 [ 0.22, 21.17 ]
Total events: 2 (Clozapine), 1 (Treatment as usual (TAU))
Heterogeneity: not applicable
Test for overall effect: Z = 0.65 (P = 0.52)
2 vomiting
Brunette 2011 3/15 3/16 100.0 % 1.07 [ 0.25, 4.49 ]
Subtotal (95% CI) 15 16 100.0 % 1.07 [ 0.25, 4.49 ]
Total events: 3 (Clozapine), 3 (Treatment as usual (TAU))
Heterogeneity: not applicable
Test for overall effect: Z = 0.09 (P = 0.93)
Test for subgroup differences: Chi2 = 0.25, df = 1 (P = 0.62), I2 =0.0%
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Analysis 3.9. Comparison 3 CANNABIS REDUCTION: ANTIPSYCHOTIC ’A’ versus ANTIPSYCHOTIC
’B’, Outcome 9 Adverse effects: 5. Metabolic - weight gain (clozapine vs other antipsychotic).
Review: Cannabis and schizophrenia
Comparison: 3 CANNABIS REDUCTION: ANTIPSYCHOTIC ’A’ versus ANTIPSYCHOTIC ’B’
Outcome: 9 Adverse effects: 5. Metabolic - weight gain (clozapine vs other antipsychotic)
Study or subgroup Clozapine
Treatment as
usual (TAU) Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Brunette 2011 6/15 2/16 3.20 [ 0.76, 13.46 ]
Test for subgroup differences: Not applicable
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Analysis 3.10. Comparison 3 CANNABIS REDUCTION: ANTIPSYCHOTIC ’A’ versus ANTIPSYCHOTIC
’B’, Outcome 10 Adverse effects: 6a. Movement disorders - various (clozapine vs other antipsychotic).
Review: Cannabis and schizophrenia
Comparison: 3 CANNABIS REDUCTION: ANTIPSYCHOTIC ’A’ versus ANTIPSYCHOTIC ’B’
Outcome: 10 Adverse effects: 6a. Movement disorders - various (clozapine vs other antipsychotic)
Study or subgroup Clozapine
Treatment as
usual (TAU) Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 agitation - increased
Brunette 2011 1/15 1/15 100.0 % 1.00 [ 0.07, 14.55 ]
Subtotal (95% CI) 15 15 100.0 % 1.00 [ 0.07, 14.55 ]
Total events: 1 (Clozapine), 1 (Treatment as usual (TAU))
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
2 akathisia
Brunette 2011 1/15 1/16 100.0 % 1.07 [ 0.07, 15.57 ]
Subtotal (95% CI) 15 16 100.0 % 1.07 [ 0.07, 15.57 ]
Total events: 1 (Clozapine), 1 (Treatment as usual (TAU))
Heterogeneity: not applicable
Test for overall effect: Z = 0.05 (P = 0.96)
3 muscle spasms
Brunette 2011 2/15 0/16 100.0 % 5.31 [ 0.28, 102.38 ]
Subtotal (95% CI) 15 16 100.0 % 5.31 [ 0.28, 102.38 ]
Total events: 2 (Clozapine), 0 (Treatment as usual (TAU))
Heterogeneity: not applicable
Test for overall effect: Z = 1.11 (P = 0.27)
Test for subgroup differences: Chi2 = 0.84, df = 2 (P = 0.66), I2 =0.0%
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Analysis 3.11. Comparison 3 CANNABIS REDUCTION: ANTIPSYCHOTIC ’A’ versus ANTIPSYCHOTIC
’B’, Outcome 11 Adverse events: 6b. Movement disorders - average score (Simpson scale, high score = poor -
olanzapine versus risperidone).
Review: Cannabis and schizophrenia
Comparison: 3 CANNABIS REDUCTION: ANTIPSYCHOTIC ’A’ versus ANTIPSYCHOTIC ’B’
Outcome: 11 Adverse events: 6b. Movement disorders - average score (Simpson scale, high score = poor - olanzapine versus risperidone)
Study or subgroup Olanzapine Risperidone
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 olanzapine vs risperidone
Akerele 2007 10 10.23 (1.39) 6 10.15 (0.93) 100.0 % 0.08 [ -1.06, 1.22 ]
Subtotal (95% CI) 10 6 100.0 % 0.08 [ -1.06, 1.22 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.14 (P = 0.89)
Test for subgroup differences: Not applicable
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Analysis 3.12. Comparison 3 CANNABIS REDUCTION: ANTIPSYCHOTIC ’A’ versus ANTIPSYCHOTIC
’B’, Outcome 12 Adverse effects: 7. Others - various (clozapine vs other antipsychotic).
Review: Cannabis and schizophrenia
Comparison: 3 CANNABIS REDUCTION: ANTIPSYCHOTIC ’A’ versus ANTIPSYCHOTIC ’B’
Outcome: 12 Adverse effects: 7. Others - various (clozapine vs other antipsychotic)
Study or subgroup Clozapine
Treatment as
usual (TAU) Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 chest pain - non-cardiac
Brunette 2011 1/15 2/16 100.0 % 0.53 [ 0.05, 5.29 ]
Subtotal (95% CI) 15 16 100.0 % 0.53 [ 0.05, 5.29 ]
Total events: 1 (Clozapine), 2 (Treatment as usual (TAU))
Heterogeneity: not applicable
Test for overall effect: Z = 0.54 (P = 0.59)
2 flu-like symptoms
Brunette 2011 0/15 2/16 100.0 % 0.21 [ 0.01, 4.10 ]
Subtotal (95% CI) 15 16 100.0 % 0.21 [ 0.01, 4.10 ]
Total events: 0 (Clozapine), 2 (Treatment as usual (TAU))
Heterogeneity: not applicable
Test for overall effect: Z = 1.03 (P = 0.30)
3 headache
Brunette 2011 2/15 1/16 100.0 % 2.13 [ 0.22, 21.17 ]
Subtotal (95% CI) 15 16 100.0 % 2.13 [ 0.22, 21.17 ]
Total events: 2 (Clozapine), 1 (Treatment as usual (TAU))
Heterogeneity: not applicable
Test for overall effect: Z = 0.65 (P = 0.52)
Test for subgroup differences: Chi2 = 1.58, df = 2 (P = 0.45), I2 =0.0%
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Analysis 3.13. Comparison 3 CANNABIS REDUCTION: ANTIPSYCHOTIC ’A’ versus ANTIPSYCHOTIC
’B’, Outcome 13 Leaving the study early: 1. Number leaving (olanzapine vs risperidone).
Review: Cannabis and schizophrenia
Comparison: 3 CANNABIS REDUCTION: ANTIPSYCHOTIC ’A’ versus ANTIPSYCHOTIC ’B’
Outcome: 13 Leaving the study early: 1. Number leaving (olanzapine vs risperidone)
Study or subgroup Olanzapine Risperidone Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 admission
Akerele 2007 1/14 1/14 100.0 % 1.00 [ 0.07, 14.45 ]
Subtotal (95% CI) 14 14 100.0 % 1.00 [ 0.07, 14.45 ]
Total events: 1 (Olanzapine), 1 (Risperidone)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
2 any
Akerele 2007 4/14 8/14 100.0 % 0.50 [ 0.19, 1.29 ]
Subtotal (95% CI) 14 14 100.0 % 0.50 [ 0.19, 1.29 ]
Total events: 4 (Olanzapine), 8 (Risperidone)
Heterogeneity: not applicable
Test for overall effect: Z = 1.44 (P = 0.15)
3 intolerable adverse effects
Akerele 2007 0/14 0/14 Not estimable
Subtotal (95% CI) 14 14 Not estimable
Total events: 0 (Olanzapine), 0 (Risperidone)
Heterogeneity: not applicable
Test for overall effect: not applicable
4 not interested
Akerele 2007 3/14 7/14 100.0 % 0.43 [ 0.14, 1.33 ]
Subtotal (95% CI) 14 14 100.0 % 0.43 [ 0.14, 1.33 ]
Total events: 3 (Olanzapine), 7 (Risperidone)
Heterogeneity: not applicable
Test for overall effect: Z = 1.47 (P = 0.14)
Test for subgroup differences: Chi2 = 0.33, df = 2 (P = 0.85), I2 =0.0%
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Analysis 3.14. Comparison 3 CANNABIS REDUCTION: ANTIPSYCHOTIC ’A’ versus ANTIPSYCHOTIC
’B’, Outcome 14 Leaving the study early: 2. Weeks in treatment (olanzapine vs risperidone).
Review: Cannabis and schizophrenia
Comparison: 3 CANNABIS REDUCTION: ANTIPSYCHOTIC ’A’ versus ANTIPSYCHOTIC ’B’
Outcome: 14 Leaving the study early: 2. Weeks in treatment (olanzapine vs risperidone)
Study or subgroup Olanzapine Risperidone
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 olanzapine vs risperidone
Akerele 2007 14 11 (4.15) 14 11 (4.86) 100.0 % 0.0 [ -3.35, 3.35 ]
Total (95% CI) 14 14 100.0 % 0.0 [ -3.35, 3.35 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
Test for subgroup differences: Not applicable
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Analysis 4.1. Comparison 4 CANNABINOID AS TREATMENT: CANNABIDIOL versus AMISULPRIDE,
Outcome 1 Mental state: 1a. Average overall score (BPRS, total endpoint, high score = poor).
Review: Cannabis and schizophrenia
Comparison: 4 CANNABINOID AS TREATMENT: CANNABIDIOL versus AMISULPRIDE
Outcome: 1 Mental state: 1a. Average overall score (BPRS, total endpoint, high score = poor)
Study or subgroup Cannabidiol Amisulpride
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Day 7 - short term
Leweke 2012 20 6.4 (6.1) 19 7.9 (9.5) 100.0 % -1.50 [ -6.54, 3.54 ]
Subtotal (95% CI) 20 19 100.0 % -1.50 [ -6.54, 3.54 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.58 (P = 0.56)
2 Day 14 - short term
Leweke 2012 20 14.5 (7.9) 19 12.7 (12) 100.0 % 1.80 [ -4.61, 8.21 ]
Subtotal (95% CI) 20 19 100.0 % 1.80 [ -4.61, 8.21 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.55 (P = 0.58)
3 Day 21 - short term
Leweke 2012 16 18.4 (10.6) 18 14.2 (14.4) 100.0 % 4.20 [ -4.24, 12.64 ]
Subtotal (95% CI) 16 18 100.0 % 4.20 [ -4.24, 12.64 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.98 (P = 0.33)
4 Day 28 - short term
Leweke 2012 17 20.5 (12.3) 18 19.4 (15.6) 100.0 % 1.10 [ -8.18, 10.38 ]
Subtotal (95% CI) 17 18 100.0 % 1.10 [ -8.18, 10.38 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.23 (P = 0.82)
Test for subgroup differences: Chi2 = 1.51, df = 3 (P = 0.68), I2 =0.0%
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Analysis 4.2. Comparison 4 CANNABINOID AS TREATMENT: CANNABIDIOL versus AMISULPRIDE,
Outcome 2 Mental state: 1b. Average overall score (PANSS, total endpoint, high score = poor).
Review: Cannabis and schizophrenia
Comparison: 4 CANNABINOID AS TREATMENT: CANNABIDIOL versus AMISULPRIDE
Outcome: 2 Mental state: 1b. Average overall score (PANSS, total endpoint, high score = poor)
Study or subgroup Cannabidiol
Amisulpride
(control)
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 day 14 (short term)
Leweke 2012 20 18.8 (10.7) 19 18.8 (19.9) 100.0 % 0.0 [ -10.10, 10.10 ]
Subtotal (95% CI) 20 19 100.0 % 0.0 [ -10.10, 10.10 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
2 day 28 (short term)
Leweke 2012 17 30.5 (16.4) 18 30.1 (24.7) 100.0 % 0.40 [ -13.42, 14.22 ]
Subtotal (95% CI) 17 18 100.0 % 0.40 [ -13.42, 14.22 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.06 (P = 0.95)
Test for subgroup differences: Chi2 = 0.00, df = 1 (P = 0.96), I2 =0.0%
-10 -5 0 5 10
Favours cannabidiol Favours amisulpride
98Cannabis and schizophrenia (Review)
Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 4.3. Comparison 4 CANNABINOID AS TREATMENT: CANNABIDIOL versus AMISULPRIDE,
Outcome 3 Mental state: 2. Average negative symptom score (PANSS, high score = poor).
Review: Cannabis and schizophrenia
Comparison: 4 CANNABINOID AS TREATMENT: CANNABIDIOL versus AMISULPRIDE
Outcome: 3 Mental state: 2. Average negative symptom score (PANSS, high score = poor)
Study or subgroup Cannabidiol Amisulpride
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Day 14 - short term
Leweke 2012 20 4.5 (4.6) 19 3.3 (5.9) 100.0 % 1.20 [ -2.13, 4.53 ]
Subtotal (95% CI) 20 19 100.0 % 1.20 [ -2.13, 4.53 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.71 (P = 0.48)
2 Day 28 - short term
Leweke 2012 17 9.1 (4.9) 18 6.4 (6) 100.0 % 2.70 [ -0.92, 6.32 ]
Subtotal (95% CI) 17 18 100.0 % 2.70 [ -0.92, 6.32 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.46 (P = 0.14)
Test for subgroup differences: Chi2 = 0.36, df = 1 (P = 0.55), I2 =0.0%
-4 -2 0 2 4
Favours cannabidiol Favours amisulpride
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Analysis 4.4. Comparison 4 CANNABINOID AS TREATMENT: CANNABIDIOL versus AMISULPRIDE,
Outcome 4 Mental state: 3. Average positive symptom score (PANSS, high score = poor).
Review: Cannabis and schizophrenia
Comparison: 4 CANNABINOID AS TREATMENT: CANNABIDIOL versus AMISULPRIDE
Outcome: 4 Mental state: 3. Average positive symptom score (PANSS, high score = poor)
Study or subgroup Cannabidiol Amisulpride
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Day 14 - short term
Leweke 2012 20 6.3 (4.7) 19 5.1 (5) 100.0 % 1.20 [ -1.85, 4.25 ]
Subtotal (95% CI) 20 19 100.0 % 1.20 [ -1.85, 4.25 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.77 (P = 0.44)
2 Day 28 - short term
Leweke 2012 17 9 (6.1) 18 8.4 (7.5) 100.0 % 0.60 [ -3.92, 5.12 ]
Subtotal (95% CI) 17 18 100.0 % 0.60 [ -3.92, 5.12 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.26 (P = 0.79)
Test for subgroup differences: Chi2 = 0.05, df = 1 (P = 0.83), I2 =0.0%
-4 -2 0 2 4
Favours cannabidiol Favours amisulpride
Analysis 4.5. Comparison 4 CANNABINOID AS TREATMENT: CANNABIDIOL versus AMISULPRIDE,
Outcome 5 Adverse effects: 1. Endocrine - prolactin (µg/l, short term - skewed data).
Adverse effects: 1. Endocrine - prolactin (µg/l, short term - skewed data)
Study Intervention Mean SD N
Leweke 2012 Amisulpride 77 28.04 21
Leweke 2012 Cannabidiol 0 31.55 21
Analysis 4.6. Comparison 4 CANNABINOID AS TREATMENT: CANNABIDIOL versus AMISULPRIDE,
Outcome 6 Adverse effects: 2. Metabolic - weight gain (kg, short term - skewed data).
Adverse effects: 2. Metabolic - weight gain (kg, short term - skewed data)
Study Intervention Mean SD N
Leweke 2012 Amisulpride 3.5 2.1 21
Leweke 2012 Cannabidiol 0 2.1 21
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Analysis 4.7. Comparison 4 CANNABINOID AS TREATMENT: CANNABIDIOL versus AMISULPRIDE,
Outcome 7 Adverse effects: 3. Movement disorders - change in extrapyramidal symptoms (EPS, short term -
skewed data).
Adverse effects: 3. Movement disorders - change in extrapyramidal symptoms (EPS, short term - skewed data)
Study Intervention Mean SD N
Leweke 2012 Amisulpride 0.17 0.12 21
Leweke 2012 Cannabidiol -0.03 0.11 21
A D D I T I O N A L T A B L E S
Table 1. Prevalence of cannabis use in people with schizophrenia
Proportion Country Study
5% Germany Soyka 1993
13% Germany Hambrecht 2000
18.9% UK Duke 2001
23% USA Regier 1990
40% UK Virgo 2001
40% Australia Baigent 1995
41.8% USA Warner 1994
42% Ireland Condren 2001
43% Italy Bersani 2002
69% Sweden Allebeck 1993
Table 2. Suggested design for study
Methods Allocation: randomised.
Blindness: double blind.
Duration: 18 months.
Funding: n/a.
Setting: multi-centre.
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Table 2. Suggested design for study (Continued)
Participants Diagnosis: psychosis with comorbid cannabis dependence (ICD-10/DSM-IV).
N: 450.*
Age: 16-65.
Sex: male/female.
History: first psychotic episode or within 3 years following onset of non-affective or affective psychosis.
Included: outpatients and inpatients.
Exclusion: learning disability; organic brain damage; unable to consent
Interventions 1. Standard care.
2. Psychosocial intervention for reduction: package including contingencymanagement, relapse prevention, cognitive
therapy
Outcomes Short term and medium term:
Mental state: Clinical Global Impression Scale.
Global state: Clinical Global Impression Scale.
Behaviour: cannabis consumption, consumption of other substances of abuse.
General functioning: Global Assessment of Functioning (GAF).
Leaving the study early: dropout rate.
Satisfaction with treatment: recipient of care not satisfied with treatment; recipient of care average satisfaction score
Service outcomes: hospitalisation.
Economic costs: direct and indirect rates.
Notes * alpha 5%, beta 80% for 20% difference in binary outcome.
ICD-10 - International Classification of Diseases
DSM-IV - Diagnostic and Statistical Manual of Mental Disorders
Table 3. Suggested design for a study
Methods Allocation: randomised.
Blindness: double blind.
Duration: 18 months.
Funding: n/a.
Setting: multi-centre.
Participants Diagnosis: Diagnosis: psychosis with comorbid cannabis dependence (ICD-10/DSM-IV).
N: 450.*
Age: 16-65.
Sex: male/female.
History: first psychotic episode or within 3 years following onset of non-affective or affective psychosis.
Included: outpatients and inpatients.
Exclusion: learning disability; organic brain damage; unable to consent
Interventions 1. Clozapine: dose 150 mg bd.
2. Risperidone: dose 2 mg bd.
3. Haloperidol: dose 5 mg tds.
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Table 3. Suggested design for a study (Continued)
Outcomes Short term and medium term:
Mental state: Clinical Global Impression Scale.
Global state: Clinical Global Impression Scale.
Behaviour: cannabis consumption, consumption of other substances of abuse.
General functioning: Global Assessment of Functioning (GAF).
Leaving the study early: dropout rate.
Satisfaction with treatment: recipient of care not satisfied with treatment; recipient of care average satisfaction score
Service outcomes: hospitalisation.
Economic costs: direct and indirect rates.
Economic costs: direct and indirect rates.
Notes * alpha 5%, beta 80% for 20% difference in binary outcome.
ICD-10 - International Classification of Diseases
DSM-IV - Diagnostic and Statistical Manual of Mental Disorders
bd - twice daily
tds - three times daily
A P P E N D I C E S
Appendix 1. Complete set of search terms
We searched the Cochrane Schizophrenia Group register (July 25, 2013) with the phrase:((*Marijuana* or *Marihuana* or *Cannabi*
or *Hashish* or *Skunk* or *Hemp* or *Ganja* or *Bhang* or *Sinsemilla*):TI or (*Marijuana* or *Marihuana* or *Cannabi* or
*Hashish* or *Skunk* or *Hemp* or *Ganja* or *Bhang* or *Sinsemilla*):AB) in REFERENCE.
This register is compiled by systematic searches of major databases, handsearches and conference proceedings
Appendix 2. Previous searches
1. Electronic searching
We searched the Cochrane Schizophrenia Group register (April 2007) with the phrase:
[canna* or marijuana* or marihuana* in title, abstract and index terms of REFERENCE] or [cana* or marijuana* or marihuana* in
interventions of STUDY]
This register is compiled by systematic searches of major databases, hand searches and conference proceedings (see Group Module).
2. Reference searching
We inspected reference lists of identified studies for more trials.
3. Personal contact
We contacted authors of relevant studies to enquire about other sources of relevant information.
103Cannabis and schizophrenia (Review)
Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Appendix 3. Previous methods and data collection
1. Study selection
We (JR, HV) independently inspected all identified citations for relevance independently. Citations were checked again byHM.Where
disagreement occurred we attempted to resolve this by discussion, where doubt still remained we acquired the full article for further
inspection.We independently decidedwhether the selected studies met the review criteria. Again, where disagreement occurred attempts
were made to resolve this through discussion; if doubt still remained we added these trials to the list of those awaiting assessment
pending acquisition of further information.
2. Assessment of quality
We assessed the methodological quality of included studies using the criteria described in the Cochrane Handbook (Higgins 2006),
which is based on the degree of allocation concealment. Poor concealment has been associated with overestimation of treatment effect
(Schulz 1995). Category A includes studies in which allocation has been randomised and concealment is explicit. Category B studies
are those which have randomised allocation but in which concealment is not explicit. Category C studies are those in which allocation
has neither been randomised nor concealed. Only trials that are stated to be randomised (categories A or B of the handbook) will be
included in this review. The categories are defined below:
A. Low risk of bias (adequate allocation concealment)
B. Moderate risk of bias (some doubt about the results)
C. High risk of bias (inadequate allocation concealment).
When disputes arose as to which category a trial should be allocated, again we attempted resolution by discussion. When this was not
possible we did not enter the data and the trial was added to the list of those awaiting assessment until further information could be
obtained.
3. Data collection
We (JR, HV) independently extracted data from selected trials. When disputes arose we attempted to resolve these by discussion. When
this was not possible and further information was necessary to resolve the dilemma, we did not enter data and added the trial to the
list of those awaiting assessment.
4. Data synthesis
4.1 Intention-to-treat analysis
We excluded data from studies where more than 50% of participants in any group were lost to follow-up (this did not include the
outcome of ’leaving the study early’). In studies with less than 50% dropout rate, we assumed that participants had a poor outcome
and were included in the analysis (intention-to-treat /ITT analysis); except for the event of death, or adverse events in studies using a
placebo comparator group. We analysed the impact of including studies with high attrition rates (30-50%) in a sensitivity analysis. If
inclusion of data from this latter group resulted in a substantive change in the estimate of effect, we did not add their data to trials with
less attrition, but presented them separately.
4.2 Binary data
For binary outcomes (improved/not improved etc.) we calculated the relative risk (RR) and its 95% confidence interval (CI) based on
a fixed-effect model. Relative Risk is more intuitive (Boissel 1999) than odds ratios, and odds ratios tend to be interpreted as RR by
clinicians (Deeks 2000). This misinterpretation then leads to an overestimate of the impression of the effect. When the overall results
were significant and homogeneous we calculated the number needed to treat (NNT) and the number needed to harm (NNH).
Where possible, efforts were made to convert outcome measures to binary data. This can be done by identifying cut-off points on rating
scales and dividing participants accordingly into “clinically improved” or “not clinically improved”. It was generally assumed that if
there had been a 50% reduction in a scale-derived score such as the Brief Psychiatric Rating Scale (BPRS, Overall 1988) or the Positive
and Negative Syndrome Scale (PANSS, Kay 1986), this could be considered as a clinically significant response (Leucht 2005a, Leucht
2005b). It was recognised that for many people, especially those with chronic or severe illness, a less rigorous definition of important
improvement (e.g. 25% on the BPRS) would be equally valid. If individual patient data were available, the 50% cut-off was used for
the definition in the case of non-chronically ill people and 25% for those with chronic illness. If data based on these thresholds were
not available, we used the primary cut-off presented by the original authors.
4.3 Continuous data
4.3.1 Normal distribution
Continuous data on outcomes in trials relevant to mental health issues are often not normally distributed. To avoid the pitfall of
applying parametric tests to non-parametric data we applied the following standards to continuous final value endpoint data before
inclusion: (a) standard deviations and means were reported in the paper or were obtainable from the authors; (b) when a scale started
from zero, the standard deviation, when multiplied by two, should be less than the mean (otherwise the mean is unlikely to be an
appropriate measure of the centre of the distribution - Altman 1996); In cases with data that are greater than the mean they were
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entered into ’Other data’ table as skewed data. If a scale starts from a positive value (such as PANSS, which can have values from 30
to 210) the calculation described above in (b) should be modified to take the scale starting point into account. In these cases skewness
is present if 2SD>(S-Smin), where S is the mean score and Smin is the minimum score. We reported non-normally distributed data
(skewed) in the ’other data types’ tables.
For change data (mean change from baseline on a rating scale) it is impossible to tell whether data are non-normally distributed (skewed)
or not, unless individual patient data are available. After consulting the ALLSTAT electronic statistics mailing list, we presented change
data in RevMan graphs to summarise available information. In doing this, we assumed either that data were not skewed or that the
analysis could cope with the unknown degree of skew.
4.3.2 Final endpoint value versus change data
Where both final endpoint data and change data were available for the same outcome category, we only presented final endpoint data .
We acknowledge that by doing this much of the published change data may be excluded, but argue that endpoint data are more clinically
relevant and that if change data were to be presented along with endpoint data, it would be given undeserved equal prominence. Where
studies reported only change data we contacted authors for endpoint figures.
4.3.3 Summary statistic
For continuous outcomes we estimated a weightedmean difference (WMD) between groups based on a fixed effectsmodel. Continuous
data presented without use of summary statistics (i.e. mean, SD, SE) were not considered good evidence, though the existence of these
data were noted in the text.
4.3.4 Conversion to a common metric
To facilitate comparison between trials, we converted variables (such as days in hospital) that could be reported in different metrics
(mean days per year, per week or per month) to a common metric (e.g. mean days per month).
4.4 Rating scales
A wide range of instruments are available to measure mental health outcomes. These instruments vary in quality and many are not
valid, and are known to be subject to bias in trials of treatments for schizophrenia (Marshall 2000). Therefore continuous data from
rating scales were included only if the measuring instrument had been described in a peer-reviewed journal.
4.5 Cluster trials
Studies increasingly employ cluster randomisation (such as randomisation by clinician or practice) but analysis and pooling of clustered
data poses problems. Firstly, authors often fail to account for intra class correlation in clustered studies, leading to a unit-of-analysis
error (Divine 1992) whereby p values are spuriously low, confidence intervals unduly narrow and statistical significance overestimated.
This causes Type I errors (Bland 1997, Gulliford 1999).
Where clustering was not accounted for in primary studies, we presented the data in a table, with a (*) symbol to indicate the presence
of a probable unit of analysis error. In subsequent versions of this review we will seek to contact first authors of studies to obtain intra-
class correlation co-efficient of their clustered data and to adjust for this using accepted methods (Gulliford 1999). Where clustering
has been incorporated into the analysis of primary studies, we will also present these data as if from a non-cluster randomised study,
but adjusted for the clustering effect.
We have sought statistical advice and have been advised that the binary data as presented in a report should be divided by a design
effect. This is calculated using the mean number of participants per cluster (m) and the intraclass correlation co-efficient (ICC) [Design
effect=1+(m-1)*ICC] (Donner 2002). If the ICC was not reported it was assumed to be 0.1 (Ukoumunne 1999). If cluster studies
had been appropriately analysed taking into account intra-class correlation coefficients and relevant data documented in the report, we
synthesised these with other studies using the generic inverse variance technique.
5. Investigation for heterogeneity
Firstly, we considered all the included studies within any comparison to judge for clinical heterogeneity. Then we visually inspected
graphs to investigate the possibility of statistical heterogeneity. We supplemented this by using primarily the I-squared statistic. This
provides an estimate of the percentage of variability due to heterogeneity rather than chance alone. Where the I-squared estimate was
greater than or equal to 50%, we interpreted this as indicating the presence of considerable levels of heterogeneity (Higgins 2003).
Where heterogeneity was present, reasons for this were investigated. If it substantially altered the results, data were not summated, but
presented separately and reasons for heterogeneity investigated.
6. Addressing publication bias
We entered data from all included studies into a funnel graph (trial effect against trial size) in an attempt to investigate the likelihood
of overt publication bias (Egger 1997).
7. Sensitivity analyses
We analysed the effect of including studies with high attrition rates in a sensitivity analysis.
8. General
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Where possible, we entered data in such a way that the area to the left of the line of no effect indicated a favourable outcome for
cannabis/cannabinoids.
Appendix 4. Previous background
The cannabis plant (Cannabis sativa L.) grows in temperate and tropical areas. Herbal cannabis consists of the dried flowering tops
and leaves. Cannabis resin is a compressed solid made from the resinous parts of the plant, and cannabis oil (hash) is a solvent extract
of cannabis. Cannabis is usually smoked but occasionally ingested in foodstuffs.
Cannabinoids are present in the flowers, leaves, seeds and stalks of cannabis sativa, otherwise known as the hemp plant (Figure 1).
Cannabinol was first isolated in 1895. An anonymous British physician working in British Guyana in 1893 (Tunving 1985) indicated
that the use of cannabis might be a cause of mental illness. Dr Warnock in 1895, from his experience with inmates of the Cairo asylum
in Egypt (Warnock 1903), also related abuse of hashish to mental illness and wondered how those outside the asylum could enjoy the
drug without becoming ill. Concerns about its psychoactive properties date from 1928, when Egyptian and South African doctors
stated that heavy use could cause mental disturbances (Berridge 2004).
Schizophrenia-like experiences have been described in cannabis smokers (Talbot 1969) and there have been anecdotal sporadic reports of
cannabis-linked psychosis (Varma 1972, Chopra 1974) including the earliest reported British case of psychosis associated with cannabis
abuse (Davison 1972). The diagnostic label of “cannabis psychosis” is less fashionable than it once was. It tended to be attached to
young Afro-Caribbean patients (McGovern 1987), a practice which was rightly disputed (Carney 1984, Littlewood 1988). However,
the relationship between cannabis and schizophrenia remains controversial.
In general, substance misuse has been reported to be the most prevalent comorbid condition associated with schizophrenia (Regier
1990) and cannabis is the most frequently used substance (Hall 1999, Farrell 1998). The reported rates of cannabis abuse among
people with schizophrenia vary widely both within and between different countries, but are consistently higher than in other people
with mental illnesses or in the general population (Smith 1994). The proportion of people with schizophrenia who use cannabis varies,
but surveys commonly find prevalence rates to be about 40% ( Table 1).
Cannabis contains the psychoactive constituent cannabinoid delta-9-tetrahydrocannabinol (THC). Concerns have been raised that
THC concentrations in cannabis are higher than in the past, and therefore today cannabis usage poses a greater risk to health. Cannabis
produced from intensive indoor cultivation methods has a higher concentration of THC than imported sources, which typically are not
intensively cultivated. The higher concentrations have been attributed to the use of specific seed strains from the female plant which
are grown in artificial light and prevented from undergoing fertilization or seed production. However, the majority of cannabis used
in the UK originates from North Africa and the available data does not indicate an upward trend in potency from imported cannabis
into Europe (EMCDDA).
Cannabis as precipitant
A longitudinal follow-up study of Swedish conscripts Andreasson 1987 has shown that the relative risk for schizophrenia was up to
six times greater in people who had reported high cannabis use (on more than 50 occasions) compared with non users, and cannabis
was felt to be an independent risk factor for schizophrenia. Similar results were obtained in studies at five years post-conscription, to
exclude the prodromal cases (Zammit 2002). This was replicated by Van Os 2002, and Arseneault 2002 in separate studies. A WHO
study (Jablensky 1992) has shown that the use of cannabis early in the onset of schizophrenia is a predictor of a poor outcome. Another
theory is that the continuous heavy use of cannabis can induce a psychotic illness, which is distinct from schizophrenia (Nunez 2002).
Cannabis as bidirectional perpetuant
In general cannabis use is felt to have a negative effect on the course and prognosis of the illness (Negrete 1986, Linszman 1994). A
number of hypotheses have been put forward regarding the association between cannabis and schizophrenia. A recently published study
(Hides 2006) examined the influence of cannabis use on psychotic relapse and the influence of psychotic symptom severity on relapse
in cannabis use in the six months following hospital admission. They found that a higher frequency of cannabis use was predictive of
psychotic relapse, after controlling for medication adherence, other substance use and duration of untreated psychosis. Also, an increase
in psychotic symptoms was predictive of relapse to cannabis use. They concluded that the relationship between cannabis and psychosis
might be “bidirectional”.
Self-medication
An alternative theory is that cannabis is used by people with distressing psychotic symptoms as a form of self-medication (Dixon 1990),
or to reduce the unpleasant adverse effects caused by antipsychotic drug treatment. It has also been proposed that the negative symptoms
of schizophrenia (affective flattening, poor volition, poverty of thought, social withdrawal) may be improved by use of cannabis.
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Technical background
The major active principle in all cannabis products is delta-9-tetrahydrocannabinol (THC) (Figure 2) It was first identified in 1964
(Gaoni 1964) and this compound seems responsible for most of the psychological effects of marijuana (Isbell 1967). As cannabis or
the cannabinoids lead to dopamine release (Tanda 1997) it would seem plausible that its use could precipitate or exacerbate illness.
Cannabinoids are a group of terpenophenolic compounds present in cannabis. Cannabinoids exert their effect through specific endoge-
nous cannabinoid receptors. THC exerts its effect by interaction with neuronal (CB1) receptors which are found in the cerebral cortex,
limbic areas, basal ganglia, thalamus and brain stem. Within the brain, THC and other cannabinoids are differentially distributed
with high concentrations in cortical, limbic, sensory and motor areas. CB2 receptors have also been identified in macrophages and
other immune cells. The cannabinoid system of the brain is modulated by endogenous cannabinoids which include anandamide and
palmitoylethanolamide. Concentrations of endogenous cannabinoids have been found to be significantly higher in the cerebrospinal
fluid of people with schizophrenia than in non-schizophrenic controls (Leweke 1999).
THC produces a euphoric effect, but it can cause perceptual alterations, impaired short termmemory and attention, anxiety and panic
attacks (Ashton 2001, Thomas 1996), and may lead to a withdrawal (Kouri 1999) or dependence syndrome (Stephens 1993). In high
doses, visual and auditory hallucinations, delusions and thought disorder may result (Lishman 1998).
WH A T ’ S N E W
Last assessed as up-to-date: 26 February 2014.
Date Event Description
8 September 2014 New citation required but conclusions have not
changed
New additional data did not change overall conclusions
of the review
26 February 2014 New search has been performed Results from 2013 update search added to review. Pro-
tocol changed and format of review updated to reflect
newmethodology. Seven new trials added to the review
H I S T O R Y
Protocol first published: Issue 3, 2004
Review first published: Issue 3, 2008
Date Event Description
18 December 2008 Amended plain language summary added
14 May 2008 New citation required and conclusions have changed Full review published
19 March 2008 Amended Converted to new review format.
22 August 2007 New citation required and conclusions have changed Substantive amendment
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C O N T R I B U T I O N S O F A U T H O R S
Please note: Benjamin McLoughlin and Jonathan Pushpa-Rajah contributed equally for this version of the review.
Benjamin McLoughlin updated protocol, selected studies, extracted data, wrote final report.
Jonathan Pushpa-Rajah updated protocol, selected studies, extracted data, wrote final report.
Donna Gillies performed reliability checks, edited/commented on protocol and review.
From previous version:
John Rathbone - updated protocol, selected studies, extracted data, wrote final report.
Hannele Variend - selected studies, extracted data.
D E C L A R A T I O N S O F I N T E R E S T
None known.
S O U R C E S O F S U P P O R T
Internal sources
• University of Nottingham, Nottingham, UK.
External sources
• No sources of support supplied
D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
Minor differences Major differences
Reordered and renamed main outcomes.
Grouped themain outcomeswithin different time frames of short,
medium and long term
Reorganised the comparisons from four arms to two comparisons
The time period for the primary outcomes were specified as
medium term
Primary outcomes: removed hospitalisation
We felt that the primary outcomes that we removed were not as pertinent to the focus of the study as change in general mental state,
relapse and behaviour.
We grouped the main outcomes by time frames to make the comparisons within the review more clear and meaningful; once we had
done this, we then had to specify a time for the primary outcome, we decided that medium term would best reflect the comparisons. We
reorganised the comparisons tomake themmore straightforward and specified the primary outcome times based on this rearrangement.
We also updated the methods section to reflect changes in Cochrane methodology since this review was first published.
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I N D E X T E R M S
Medical Subject Headings (MeSH)
Antipsychotic Agents [∗therapeutic use]; Benzodiazepines [therapeutic use]; Cannabinoids [∗therapeutic use]; Marijuana Abuse [psy-
chology; ∗therapy]; Medical Marijuana [∗therapeutic use]; Psychotherapy; Randomized Controlled Trials as Topic; Risperidone [ther-
apeutic use]; Schizophrenia [∗drug therapy]; Sulpiride [analogs & derivatives; therapeutic use]
MeSH check words
Humans
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